Document

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters

In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall; Recognition and Measurement of Financial Assets and Financial Liabilities.

The new guidance supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities to be measured at fair value with changes in the fair value recognized through net income. The new guidance requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement.

January 1, 2018.

We currently do not hold equity securities, and we are evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.

0001159036-17-000030.txt : 20170509 0001159036-17-000030.hdr.sgml : 20170509 20170509162325 ACCESSION NUMBER: 0001159036-17-000030 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170509 DATE AS OF CHANGE: 20170509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS INC CENTRAL INDEX KEY: 0001159036 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 880488686 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32335 FILM NUMBER: 17826759 BUSINESS ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121-1345 BUSINESS PHONE: (858) 794-8889 MAIL ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121-1345 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC DATE OF NAME CHANGE: 20010912 10-Q 1 halo1q2017-10q.htm 10-Q Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)



ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-32335

___________________________

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

___________________________



Delaware		88-0488686
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

11388 Sorrento Valley Road, San Diego, CA		92121
(Address of principal executive offices)		(Zip Code)

(858) 794-8889

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer ý	Accelerated filer ¨	Non-accelerated filer ¨	Smaller reporting company ¨	Emerging growth company ¨
		(Do not check if a smaller reporting company)
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No ý

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 129,840,030 as of May 1, 2017.

HALOZYME THERAPEUTICS, INC.

INDEX



		Page
PART I — FINANCIAL INFORMATION
Item 1.	Financial Statements
	Condensed Consolidated Balance Sheets (Unaudited) – March 31, 2017 and December 31, 2016	3
	Condensed Consolidated Statements of Operations (Unaudited) – Three Months Ended March 31, 2017 and 2016	4
	Condensed Consolidated Statements of Comprehensive Loss (Unaudited) – Three Months Ended March 30, 2017 and 2016	5
	Condensed Consolidated Statements of Cash Flows (Unaudited) – Three Months Ended March 31, 2017 and 2016	6
	Notes to Condensed Consolidated Financial Statements (Unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	31
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	63
Item 4.	Controls and Procedures	64

PART II — OTHER INFORMATION
Item 1.	Legal Proceedings	65
Item 1A.	Risk Factors	65
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	65
Item 3.	Defaults Upon Senior Securities	65
Item 4.	Mine Safety Disclosures	65
Item 5.	Other Information	65
Item 6.	Exhibits	66
	SIGNATURES	67

PART I — FINANCIAL INFORMATION


Item 1.	Financial Statements

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except per share amounts)



	March 31, 2017			December 31, 2016
ASSETS
Current assets:
Cash and cash equivalents	$	45,188		$	66,764
Marketable securities, available-for-sale	133,797			138,217
Accounts receivable, net	12,452			15,680
Inventories	14,290			14,623
Prepaid expenses and other assets	16,627			21,248
Total current assets	222,354			256,532
Property and equipment, net	3,741			4,264
Prepaid expenses and other assets	172			219
Restricted cash	500			500
Total assets	$	226,767		$	261,515

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	3,079		$	3,578
Accrued expenses	24,935			28,821
Deferred revenue, current portion	4,093			4,793
Current portion of long-term debt, net	29,601			17,393
Total current liabilities	61,708			54,585
Deferred revenue, net of current portion	38,802			39,825
Long-term debt, net	184,430			199,228
Other long-term liabilities	326			358
Commitments and contingencies (Note 9)
Stockholders’ deficit:
Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding	—			—
Common stock - $0.001 par value; 200,000 shares authorized; 129,822 and 129,502 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	130			130
Additional paid-in capital	559,659			552,737
Accumulated other comprehensive loss	(49		)	(6		)
Accumulated deficit	(618,239		)	(585,342		)
Total stockholders’ deficit	(58,499		)	(32,481		)
Total liabilities and stockholders’ deficit	$	226,767		$	261,515

See accompanying notes to condensed consolidated financial statements.

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share amounts)



	Three Months Ended March 31,
	2017			2016
Revenues:
Product sales, net	$	11,434		$	12,940
Royalties	13,982			11,387
Revenues under collaborative agreements	4,152			18,172
Total revenues	29,568			42,499
Operating expenses:
Cost of product sales	7,544			7,762
Research and development	36,935			40,100
Selling, general and administrative	12,615			10,806
Total operating expenses	57,094			58,668
Operating loss	(27,526		)	(16,169		)
Other income (expense):
Investment and other income, net	287			229
Interest expense	(5,448		)	(3,876		)
Net loss before income taxes	(32,687		)	(19,816		)
Income tax expense	210			—
Net loss	$	(32,897	)	$	(19,816	)

Net loss per share:
Basic and diluted	$	(0.26	)	$	(0.16	)

Shares used in computing net loss per share:
Basic and diluted	128,615			127,615

See accompanying notes to condensed consolidated financial statements.

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

(In thousands)



	Three Months Ended March 31,
	2017			2016
Net loss	$	(32,897	)	$	(19,816	)
Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities	(40		)	187
Foreign currency translation adjustment	(4		)	—
Unrealized gain on foreign currency	1			—
Total comprehensive loss	$	(32,940	)	$	(19,629	)

See accompanying notes to condensed consolidated financial statements.

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)



	Three Months Ended March 31,
	Three Months Ended March 31,
	2017			2016
Operating activities:
Net loss	$	(32,897	)	$	(19,816	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	7,315			5,817
Depreciation and amortization	602			489
Non-cash interest expense	487			1,054
Payment-in-kind interest expense on long-term debt	—			1,890
Amortization of premiums on marketable securities, net	16			213
Loss on disposal of equipment	44			—
Recognition of deferred revenue	(1,723		)	(1,524		)
Recognition of deferred rent	(114		)	(70		)
Other	(5		)	—
Changes in operating assets and liabilities:
Accounts receivable, net	3,228			6,867
Inventories	333			(856		)
Prepaid expenses and other assets	4,668			(2,522		)
Accounts payable and accrued expenses	(4,413		)	(4,565		)
Net cash used in operating activities	(22,459		)	(13,023		)
Investing activities:
Purchases of marketable securities	(54,830		)	(126,431		)
Proceeds from maturities of marketable securities	59,194			21,908
Purchases of property and equipment	(99		)	(1,099		)
Net cash provided by (used in) investing activities	4,265			(105,622		)
Financing activities:
Proceeds from issuance of long-term debt, net	—			148,046
Repayment of long-term debt	(2,989		)	(3,885		)
Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement	(393		)	285
Net cash (used in) provided by financing activities	(3,382		)	144,446
Net (decrease) increase in cash, cash equivalents and restricted cash	(21,576		)	25,801
Cash, cash equivalents and restricted cash at beginning of period	67,264			43,792
Cash, cash equivalents and restricted cash at end of period	$	45,688		$	69,593

See accompanying notes to condensed consolidated financial statements.

HALOZYME THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization and Business

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.

Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators’ proprietary compounds.

The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex^® recombinant, and it works by temporarily breaking down hyaluronan (or “HA”), a naturally occurring complex carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE^™ Technology. We license the ENHANZE Technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.

We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), and Eli Lilly and Company (“Lilly”). We receive royalties from two of these collaborations, including royalties from sales of one product approved in both the United States and outside the United States from the Baxalta collaboration and from sales of two products approved for marketing outside the United States from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.

Our proprietary development pipeline consists primarily of pre-clinical and clinical stage product candidates in oncology. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 has been demonstrated in animal models to work by temporarily degrading HA surrounding cancer cells resulting in reduced pressure and increased blood flow to the tumor thereby enabling increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. Through our efforts and efforts of our partners and collaborators, we are currently in Phase 3 clinical testing for PEGPH20 with ABRAXANE^®(nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (“PDA”) (Study 109-301), in Phase 1b clinical testing for PEGPH20 with KEYTRUDA^®(pembrolizumab) in non-small cell lung cancer and gastric cancer (Study 107-101) and

in Phase 1b/2 clinical testing for PEGPH20 with HALAVEN^® (eribulin) in patients treated with up to two lines of prior therapy for HER2-negative metastatic breast cancer.

Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC and Halozyme Switzerland GmbH.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on February 28, 2017. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.

The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC and Halozyme Switzerland GmbH. All intercompany accounts and transactions have been eliminated.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.

Cash Equivalents and Marketable Securities

Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of March 31, 2017, our cash equivalents consisted of money market funds and commercial paper.

Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders’ deficit. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the condensed consolidated statements of operations.

Restricted Cash

Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At March 31, 2017 and December 31, 2016, restricted cash of $0.5 million was pledged as collateral for the letters of credit.

Fair Value of Financial Instruments

The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.

Available-for-sale marketable securities consist of corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.

Inventories

Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.

Prior to receiving marketing approval from the U.S. Food and Drug Administration (“FDA”) or comparable regulatory agencies in foreign countries, costs related to purchases of bulk rHuPH20 and raw materials and the manufacturing of the product candidates are recorded as research and development expense. All direct manufacturing costs incurred after receiving marketing approval are capitalized as inventory. Inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials.

As of March 31, 2017 and December 31, 2016, inventories consisted of $1.7 million and $2.3 million, respectively, of Hylenex recombinant inventory, net, and $12.6 million and $12.3 million, respectively, of bulk rHuPH20 for use in the manufacture of Baxalta’s and Roche’s collaboration products.

Revenue Recognition

We generate revenues from product sales and payments received under collaborative agreements. Collaborative agreement payments may include nonrefundable fees at the inception of the agreements, license fees, milestone and event-based payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk rHuPH20, and/or royalties on sales of products resulting from collaborative arrangements.

We recognize revenues in accordance with the authoritative guidance for revenue recognition. We recognize revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured.

Product Sales, Net

Hylenex Recombinant

We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers provide for selling prices that are fixed on the date of sale, although we offer discounts to certain group purchasing organizations (“GPOs”), hospitals and government programs. The wholesalers take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales.

We have developed sufficient historical experience and data to reasonably estimate future returns and chargebacks of Hylenex recombinant. As a result, we recognize Hylenex recombinant product sales and related cost of product sales at the time title transfers to the wholesalers.

Upon recognition of revenue from product sales of Hylenex recombinant, we record certain sales reserves and allowances as a reduction to gross revenue. These reserves and allowances include amounts for product returns (based primarily on an analysis of historical return patterns), distribution fees, prompt payment discounts, and GPO fees and other discounts and fees.

We recognize product sales reserves and allowances as a reduction of product sales in the same period the related revenue is recognized. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. If actual product return results differ from our estimates, we will be required to make adjustments to these allowances in the future, which could have an effect on product sales revenue and earnings in the period of adjustments.

Bulk rHuPH20

Subsequent to receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries, sales of bulk rHuPH20 for use in collaboration commercial products are recognized as product sales when the materials have met all the specifications required for the customer’s acceptance and title and risk of loss have transferred to the customer. Following the receipt of European marketing approvals of Roche’s Herceptin SC product in August 2013 and MabThera^® SC product in March 2014 and Baxalta’s HYQVIA product in May 2013, revenue from the sales of bulk rHuPH20 for these collaboration products has been recognized as product sales.

Revenues under Collaborative Agreements

We have entered into license and collaboration agreements under which our collaborators obtained worldwide rights for the use of our proprietary rHuPH20 enzyme in the development and commercialization of their biologic compounds identified as targets. These agreements may also contain other elements. Pursuant to the terms of these agreements, collaborators could be required to make various payments to us for each target, including nonrefundable upfront license fees, exclusivity fees, payments based on achievement of specified milestones designated in the collaborative agreements, annual maintenance fees, reimbursements of research and development services, payments for supply of bulk rHuPH20 used by the collaborator and/or royalties on sales of products resulting from collaborative agreements.

In order to account for the multiple-element arrangements, we identify the deliverables included within the collaborative agreement and evaluate which deliverables represent units of accounting. We then determine the appropriate method of revenue recognition for each unit based on the nature and timing of the delivery process. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The deliverables under our collaborative agreements include (i) the license to our rHuPH20 technology, (ii) at the collaborator’s request, research and development services which are reimbursed at contractually determined rates, and (iii) at the collaborator’s request, supply of bulk rHuPH20 which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. We base this determination on the collaborators’ ability to use the delivered items on their own without us supplying undelivered items, which we determine taking into consideration factors such as the research capabilities of the collaborator, the availability of research expertise in this field in the general marketplace, and the ability to procure the supply of bulk rHuPH20 from the marketplace.

Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (“VSOE”) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are not contingent upon the delivery of additional items or meeting other specified performance conditions. The consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement.

Nonrefundable upfront license fees are recognized upon delivery of the license if facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of bulk rHuPH20, the relative selling price allocation of the license is equal to or exceeds the upfront license fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable and collectibility is reasonably assured. Upfront license fees are deferred if facts and circumstances dictate that the license does not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period.

When collaborators have rights to elect additional targets, the rights are assessed as to whether they represent deliverables at the inception of the arrangement. In assessing these contingent deliverables, we consider whether the right is a substantive option. We consider a right to be a substantive option if the election of the additional targets is not essential to the functionality of the other elements in the arrangement and if we are truly at risk of the right being exercised. If the right is determined to be a substantive option, we further consider whether the right is priced at a significant and incremental discount that should be accounted for as an element of the arrangement. If a right is determined to be a substantive option and is not priced at a significant and incremental discount, it is not treated as a deliverable in the arrangement and receives no allocation at the inception of the arrangement of the original arrangement consideration. The right is then accounted for when and if it is exercised.

Certain of our collaborative agreements provide for milestone payments upon achievement of development and regulatory events and/or specified sales volumes of commercialized products by the collaborator. We account for milestone payments in accordance with the provisions of ASU No. 2010-17, Revenue Recognition - Milestone Method (“Milestone Method of Accounting”). We recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:


1.	The consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone;


2.	The consideration relates solely to past performance; and


3.	The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.

A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the vendor.

Reimbursements of research and development services are recognized as revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Revenue from the manufacture of bulk rHuPH20 is recognized when the materials have met all specifications required for the collaborator’s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control when any collaborator will request research and development services or supply of bulk rHuPH20; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of bulk rHuPH20.

Since we receive royalty reports 60 days after quarter end, royalty revenue from sales of collaboration products by our collaborators is recognized in the quarter following the quarter in which the corresponding sales occurred.

The collaborative agreements typically provide the collaborators the right to terminate such agreement in whole or on a product-by-product or target-by-target basis at any time upon 30 to 90 days prior written notice to us. There are no performance, cancellation, termination or refund provisions in any of our collaborative agreements that contain material financial consequences to us.

Refer to Note 4, Collaborative Agreements, for further discussion on our collaborative arrangements.

Cost of Product Sales

Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of Hylenex recombinant and bulk rHuPH20 for use in approved collaboration products. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.

Research and Development Expenses

Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses. After receiving approval from the FDA or comparable regulatory agencies in foreign countries for a product, costs related to purchases and manufacturing of bulk rHuPH20 for such product are capitalized as inventory. The manufacturing costs of bulk rHuPH20 for the collaboration products, Herceptin SC, MabThera SC and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory.

We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.

Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have no in-licensed technologies that have alternative future uses in research and development projects or otherwise.

Clinical Trial Expenses

We make payments in connection with our clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.

Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.

Share-Based Compensation

We record compensation expense associated with stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and RSUs with performance conditions (“PRSUs”) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.

Income Taxes

We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. While we have begun to utilize certain of our net operating losses, we have not yet established a track record of profitability. Accordingly, valuation allowances have been recorded to reduce our net deferred tax assets to zero until such time we can demonstrate an ability to realize them.

Net Loss Per Share

Basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. Because of our net loss, outstanding common stock equivalents totaling approximately 16.4 million and 13.0 million were excluded from the calculation of diluted net loss per common share for the three months ended March 31, 2017 and 2016, respectively, because their effect was anti-dilutive.

Segment Information

We operate our business in one segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of Hylenex recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment. Our long-lived assets located in foreign countries had minimal book value as of March 31, 2017 and December 31, 2016.

Adoption and Pending Adoption of Recent Accounting Pronouncements

The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:



Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters

In July 2015, the FASB issued ASU 2015-11, Inventory: Simplifying the Measurement of Inventory.	The new guidance requires that for entities that measure inventory using the first-in, first-out method, inventory should be measured at the lower of cost or net realizable value. Topic 330, Inventory, currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximate normal profit margin. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.	January 1, 2017.	The adoption did not have a material impact on our condensed consolidated financial position or results of operations.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash.	Current U.S. GAAP either is unclear or does not include specific guidance on the eight cash flow classification issues included in ASU 2016-15. The new guidance is an improvement to U.S. GAAP and is intended to reduce the current and potential future diversity in practice. ASU 2016-18 provides additional classification guidance for restricted cash, which requires that restricted cash be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows.	January 1, 2018. We have elected to early adopt as of January1, 2017.	Cash and cash equivalents at the beginning-of-period and end-of-period total amounts in the Condensed Consolidated Statements of Cash Flows have been adjusted to include $0.5 million of restricted cash for each of the periods presented.

_______________

(1)

Under the new standard, we are required to assess whether licenses granted under our collaboration and license agreements are distinct from other performance obligations and functional when granted. We expect that license-related amounts, including upfront payments, exclusive designation fees, annual license maintenance fees and sales-based milestones will be recognized, generally, when earned. Currently, these amounts related to certain of our license and collaboration agreements are being amortized over the term of the collaboration agreement. For example, during the year ended December 31, 2016, we recognized revenue from amortization of license payments of $4.1 million, and total deferred revenue related to license payments under collaboration agreements as of December 31, 2016 was $43.9 million. While we have not completed our evaluation at this time, we anticipate a potential reduction or elimination of our associated deferred revenue balances upon adoption of Topic 606.

(2)

Under the new standard, we expect sales-based royalties will be recognized in the quarter they are earned based on estimates, with true-up to actual results following in the subsequent quarter. Sales-based royalty revenue earned under our collaboration and license agreements is presently recognized when the royalty reports are made available. Upon adoption of Topic 606, we will evaluate and reduce our accumulated deficit and increase our accounts receivable, net, by the amount earned but not yet reported in our consolidated balance sheet at the time of adoption. We are establishing a process to estimate sales-based royalty revenues in the quarter in which the sales occur.

3. Fair Value Measurement

Available-for-sale marketable securities consisted of the following (in thousands):



	March 31, 2017
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
Corporate debt securities	$	33,158	$	—	$	(18	)	$	33,140
U.S. Treasury securities	70,002		1		(29		)	69,974
Commercial paper	30,683		—		—			30,683
	$	133,843	$	1	$	(47	)	$	133,797



	December 31, 2016
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
Corporate debt securities	$	40,221	$	1	$	(15	)	$	40,207
U.S. Treasury securities	94,002		24		(16		)	94,010
Commercial paper	$	4,000	$	—	$	—		$	4,000
	$	138,223	$	25	$	(31	)	$	138,217

As of March 31, 2017, $124.8 million of our available-for-sale marketable securities were scheduled to mature within the next 12 months. As of March 31, 2017, eight available-for-sale marketable securities were in a gross unrealized loss position, all of which had been in such position for less than 12 months. Based on our review of these marketable securities, we believe we had no other-than-temporary impairments on these securities as of March 31, 2017 because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.

The following table summarizes, by major security type, our cash equivalents and marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):



	March 31, 2017						December 31, 2016
	Level 1		Level 2		Total estimated fair value		Level 1		Level 2		Total estimated fair value
Cash equivalents:
Money market funds	$	34,814	$	—	$	34,814	$	60,916	$	—	$	60,916
Commercial paper			4,000		4,000		—		—		—

Available-for-sale marketable securities:
Corporate debt securities	—		33,140		33,140		—		40,207		40,207
U.S. Treasury securities	69,974		—		69,974		94,010		—		94,010
Commercial paper	—		30,683		30,683		—		4,000		4,000
	$	104,788	$	67,823	$	172,611	$	154,926	$	44,207	$	199,133

There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the three months ended March 31, 2017. We have no instruments that were classified within Level 3 as of March 31, 2017 and December 31, 2016.

4. Collaborative Agreements

Roche Collaboration

In December 2006, we and Roche entered into a collaboration and license agreement, under which Roche obtained a worldwide license to develop and commercialize product combinations of rHuPH20 and up to thirteen Roche target compounds (the “Roche Collaboration”). Roche initially had the exclusive right to apply rHuPH20 to three pre-defined Roche biologic targets with the option to develop and commercialize rHuPH20 with ten additional targets. Roche had the right to exercise this option to identify additional targets for ten years. As of the ten year anniversary in December 2016, Roche had elected a total of eight targets, two of which are exclusive.

In August 2013, Roche received European marketing approval for its collaboration product, Herceptin SC, for the treatment of patients with HER2-positive breast cancer and launched Herceptin SC in the European Union (“EU”) in September 2013. In March 2014, Roche received European marketing approval for its collaboration product, MabThera SC, for the treatment of patients with common forms of non-Hodgkin lymphoma (“NHL”). In June 2014, Roche launched MabThera SC in the EU. In May 2016, Roche announced that the EMA approved Mabthera SC to treat patients with chronic lymphocytic leukemia (“CLL”). In November 2016, the FDA accepted Genentech’s (a member of the Roche Group) Biologics License Application (“BLA”) for a subcutaneous formulation of rituximab for CLL and NHL. This is a co-formulation with rHuPH20, which is approved and marketed under the MabThera SC brand in countries outside the U.S. In March 2017, an Oncologic Drug Advisory Committee of the FDA voted 11 to 0 that the benefit/risk of rituximab SC was favorable for patients in the proposed indications in CLL and two types of NHL, follicular lymphoma and diffuse large B-cell lymphoma. The FDA action date is June 26, 2017.

Roche assumes all development, manufacturing, clinical, regulatory, sales and marketing costs under the Roche Collaboration, while we are responsible for the supply of bulk rHuPH20. We are entitled to receive reimbursements for providing research and development services and supplying bulk rHuPH20 to Roche at its request.

Under the terms of the Roche Collaboration, Roche pays us a royalty on each product commercialized under the agreement consisting of a mid-single digit percent of the net sales of such product. Unless terminated earlier in accordance with its terms, the Roche Collaboration continues in effect until the expiration of Roche’s obligation to pay royalties. Roche has the obligation to pay royalties to us with respect to each product commercialized in each country, during the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the Roche Collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term.

Payments received from Roche, excluding royalties and reimbursements for providing research and development services and supplying bulk rHuPH20, since inception of the collaboration agreement are as follows (in thousands):



	As of March 31, 2017
Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets	$	20,000
Election of additional exclusive targets and annual license maintenance fees for the right to designate the remaining targets as exclusive targets	23,000
Clinical development milestone payments	13,000
Regulatory milestone payments	8,000
Sales-based milestone payments	15,000
Total payments received	$	79,000

Due to our continuing involvement obligations (for example, support activities associated with rHuPH20), revenues from the upfront payment, exclusive designation fees, annual license maintenance fees and sales-based milestone payments were deferred and are being amortized over the remaining term of the Roche Collaboration.

For each of the three months ended March 31, 2017 and 2016, we recognized $0.8 million of Roche deferred revenues, excluding reimbursements for providing research and development services and supplying bulk rHuPH20, as revenues under collaborative agreements. Total Roche deferred revenues, excluding deferred revenues related to reimbursements for providing research and development services and supplying bulk rHuPH20, were $34.9 million and $35.7 million as of March 31, 2017 and December 31, 2016, respectively.

Baxalta Collaboration

In September 2007, we and Baxalta entered into a collaboration and license agreement, under which Baxalta obtained a worldwide, exclusive license to develop and commercialize HYQVIA, a combination of Baxalta’s current product GAMMAGARD LIQUID^™ and our patented rHuPH20 enzyme (the “Baxalta Collaboration”). In 2013, the European Commission granted Baxalta marketing authorization in all EU Member States for the use of HYQVIA (solution for subcutaneous use), a combination of GAMMAGARD LIQUID and rHuPH20 in dual vial units, as replacement therapy for adult patients with primary and secondary immunodeficiencies, and Baxalta launched HYQVIA in the EU. In 2014, Baxalta launched HYQVIA in the U.S following the FDA’s approval of HYQVIA for treatment of adult patients with primary immunodeficiency. In May 2016, Baxalta announced that HYQVIA received a marketing authorization from the European Commission for a pediatric indication, which is being launched in Europe to treat primary and certain secondary immunodeficiencies.

The Baxalta Collaboration is applicable to both kit and formulation combinations. Baxalta assumes all development, manufacturing, clinical, regulatory, sales and marketing costs under the Baxalta Collaboration, while we are responsible for the supply of bulk rHuPH20. We perform research and development activities and supply bulk rHuPH20 at the request of Baxalta, and are reimbursed by Baxalta under the terms of the Baxalta Collaboration. In addition, Baxalta has certain product development and commercialization obligations in major markets identified in the Baxalta Collaboration.

Under the terms of the Baxalta Collaboration, Baxalta pays us a royalty consisting of a mid-single digit percent of the net sales of HYQVIA. Unless terminated earlier in accordance with its terms, the Baxalta Collaboration continues in effect until the expiration of Baxalta’s obligation to pay royalties to us. Baxalta has the obligation to pay royalties to us, with respect to each product commercialized in each country, during the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the Baxalta Collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term.

Payments received from Baxalta, excluding royalties and reimbursements for providing research and development services and supplying bulk rHuPH20, since inception of the collaboration agreement are as follows (in thousands):



	As of March 31, 2017
Upfront license fee payment for the application of rHuPH20 to the initial exclusive target	$	10,000
Regulatory milestone payments	3,000
Sales-based milestone payments	4,000
Total payments received	$	17,000

Due to our continuing involvement obligations (for example, support activities associated with rHuPH20 enzyme), the upfront license fee and sales-based milestone payments were deferred and are being recognized over the term of the Baxalta Collaboration.

For each of the three months ended March 31, 2017 and 2016, we recognized $0.2 million of Baxalta deferred revenues, excluding reimbursements for providing research and development services and supplying bulk rHuPH20, as revenues under collaborative agreements. Total Baxalta deferred revenues, excluding reimbursements for providing research and development services and supplying bulk rHuPH20, were $8.0 million and $8.2 million as of March 31, 2017 and December 31, 2016, respectively.

Other Collaborations

In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Lilly proprietary biologics directed at up to five targets (the “Lilly Collaboration”). Targets, once selected, will be on an exclusive, global basis, with the exception of one semi-exclusive target. As of March 31, 2017, Lilly has elected two specified exclusive targets and one specified semi-exclusive target. Lilly has the right to elect up to two additional targets for additional fees. The upfront license payment may be followed by event-based payments subject to Lilly’s achievement of specified development, regulatory and sales-based milestones. In addition, Lilly will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Lilly Collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Lilly Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. Lilly may terminate the agreement prior to expiration for any reason in its entirety upon 60 days prior written notice to us. Upon any such termination, the license granted to Lilly (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.

In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with AbbVie proprietary biologics directed at up to nine targets (the “AbbVie Collaboration”). Targets, once selected, will be on an exclusive, global basis. As of March 31, 2017, AbbVie has elected one specified exclusive target, and subsequently returned the target. AbbVie has the right to elect up to nine additional targets for additional fees. The upfront license payment may be followed by event-based payments subject to AbbVie’s achievement of specified development, regulatory and sales-based milestones. In addition, AbbVie will pay tiered royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the AbbVie Collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the AbbVie Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. AbbVie may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis upon 90 days prior written notice to us. Upon any such termination, the license granted to AbbVie (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.

In December 2014, we and Janssen entered into a collaboration and license agreement, under which Janssen has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Janssen proprietary biologics directed at up to five targets (the “Janssen Collaboration”). Targets, once selected, will be on an exclusive, global basis. As of March 31, 2017, Janssen has elected one specified exclusive target. Janssen has the right to elect four additional targets in the future upon payment of additional fees. In addition, Janssen will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Janssen Collaboration continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Janssen Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our

patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. Janssen may terminate the agreement prior to expiration for any reason in its entirety or on a product-by-product basis upon 90 days prior written notice to us. Upon any such termination, the license granted to Janssen (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.

In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Pfizer proprietary biologics directed at up to six targets (the “Pfizer Collaboration”). Targets may be selected on an exclusive or non-exclusive basis. As of March 31, 2017, Pfizer has elected five specified exclusive targets. In December 2016, Pfizer returned one of its elected targets. Pfizer has the right to elect two additional targets in the future upon payment of additional fees. In addition, Pfizer will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Pfizer Collaboration continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Pfizer Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. Royalties are subject to adjustment as set forth in the agreement. Pfizer may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis upon 30 days prior written notice to us. Upon any such termination, the license granted to Pfizer (in total or with respect to the terminated target, as applicable) will terminate, provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.

Payments received from other collaborators for upfront license fees, license fees for the election of additional targets, maintenance fees and event-based payments since inception of the collaboration agreements are as follows (in thousands):



	As of March 31, 2017
Lilly	$	33,000
AbbVie	29,000
Janssen	15,250
Pfizer	16,500
Total payments received	$	93,750

At the inception of the Pfizer, Janssen, AbbVie and Lilly arrangements, we identified the deliverables in each arrangement to include the license, research and development services and supply of bulk rHuPH20. We have determined that the license, research and development services and supply of bulk rHuPH20 individually represent separate units of accounting, because each deliverable has standalone value. We determined that the rights to elect additional targets in the future upon the payment of additional license fees are substantive options that are not priced at a significant and incremental discount. Therefore, we determined for each collaboration that the rights to elect additional targets are not deliverables at the inception of the arrangement. The estimated selling prices for the units of accounting we identified were determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous collaborative agreements, our pricing practices and pricing objectives. The arrangement consideration was allocated to the deliverables based on the relative selling price method and the nature of the research and development services to be performed for the collaborator.

The amount allocable to the delivered unit or units of accounting is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions (non-contingent amount). As such, we excluded from the allocable arrangement consideration the event-based payments, milestone payments, annual exclusivity fees and royalties

regardless of the probability of receipt. Based on the results of our analysis, we allocated the $12.5 million license fees from Pfizer, the $15.3 million license fee from Janssen, the $23.0 million upfront license fee from AbbVie and the $33.0 million license fees from Lilly to the license fee deliverable under each of the arrangements. We determined that the upfront payments were earned upon the granting of the worldwide, exclusive right to our technology to the collaborators in these arrangements. As a result, we recognized the $12.5 million license fees under the Pfizer Collaboration, the $15.3 million license fee under the Janssen Collaboration, the $23.0 million upfront license fee under the AbbVie Collaboration, and the $33.0 million license fees under the Lilly Collaboration as revenues under collaborative agreements in the period when such license fees were earned. We recognized no revenue for the three months ended March 31, 2017 and $6.0 million for the three months ended March 31, 2016 related to event-based payments or milestone payments under these collaborations.

The collaborators are each solely responsible for the development, manufacturing and marketing of any products resulting from their respective collaborations. We are entitled to receive payments for research and development services and supply of bulk rHuPH20 if requested by any collaborator. We recognize amounts allocated to research and development services as revenues under collaborative agreements as the related services are performed. We recognize amounts allocated to the sales of bulk rHuPH20 as revenues under collaborative agreements or product sales, as appropriate, when such bulk rHuPH20 has met all required specifications by the collaborators and the related title and risk of loss and damages have passed to the collaborators. We cannot predict the timing of delivery of research and development services and bulk rHuPH20 as they are at the collaborators’ requests.

Pursuant to the terms of our collaboration agreements with Roche and Pfizer, certain future payments meet the definition of a milestone in accordance with the Milestone Method of Accounting. We are entitled to receive additional milestone payments under our collaboration agreements with Roche and Pfizer for the successful development of the elected targets in the aggregate of up to $62.5 million upon achievement of specified clinical development milestone events and up to $12.0 million upon achievement of specified regulatory milestone events in connection with specified regulatory filings and receipt of marketing approvals.

5. Certain Balance Sheet Items

Accounts receivable, net consisted of the following (in thousands):



	March 31, 2017			December 31, 2016
Accounts receivable from product sales to collaborators	$	8,023		$	7,854
Accounts receivable from other product sales	2,090			2,234
Accounts receivable from revenues under collaborative agreements	2,921			6,151
Subtotal	13,034			16,239
Allowance for distribution fees and discounts	(582		)	(559		)
Total accounts receivable, net	$	12,452		$	15,680

Inventories consisted of the following (in thousands):



	March 31, 2017		December 31, 2016
Raw materials	$	868	$	761
Work-in-process	12,885		12,850
Finished goods	537		1,012
Total inventories	$	14,290	$	14,623

Prepaid expenses and other assets consisted of the following (in thousands):



	March 31, 2017		December 31, 2016
Prepaid manufacturing expenses	$	6,327	$	9,663
Prepaid research and development expenses	8,345		8,613
Other prepaid expenses	1,525		1,661
Other assets	602		1,530
Total prepaid expenses and other assets	16,799		21,467
Less long-term portion	172		219
Total prepaid expenses and other assets, current	$	16,627	$	21,248

Prepaid manufacturing expenses include slot reservation fees and other amounts paid to contract manufacturing organizations. Such amounts are reclassified to work-in-process inventory once the manufacturing process has commenced.

Property and equipment, net consisted of the following (in thousands):



	March 31, 2017			December 31, 2016
Research equipment	$	10,483		$	10,479
Computer and office equipment	3,395			3,373
Leasehold improvements	2,345			2,331
Subtotal	16,223			16,183
Accumulated depreciation and amortization	(12,482		)	(11,919		)
Property and equipment, net	$	3,741		$	4,264

Depreciation and amortization expense totaled $0.6 million and $0.5 million for the three months ended March 31, 2017 and 2016, respectively.

Accrued expenses consisted of the following (in thousands):



	March 31, 2017		December 31, 2016
Accrued outsourced research and development expenses	$	11,970	$	9,522
Accrued compensation and payroll taxes	5,045		11,539
Accrued outsourced manufacturing expenses	3,670		3,225
Other accrued expenses	4,276		4,552
Total accrued expenses	24,961		28,838
Less long-term portion	26		17
Total accrued expenses, current	$	24,935	$	28,821

Deferred revenue consisted of the following (in thousands):



	March 31, 2017		December 31, 2016
Collaborative agreements
License fees and event-based payments:
Roche	$	34,877	$	35,709
Other	8,018		8,209
	42,895		43,918
Reimbursement for research and development services	—		700
Total deferred revenue	42,895		44,618
Less current portion	4,093		4,793
Deferred revenue, net of current portion	$	38,802	$	39,825

6. Long-Term Debt, Net

Royalty-backed Loan

In January 2016, through our wholly-owned subsidiary Halozyme Royalty LLC (“Halozyme Royalty”), we received a $150 million loan (the “Royalty-backed Loan”) pursuant to a credit agreement (the “Credit Agreement”) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the “Royalty-backed Lenders”). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (“Collaboration Agreements”). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the “Royalty Payments”). The Royalty-backed Loan bears interest at a per annum rate of 8.75% plus the three-month LIBOR rate. The three-month LIBOR rate is subject to a floor of 0.7% and a cap of 1.5%. The interest rate as of March 31, 2017 was 9.9%.

The Credit Agreement provides that none of the Royalty Payments were required to be applied to the Royalty-backed Loan prior to January 1, 2017, 50% of the Royalty Payments are required to be applied to the Royalty-backed Loan between January 1, 2017 and January 1, 2018 and thereafter all Royalty Payments must be applied to the Royalty-backed Loan. However, the amounts available to repay the Royalty-backed Loan are subject to caps of $13.75 million per quarter in 2017, $18.75 million per quarter in 2018, $21.25 million per quarter in 2019 and $22.5 million per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first to pay interest and second to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date. Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps.

Because the repayment of the term loan is contingent upon the level of Royalty Payments received, the repayment term may be shortened or extended depending on the actual level of Royalty Payments. The final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050. Currently, we estimate that the loan will be repaid in the first quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January 1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to 105% of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan.

As of March 31, 2017, we were in compliance with all covenants under the Royalty-backed Loan and there was no material adverse change in our business, operations or financial condition.

During the three months ended March 31, 2016, accrued interest in the amount of $1.9 million was capitalized and added to the principal balance of the Royalty-backed Loan. We began making principal and interest payments against the Royalty-backed Loan in the first quarter of 2017 and therefore had no capitalized interest in the three months ended March 31, 2017. In addition, we recorded accrued interest, which is included in accrued expenses, of $0.7 million as of March 31, 2017 and December 31, 2016.

In connection with the Royalty-backed Loan, we paid the Royalty-backed Lenders a fee of $1.5 million and incurred additional debt issuance costs totaling $0.4 million, which includes expenses that we paid on behalf of the Royalty-backed Lenders and expenses incurred directly by us. Debt issuance costs and the lender fee have been netted against the debt as of March 31, 2017, and are being amortized over the estimated term of the debt using the effective interest method. For the three months ended March 31, 2017 and 2016, the Company recognized interest expense, including amortization of the debt discount, related to the Royalty-backed Loan of $4.0 million and $2.6 million, respectively. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. The outstanding balance of the Royalty-backed Loan as of March 31, 2017 was $158.9 million, inclusive of payment-in-kind interest expense of $10.2 million and net of unamortized debt discount of $1.3 million.

Oxford and SVB Loan and Security Agreement

In December 2013, we entered into an Amended and Restated Loan and Security Agreement (the “Original Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”) (collectively, the “Lenders”), amending and restating in its entirety our previous loan agreement with the Lenders, dated December 2012. The Original Loan Agreement provided for an additional $20 million principal amount of new term loan, bringing the total term loan balance to $50 million. The amended term loan facility was scheduled to mature on January 1, 2018.

In January 2015, we entered into the second amendment to the Original Loan Agreement with the Lenders, amending and restating the term loan repayment schedules of the Original Loan Agreement. The amended and restated term loan repayment schedule provided for interest only payments through January 2016, followed by consecutive equal monthly payments of principal and interest in arrears starting in February 2016 and continuing through the previously established maturity date of January 1, 2018. Consistent with the original loan, the amended Original Loan Agreement provided for a 7.55% interest rate on the term loan and a final payment equal to 8.5% of the original principal amount, or $4.25 million, which was due when the term loan became due or upon the prepayment of the facility.

In June 2016, we entered into a Loan and Security Agreement (the “Loan Agreement”) with the Lenders, providing a senior secured loan facility of up to an aggregate principal amount of $70.0 million, comprising a $55.0 million draw in June 2016 and an additional $15.0 million tranche, which we have the option to draw during the second quarter of 2017. The initial proceeds carry an interest rate of 8.25% and were partially used to pay the outstanding principal and final payment of $4.25 million owed on the previous loan agreement with the Lenders. The remaining proceeds, including any drawdown of the additional $15.0 million, are to be used for working capital and general business requirements. The remaining $15.0 million tranche is subject to an annual interest rate equal to the prime rate as reported in The Wall Street Journal on the draw-down date plus 4.75%. The repayment schedule provides for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of January 1, 2021. The Loan Agreement provides for a final payment equal to 5.50% of the initial $55.0 million principal amount and, if we exercise our option to draw an additional $15.0 million in 2017, 7.25% of the principal amount of the second draw. The final payment is due when the Loan Agreement becomes due or upon the prepayment of the facility. We have the option to prepay the outstanding balance of the Loan Agreement in full, subject to a prepayment fee of 2% in the first year and 1% in the second year of the Loan Agreement.

In connection with the Loan Agreement, the debt offering costs have been recorded as a debt discount in our condensed consolidated balance sheets which, together with the final payment and fixed interest rate payments, are being amortized and recorded as interest expense throughout the life of the loan using the effective interest rate method.

The Loan Agreement is secured by substantially all of the assets of the Company and our subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc., any of our intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same; and make any voluntary prepayment of or modify certain terms of the Royalty-backed Loan. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our subsidiary, Halozyme, Inc.

The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, a material impairment in the perfection or priority of the Lender’s lien in the collateral or in the value of such collateral or the occurrence of an event of default under the Royalty-backed Loan. In the event of default by us under the Loan Agreement, the Lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Loan Agreement, which could harm our financial condition.

As of March 31, 2017, we were in compliance with all covenants under the Loan Agreement and there was no material adverse change in our business, operations or financial condition.

Interest expense, including amortization of the debt discount, related to the Loan Agreement totaled $1.4 million and $1.3 million for the three months ended March 31, 2017 and 2016, respectively. Accrued interest, which is included in accrued expenses, was $0.4 million and $1.1 million as of March 31, 2017 and December 31, 2016, respectively. The outstanding term loan balance was $55.1 million as of March 31, 2017, inclusive of $0.1 million of accretion of the final payment and net of unamortized debt discount of $2.9 million.

7. Share-based Compensation

Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):



	Three Months Ended March 31,
	2017		2016
Research and development	$	3,274	$	2,584
Selling, general and administrative	4,041		3,233
Share-based compensation expense	$	7,315	$	5,817

Share-based compensation expense by type of share-based award (in thousands):



	Three Months Ended March 31,
	2017		2016
Stock options	$	4,749	$	3,708
RSAs, RSUs and PRSUs	2,566		2,109
	$	7,315	$	5,817

We granted stock options to purchase approximately 2.2 million and 2.8 million shares of common stock during the three months ended March 31, 2017 and 2016, respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (“Black-Scholes model”). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes model were as follows:



	Three Months Ended March 31,
	2017	2016
Expected volatility	71.0-71.7%	67.5-69.1%
Average expected term (in years)	5.6	5.4
Risk-free interest rate	1.92-1.94%	1.27-1.73%
Expected dividend yield	—	—

Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):



	March 31, 2017
	Unrecognized Expense		Remaining Weighted-Average Recognition Period (years)
Stock options	$	53,470	2.9
RSAs	$	7,281	2.1
RSUs	$	22,742	3.3

8. Stockholders’ Deficit

During the three months ended March 31, 2017 and 2016, we issued an aggregate of 74,522 and 156,185 shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $7.78 and $6.22 per share, respectively, for net proceeds of approximately $0.6 million and $1.0 million, respectively. For the three months ended March 31, 2017 and 2016, we issued 252,305 and 106,389 shares of common stock, respectively, upon vesting of certain RSUs for which the RSU holders surrendered 79,499 and 70,288 RSUs, respectively, to pay for minimum withholding taxes totaling approximately $1.7 million and $0.7 million, respectively. In addition, we issued zero and 807,036 shares of common stock in connection with the grants of RSAs during the three months ended March 31, 2017 and 2016, respectively. Stock options and unvested restricted units totaling approximately 15.5 million shares and 12.5 million shares of our common stock were outstanding as of March 31, 2017 and December 31, 2016, respectively.

9. Commitments and Contingencies

From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.


Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations

As used in this report, unless the context suggests otherwise, references to “Halozyme,” “the Company,” “we,” “our,” “ours,” and “us” refer to Halozyme Therapeutics, Inc., its wholly owned subsidiary, Halozyme, Inc. and Halozyme Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC and Halozyme Switzerland GmbH. References to “Notes” refer to the Notes to Condensed Consolidated Financial Statements included herein (refer to Item 1 of Part I).

The following information should be read in conjunction with the interim unaudited condensed consolidated financial statements and Notes thereto included in Item 1 of this Quarterly Report on Form 10-Q, as well as the audited financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the fiscal year ended December 31, 2016, included in our Annual Report on Form 10-K for the year ended December 31, 2016. Past financial or operating performance is not necessarily a reliable indicator of future performance, and our historical performance should not be used to anticipate results or future period trends.

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this report other than statements of historical fact are, or may be deemed to be, forward-looking statements. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “think,” “may,” “could,” “will,” “would,” “should,” “continue,” “potential,” “likely,” “opportunity,” “project” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this report. Additionally, statements concerning future matters such as the anticipated timing and scope of planned clinical trials, the development or regulatory approval of new products, enhancements of existing products or technologies, timing and success of the launch of new products by us or by our collaborators, third party performance under key collaboration agreements, revenue, expense and cash burn levels, expected repayment of the Royalty-backed Loan and trends and other statements regarding matters that are not historical are forward-looking statements. Such statements reflect management’s current forecast of certain aspects of our future, are based on currently available operating, financial and competitive information and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially from those anticipated or implied in our forward-looking statements due to a number of factors including, but not limited to, those set forth below under the section entitled “Risks Factors” and elsewhere in this Quarterly Report on Form 10-Q and our most recent Annual Report on Form 10-K. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report.

Overview

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators’ proprietary compounds.

The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. Our proprietary development pipeline consists primarily of pre-clinical and clinical stage product candidates in oncology. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. Through our efforts and efforts of our partners and collaborators, we are currently in Phase 3 clinical testing for PEGPH20 with ABRAXANE® (nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (PDA) (Study 109-301), in Phase 1b clinical testing for PEGPH20 with KEYTRUDA® (pembrolizumab) in non-small cell lung cancer and gastric cancer (Study 107-101) and in Phase 1b/2 clinical testing for PEGPH20 with HALAVEN® (eribulin) in patients treated with up to two lines of prior therapy for HER2-negative metastatic breast cancer.

We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE™ Technology. We license the ENHANZE Technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (Baxalta), Pfizer Inc. (Pfizer), Janssen Biotech, Inc. (Janssen), AbbVie, Inc. (AbbVie), and Eli Lilly and Company (Lilly). We receive royalties from two of these collaborations, including royalties from sales of one product approved in both the United States and outside the United States from the Baxalta collaboration and from sales of two products approved for marketing outside the United States from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.

Our first quarter of 2017 and recent highlights include:

•

As announced in March 2017, SWOG, an independent network of researchers that design and conduct cancer clinical trials, stopped enrollment in a Phase 1b/2 trial evaluating PEGPH20 plus modified FOLFIRINOX chemotherapy versus modified FOLFIRINOX alone in patients with previously untreated metastatic pancreas cancer. PEGPH20 is a targeted investigational therapy for patients with high levels of HA. The SWOG study, which was initiated in October 2013, was enrolling patients irrespective of HA levels, referred to as an all-comer population. During a planned early futility analysis, SWOG’s independent Data Monitoring Committee found, based on preliminary data, that the addition of PEGPH20 given every two weeks to modified FOLFIRINOX in this all-comer population would be unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival. SWOG further reported that a higher rate of death was observed in the PEGPH20 arm versus modified FOLFIRINOX alone. SWOG has stopped the study and continues its ongoing effort to collect and clean outstanding data. Upon completion, we will work with SWOG to analyze and evaluate the dataset. Our PEGPH20 studies and clinical collaborations in combination with agents other than modified FOLFIRINOX continue unchanged.

•

In April 2017, we presented at the annual meeting of the American Association of Cancer Research (AACR) that, in preclinical models, PEGPH20 increases the number of cancer-fighting white blood cells accumulating in the tumor and the effectiveness of immunotherapies, which builds upon prior preclinical findings and continues to support the potential benefits of remodeling the tumor microenvironment.

•

In March 2017, an Oncologic Drug Advisory Committee of the FDA voted 11 to 0 that the benefit/risk of rituximab SC was favorable for patients in the proposed indications in follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia. The FDA action date is June 26, 2017. Efficacy, safety, pharmacokinetic and patient-reported outcome data from five clinical studies presented by Genentech, a member of the Roche Group, at the advisory committee meeting supported the rituximab SC application. This is a co-formulation with rHuPH20, which is approved and marketed under the MabThera SC brand in countries outside the U.S.

•

In January 2017, we announced topline results from the combined analysis of Stage 1 and Stage 2, and Stage 2 alone, of the Study 109-202, based on a December 2016 data cutoff. Among the findings, the overall study population showed a statistically significant increase in progression-free survival (PFS) in the 84 total HA-High patients treated with PEGPH20 plus ABRAXANE and gemcitabine when compared to HA-High patients receiving ABRAXANE and gemcitabine alone. Stage 2 of the study, which completed enrollment in February 2016, showed a 91 percent improvement in median PFS for HA-High patients in the PEGPH20 arm, 8.6 months compared to 4.5 months in the control arm, and achieved its primary endpoint to evaluate and demonstrate a reduction in the rate of TE events in the PEGPH20 arm.

Product and Product Candidates

We have one marketed proprietary product, three partnered products, one proprietary product candidate targeting several indications in various stages of development, and two preclinical product candidates. The following table summarizes our proprietary product and product candidate as well as products and product candidates under development with our collaborators:

Proprietary Pipeline

Hylenex Recombinant (hyaluronidase human injection)

Hylenex recombinant is a formulation of rHuPH20 that has received U.S. Food and Drug Administration (FDA) approval to facilitate subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Hylenex recombinant is currently the number one prescribed branded hyaluronidase.

PEGPH20

We are developing PEGPH20 in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. ‘PEG’ refers to the attachment of polyethylene glycol to rHuPH20, thereby creating PEGPH20. One of the novel properties of PEGPH20 is that it lasts for an extended duration in the bloodstream and, therefore, can be administered systemically to maintain its therapeutic effect to treat disease.

Cancer malignancies, including pancreatic, lung, breast, gastric, colon and prostate cancers can accumulate high levels of HA and therefore we believe that PEGPH20 has the potential to help patients with these types of cancer when used with certain currently approved cancer therapies. Among solid tumors, PDA has been reported to be associated with the highest frequency of HA accumulation. There are approximately 65,000 annual diagnoses of PDA in the United States and the European Union, and we estimate that 35-40% have high levels of HA.

The pathologic accumulation of HA, along with other matrix components, creates a unique microenvironment for the growth of tumor cells compared to normal cells. We believe that depleting the HA component of the tumor microenvironment with PEGPH20 remodels the tumor microenvironment, resulting in tumor growth inhibition in animal models. Removal of HA from the tumor microenvironment results in expansion of previously constricted blood vessels allowing increased blood flow, potentially increasing the access of activated immune cells and factors in the blood into the tumor microenvironment. If PEGPH20 is administered in conjunction with other anti-cancer therapies, the increase in blood flow may allow anti-cancer therapies to have greater access to the tumor, which may enhance the treatment effect of therapeutic modalities like chemotherapies, monoclonal antibodies and other agents.

We are developing PEGPH20 as a targeted therapy, for patients who have tumors with high levels of HA. We have a collaboration with Ventana Medical Systems Inc. (Ventana), a member of the Roche Group, to develop, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with PEGPH20. The companion diagnostic assay is being used to identify high levels of HA in tumor biopsies, and may be the first diagnostic to target tumor-associated HA and possibly the first companion diagnostic assay in pancreatic cancer.

Pancreatic cancer indications:

Study Halo 109-201:

In January 2015, we presented the final results from Study 109-201, a multi-center, international open label dose escalation Phase 1b clinical study of PEGPH20 in combination with gemcitabine for the treatment of patients with stage IV PDA at the 2015 Gastrointestinal Cancers Symposium (also known as ASCO-GI meeting). This study enrolled 28 patients with previously untreated stage IV PDA. Patients were treated with one of three doses of PEGPH20 (1.0, 1.6 and 3.0 µg/kg twice weekly for four weeks, then weekly thereafter) in combination with gemcitabine 1000 mg/m2 administered intravenously. In this study, the confirmed overall response rate (complete response + partial response confirmed on a second scan as assessed by an independent radiology review) was 29 percent (7 of 24 patients) for those treated at therapeutic dose levels of PEGPH20 (1.6 and 3.0 µg/kg). Median progression-free survival (PFS) was 154 days (95% CI, 50-166) in the efficacy-evaluable population (n = 24). Among efficacy-evaluable patients with baseline tumor HA staining (n = 17), the median PFS in patients with high baseline tumor HA staining (6/17 patients) was substantially longer, 219 days, than in the patients with low baseline tumor HA staining (11/17 patients), 108 days. Median overall survival (OS) was 200 days (95% CI, 123-370) in the efficacy-evaluable population (n = 24). Among efficacy-evaluable patients with baseline tumor HA staining (n = 17), the median OS in patients with high baseline tumor HA staining (6/17 patients) was substantially longer, 395 days, than in the patients with low baseline tumor HA staining (11/17 patients), 174 days. The most common treatment-emergent adverse events (occurring in ≥ 15% of patients) were peripheral edema, muscle spasms, thrombocytopenia, fatigue, myalgia, anemia, and nausea. Thromboembolic (TE) events were reported in 8 patients (28.6%) and musculoskeletal events were reported in 21 patients (75%) which were generally grade 1/2 in severity.

Study Halo 109-202:

In the second quarter of 2013, we initiated Study 109-202, a Phase 2 multicenter randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV PDA. The study was designed to enroll patients who would receive gemcitabine and nab-paclitaxel (ABRAXANE®) either with or without PEGPH20. The primary endpoint is to measure the improvement in PFS in patients receiving PEGPH20 plus gemcitabine and ABRAXANE (PAG arm) compared to those who are receiving gemcitabine and ABRAXANE alone (AG arm). In April 2014, after 146 patients had been enrolled, the trial was put on clinical hold by Halozyme and the FDA to assess a question raised by the Data Monitoring Committee regarding a possible difference in the TE events rate between the group of patients treated in the PAG arm versus the group of patients treated in the AG arm. This portion of the study and patients in this portion are now referred to as Stage 1. At the time of the clinical hold all patients remaining in the study continued on gemcitabine and ABRAXANE. In July 2014, Study 109-202 was reinitiated (Stage 2) under a revised protocol, which excludes patients that are expected to be at a greater risk for TE events. The revised protocol provides for thromboembolism prophylaxis of all patients in both arms of the study with low molecular weight heparin, and adds evaluation of the TE events rate in Stage 2 PEGPH20-treated patients as a co-primary end point. Stage 2 of Study 109-202 enrolled an additional 133 patients, to add to the 146 patients already in the clinical trial, with a 2:1 randomization for the PAG arm compared to the AG arm.

In March 2016, our partner Ventana received approval for an investigational device exemption (IDE) application from the FDA for our companion diagnostic test to enable patient selection in our Phase 3 Study 301 of PEGPH20 in HA-High patients. Based on the cutpoint for the Ventana diagnostic, we expect approximately 35 to 40 percent of stage IV PDA patients to have HA-High tumors, similar to the previously reported interim results from Stage 1 of Study 202 using the Halozyme prototype assay.

In January 2017, we announced topline results from the combined analysis of Stage 1 and Stage 2, and Stage 2 alone, based on a December 2016 data cutoff. The combined analysis included 135 treated patients in Stage 1, of whom a total of 45 patients (25 in the PAG arm and 21 in the AG arm) were determined to have high HA, and 125 treated patients in Stage 2, of whom a total of 35 patients (24 in the PAG arm and 11 in the AG arm) were determined to have high HA. This analysis of secondary and exploratory endpoints was conducted using the Ventana companion diagnostic to prospectively identify high levels of HA. The key results showed in the combined Stage 1 and Stage 2 dataset:


•	The primary endpoint of PFS in the efficacy evaluable population (total of 231 patients) was met with statistical significance with a median PFS of 6.0 months in the PAG arm compared to 5.3 months in the AG arm, hazard ratio (HR) with a 95% confidence interval (CI): 0.73 (0.53, 1.00); p=0.048;


•	The secondary endpoint of PFS in the HA-High intent to treat population (total of 84 HA-High patients) was met with statistical significance with a median PFS of 9.2 months in the PAG arm compared to 5.2 months in the AG arm, HR 0.51 (95% CI: 0.26, 1.00); p=0.048;

•

The exploratory analysis of median OS was 11.5 months vs. 8.5 months in the PAG vs. AG arms, respectively. Factors potentially having an impact on these results include less aggressive disease among patients in the AG arm within the Stage 1 patient population, and 9 of the 24 patients in the PAG arm (approximately 40 percent) discontinued PEGPH20 treatment at the time of the clinical hold, resulting in many patients receiving AG alone in both arms.

In the Stage 2 cohort population, in a total of 35 HA-High patients, the key results showed:


•	Median PFS was 8.6 months in the PAG arm compared to 4.5 months in the AG arm, hazard ratio of 0.63 (95% CI: 0.21, 1.93);


•	Median overall survival (OS) was 11.7 months in the PAG arm compared to 7.8 months in the AG arm, hazard ratio of 0.52 (95% CI: 0.22, 1.23);

•

The primary safety endpoint of decreasing the rate of TE events in Stage 2 was also met with the rate of TE events reducing from 43 percent to 10 percent in the PAG arm and from 25 percent to 6 percent in the AG arm, following a protocol amendment that excluded patients at high risk of TE events and with the introduction of prophylaxis with low molecular weight heparin (enoxaparin) in Stage 2 of the study with the current 1mg/kg/day dose of enoxaparin prophylaxis given in both treatment arms of the study.

Study 202 is an ongoing study with an open database and therefore we continue to collect and receive data on both Stage 1 and Stage 2 patients. When the database is considered complete and locked, an updated analysis and Final Study Report will be generated.

Study Halo 109-301:

In March 2015, we met with the FDA to discuss both the interim efficacy and safety data from Study 109-202, which included the potential risk profile including TE event rate. Based on the feedback from that meeting, we proceeded with a Phase 3 clinical study (Study 109-301) of PEGPH20 in patients with stage IV PDA, using a design allowing for potential marketing application based on either PFS or OS. The study will enroll patients whose tumors accumulate high levels of HA measured using the Ventana companion diagnostic test. The FDA provided feedback on the current companion diagnostic approach and confirmed that an approved IDE is required for the Phase 3 study.

The use of PFS as the basis for marketing approval will be subject to the overall benefit and risk associated with PEGPH20 combined with gemcitabine and ABRAXANE therapy, including the:


•	Magnitude of the PFS treatment effect observed;


•	Toxicity profile; and


•	Interim OS data.

In June 2015, we received scientific advice/protocol assistance from the European Medicines Agency (EMA) regarding our Phase 3 study. The EMA agreed to the patient population, and the use of both PFS and OS as co-primary endpoints stating that OS is the preferred endpoint and that ultimate approval would require an overall positive benefit:risk balance.

In March 2016, we dosed the first patient in Study 109-301, a Phase 3 multicenter randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV PDA. The study will evaluate the effects on PFS and OS of PEGPH20 with gemcitabine and ABRAXANE compared with gemcitabine and ABRAXANE alone in stage IV PDA patients. As of March 2017, approximately 200 sites in 22 countries located in North America, Europe, South America and Asia Pacific have been initiated to participate in the HALO 301 study. Our Data Safety Monitoring Committee recently met to review ongoing safety data from the trial and informed us the study should proceed as planned.

SWOG Study S1313:

In October 2013, SWOG, a cancer research cooperative group of more than 4,000 researchers in over 500 institutions around the world, initiated a 144 patient Phase 1b/2 randomized clinical trial in some of their study centers, examining PEGPH20 in combination with modified FOLFIRINOX chemotherapy compared to modified FOLFIRINOX treatment alone in patients with stage IV PDA (funded by the National Cancer Institute). As announced in March 2017, SWOG stopped enrollment in the Phase 1b/2 trial. While PEGPH20 is a targeted investigational therapy for patients with high levels of HA, the SWOG study was enrolling patients irrespective of HA levels, referred to as an all-comer population. During a planned early futility analysis, SWOG’s independent Data Monitoring Committee found, based on preliminary data, that the addition of PEGPH20 given every two weeks to modified FOLFIRINOX in this all-comer population would be unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival. SWOG further reported that a higher rate of death was observed in the PEGPH20 arm versus modified FOLFIRINOX alone. SWOG has stopped the study and continues its ongoing effort to collect and clean outstanding data. Upon completion, we will work with SWOG to analyze and evaluate the dataset. Our PEGPH20 studies and clinical collaborations in combination with agents other than modified FOLFIRINOX continue unchanged.

Clinical collaboration:

In October 2016, we announced that PEGPH20 will be included in a pancreatic cancer clinical trial initiative called Precision Promise, an initiative that aims to change the current treatment approach to pancreatic cancer by offering options to patients based on the molecular profile of their tumor. This is being accomplished through the Pancreatic Cancer Action Network leading a collaboration that brings together clinicians, researchers, and drug developers. Pancreatic Cancer Action Network continues to work to finalize the trial design and protocol with expected start date now in the fourth quarter of 2017.

Other indications outside of pancreatic cancer:

Study HALO 107-101:

In November 2015, we initiated a Phase 1b study exploring the combination of PEGPH20 and KEYTRUDA®, an immuno-oncology agent in relapsed non-small cell lung cancer (NSCLC) and gastric cancer. In December 2016, we identified a dose of PEGPH20, namely 2.2 ug/kg, to move into the dose expansion phase of the study with KEYTRUDA in combination with PEGPH20. We are now enrolling both NSCLC and gastric cancer patients prospectively based on a patient being determined to be HA-High using the Ventana companion diagnostic test.

Clinical collaborations:

In July 2015, we entered into a clinical collaboration agreement with Eisai Co., Ltd.. (Eisai) to evaluate Eisai's HALAVEN® (eribulin) with PEGPH20 in HER2-negative metastatic breast cancer. In July 2016, the first patient was dosed in a Phase 1b/2 study for patients treated with up to two lines of prior therapy for HER2-negative HA-High metastatic breast cancer. Halozyme and Eisai are jointly sharing the costs to conduct this global study which remains in dose escalation.

In November 2016, we entered into an agreement with Genentech, a member of the Roche Group, to collaborate on clinical studies evaluating up to eight different tumor types, which we expect will begin in the second half of 2017. The first study will be a Phase 1b/2 open-label, multi-arm randomized global study, led by Genentech to evaluate their cancer immunotherapy Tecentriq® (atezolizumab), an anti-PD-L1 monoclonal antibody, in combination with PEGPH20 in up to six tumor types. Halozyme will supply PEGPH20 for the Genentech study, which will have an initial focus on gastrointestinal malignancies, including pancreatic and gastric cancers. The second study will be a Phase 1b open-label randomized study led by Halozyme to assess Tecentriq in combination with PEGPH20 and chemotherapy in advanced or metastatic biliary and gall bladder cancers. Genentech will supply Tecentriq for the Halozyme study.

Regulatory

The FDA has granted Fast Track designation for our program investigating PEGPH20 in combination with gemcitabine and nab-paclitaxel for the treatment of patients with stage IV PDA to demonstrate an improvement in OS. The Fast Track designation process was developed by the FDA to facilitate the development and expedite the review of drugs to treat serious or life-threatening diseases and address unmet medical needs.

The FDA has granted Orphan Drug designation for PEGPH20 for the treatment of pancreatic cancer. The FDA Office of Orphan Products Development’s mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. Similarly, the European Committee for Orphan Medicinal Products of the EMA designated PEGPH20 an orphan medicinal product for the treatment of pancreatic cancer.

Other Pipeline Assets

HTI-1511: HTI-1511 is a novel antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) to treat solid tumors, including those with drug-resistant mutations. We are in preclinical development with a lead candidate selected. In May 2017 we decided to explore potential collaboration or partnership interest in this program prior to making the additional investments in toxicity studies and manufacturing that would be required to support an investigational new drug (IND) filing.

PEG-ADA2: PEGylated adenosine deaminase 2, or PEG-ADA2, is an immune checkpoint inhibitor that targets adenosine, which may accumulate to high levels in the tumor microenvironment and has been linked to immunosuppression. We are currently in preclinical development with PEG-ADA2, with the next milestone expected to be final drug candidate selection to determine its suitability for continued evaluation as a targeted therapy for clinical development.

ENHANZE Collaborations

Roche Collaboration

In December 2006, we and Roche entered into a collaboration and license agreement under which Roche obtained a worldwide, license to develop and commercialize product combinations of rHuPH20 and up to thirteen Roche target compounds (the Roche Collaboration). Roche initially had the exclusive right to apply rHuPH20 to three pre-defined Roche biologic targets with the option to develop and commercialize rHuPH20 with ten additional targets. Roche had the right to exercise this option to identify additional targets for ten years. As of the ten year anniversary of the Roche Collaboration in December 2016, Roche had elected a total of eight targets, two of which are exclusive.

In September 2013, Roche launched a subcutaneous (SC) formulation of Herceptin (trastuzumab) (Herceptin SC) in Europe for the treatment of patients with HER2-positive breast cancer. This formulation utilizes our patented ENHANZE Technology and is administered in two to five minutes, compared to 30 to 90 minutes with the standard intravenous form. Roche received European marketing approval for Herceptin SC in August 2013. Breast cancer is the most common cancer among women worldwide. HER2-positive cancer is reported to be a particularly aggressive form of breast cancer. Directed at the same target, Roche initiated a Phase 1 study of rHuPH20 with PERJETA® (pertuzumab) in patients with early breast cancer in March 2016.

In June 2014, Roche launched MabThera SC in Europe for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL). This formulation utilizes our patented ENHANZE Technology and is administered in approximately five minutes

compared to the approximately 1.5 to 4 hour infusion time for intravenous MabThera. The European Commission approved MabThera SC in March 2014. In May 2016, Roche announced that the EMA approved Mabthera SC to treat patients with chronic lymphocytic leukemia (CLL).

In November 2016, the FDA accepted Genentech’s (a member of the Roche Group) Biologic License Application (BLA) for a subcutaneous formulation of rituximab for CLL and NHL. This is a co-formulation with rHuPH20, which is approved and marketed under the MabThera SC brand in countries outside the U.S. In March 2017, an Oncologic Drug Advisory Committee of the FDA voted 11 to 0 that the benefit/risk of rituximab SC was favorable for patients in the proposed indications in CLL and two types of NHL, follicular lymphoma and diffuse large B-cell lymphoma. The FDA action date is June 26, 2017.

Baxalta Collaboration

In September 2007, we and Baxalta entered into a collaboration and license agreement under which Baxalta obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 with GAMMAGARD LIQUID (HYQVIA) (the Baxalta Collaboration). HYQVIA is indicated for the treatment of primary immunodeficiency disorders associated with defects in the immune system.

In May 2013, the European Commission granted Baxalta marketing authorization in all EU Member States for the use of HYQVIA (solution for subcutaneous use) as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxalta launched HYQVIA in the first EU country in July 2013 and has continued to launch in additional countries.

In September 2014, HYQVIA was approved by the FDA for treatment of adult patients with primary immunodeficiency in the U.S. HYQVIA is the first subcutaneous immune globulin (IG) treatment approved for adult primary immunodeficiency patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion in most patients, to deliver a full therapeutic dose of IG. Prior to the approval of HYQVIA, the majority of primary immunodeficiency patients received intravenous infusions in a doctor’s office or infusion center, and other subcutaneous IG treatments require weekly or bi-weekly treatment with multiple infusion sites per treatment. The FDA’s approval of HYQVIA was a significant milestone for us as it represented the first U.S. approved BLA which utilizes our rHuPH20 platform.

In May 2016, Baxalta announced that HYQVIA received a marketing authorization from the European Commission for a pediatric indication, which is being launched in Europe to treat primary and certain secondary immunodeficiencies.

Pfizer Collaboration

Janssen Collaboration

AbbVie Collaboration

Lilly Collaboration

For a further discussion of the material terms of our collaboration agreements, refer to Note 4, Collaborative Agreements, to our condensed consolidated financial statements.

Results of Operations

Three Months Ended March 31, 2017 Compared to Three Months Ended March 31, 2016

Product Sales, Net – Product sales, net were as follows (in thousands):



	Three Months Ended
	March 31,
	2017		2016		Change
Sales of bulk rHuPH20:
Roche	$	5,268	$	6,357	$	(1,089	)
Baxalta	2,716		2,327		389
Other	245		386		(141		)
Sales of Hylenex	3,205		3,870		(665		)
Total product sales, net	$	11,434	$	12,940	$	(1,506	)

Product sales, net decreased in the three months ended March 31, 2017 compared to the same period in 2016, due to a decrease in the sales of bulk rHuPH20 to Roche and a decrease in the sales of Hylenex. We expect that product sales of bulk rHuPH20 will fluctuate in future periods based on the needs of our collaborators. In 2016, we performed services for Roche to bring on-line a second contract manufacturing facility for bulk rHuPH20. Once this new facility is approved, it will become the primary source for Roche of bulk rHuPH20. As a result, we anticipate Roche will deplete their existing inventory of rHuPH20 ahead of the transition to the new facility, which will result in lower bulk product sales during 2017 and 2018. We expect that future product sales of Hylenex to be flat or experience modest growth, although there may be periods with declining revenue as we experience competition for market share.

Royalties – Royalty revenue was $14.0 million for the three months ended March 31, 2017 compared to $11.4 million for the three months ended March 31, 2016. The increase was driven by higher sales of Herceptin SC and MabThera SC by Roche and of HYQVIA by Baxalta. We recognize royalties on sales of the collaboration products by the collaborators in the quarter following the quarter in which the corresponding sales occurred. In general, we expect royalty revenue to increase in future periods reflecting expected increases in sales of collaboration products, although there may be periods with flat or declining royalty revenue as sales of products under collaborations vary.

Revenues Under Collaborative Agreements – Revenues under collaborative agreements were as follows (in thousands):



	Three Months Ended
	March 31,
	2017		2016		Change
Upfront license fees, license fees for the election of additional targets, license maintenance fees and amortization of deferred upfront and other license fees and event-based payments:
Roche	$	832	$	832	$	—
Baxalta	191		191		—
Other	—		15,500		(15,500		)
	1,023		16,523		(15,500		)
Reimbursements for research and development services	3,129		1,649		1,480
Total revenues under collaborative agreements	$	4,152	$	18,172	$	(14,020	)

For the three months ended March 31, 2016, we recognized $15.5 million in license and milestone revenue in connection with the Lilly, AbbVie and Pfizer collaborations. No such revenues were recognized in the three months ended March 31, 2017. Revenue from upfront licenses fees, license fees for the election of additional targets, license maintenance fees and amortization of deferred upfront and other license fees and event-based payments vary from period to period based on our ENHANZE collaboration activity. We expect these revenues to continue to fluctuate in future periods based on our collaborators’ abilities to meet various clinical and regulatory milestones set forth in such agreements and our abilities to obtain new collaborative agreements.

Revenue from reimbursements for research and development services increased in the three months ended March 31, 2017, compared to the same period in 2016 mainly due to an increase in services provided to Roche related to work associated with bringing on-line a second contract manufacturing facility. The validation of the new facility is scheduled to end in the second quarter of 2017 and, therefore, we expect to see a decrease in research and development service revenue from Roche going forward. Research and development services rendered by us on behalf of our collaborators are at the request of the collaborators; therefore, the amount and timing of future revenues related to reimbursable research and development services is uncertain.

Cost of Product Sales – Cost of product sales were $7.5 million for the three months ended March 31, 2017 compared to $7.8 million for the three months ended March 31, 2016. The decrease of $0.3 million in cost of product sales was mainly due to a decrease in sales of bulk rHuPH20 to Roche.

Research and Development – Research and development expenses consist of external costs, salaries and benefits and allocation of facilities and other overhead expenses related to research manufacturing, clinical trials, preclinical and regulatory activities. Research and development expenses incurred were as follows (in thousands):



	Three Months Ended
	March 31,
Programs	2017		2016		Change
PEGPH20	$	27,737	$	32,109	$	(4,372	)
Enhanze collaborations and rHuPH20 platform	4,748		5,242		(494		)
Other	4,450		2,749		1,701
Total research and development expenses	$	36,935	$	40,100	$	(3,165	)

Research and development expenses relating to our PEGPH20 programs for the three months ended March 31, 2017 decreased by 14%, compared to the same period in 2016. The decrease is driven primarily by one-time payments made in the first quarter of 2016 related to a purchase of drug supply, a license payment and development of the Ventana companion diagnostic, none of which occured in the first quarter of 2017. These decreases were offset by an increase in clinical activity. We expect PEGPH20 program expenses to increase in future periods reflecting expected increases in our PEGPH20 development activities.

Research and development expenses relating to our Enhanze collaborations and our rHuPH20 platform for the three months ended March 31, 2017 decreased by 9%, compared to the same period in 2016, primarily due to a decrease in rHuPH20 manufactured for research and development, partially offset by an increase in manufacturing expenses related to Roche, due to work associated with bringing on-line a second contract manufacturing facility. As we plan to complete validation of the new manufacturing facility in the second quarter of 2017, we expect these expenses to decrease going forward. The rHuPH20 platform includes research, development and manufacturing expenses related to our proprietary rHuPH20 enzyme. These expenses were not designated to a specific program at the time the expenses were incurred.

Research and development expenses relating to other programs for the three months ended March 31, 2017 increased by 62%, compared to the same period in 2016, related to preclinical development of HTI-1511.

Selling, General and Administrative – Selling, general and administrative (SG&A) expenses were $12.6 million for the three months ended March 31, 2017 compared to $10.8 million for the three months ended March 31, 2016. The increase of $1.8 million, or 17%, was primarily due to an increase in compensation expense from higher average headcount. We expect SG&A expenses to increase moderately in future periods as our operations expand.

Interest Expense – Interest expense was $5.4 million for the three months ended March 31, 2017 compared to $3.9 million for the three months ended March 31, 2016. The increase of $1.5 million was primarily due to recognizing a full quarter of interest expense for the three months ended March 31, 2017 on the Royalty-backed Loan we received in January 2016.

Income Tax Expense – Income tax expense of $0.2 million for the three months ended March 31, 2017 comprised U.S. federal alternative minimum tax. For the three months ended March 31, 2017, we generated taxable income in the U.S., which was partially offset by utilizing net operating losses carried forward from earlier years. No income tax expense was recognized during the three months ended March 31, 2016.

Liquidity and Capital Resources

Overview

Our principal sources of liquidity are our existing cash, cash equivalents and available-for-sale marketable securities. As of March 31, 2017, we had cash, cash equivalents and marketable securities of $179.0 million. We will continue to have significant cash requirements to support product development activities. The amount and timing of cash requirements will depend on the progress and success of our clinical development programs, regulatory and market acceptance, and the resources we devote to research and commercialization activities. The amount of cash on hand will depend on the progress of various preclinical and clinical programs, the timing of our manufacturing scale-up and the achievement of various milestones and royalties under our existing collaborative agreements.

We believe that our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. We expect to fund our operations going forward with existing cash resources, anticipated revenues from our existing collaborations and cash that we may raise through future transactions. We may raise cash through any one of the following financing vehicles: (i) the public offering of securities; (ii) new collaborative agreements; (iii) expansions or revisions to existing collaborative relationships; (iv) private financings; (v) other equity or debt financings; and/or (vi) monetizing assets.

In February 2017, we filed an automatic shelf registration statement on Form S-3 (Registration No. 333-216315) with the SEC, which allow us, from time to time, to offer and sell equity, debt securities and warrants to purchase any of such securities, either individually or in units. We may, in the future, offer and sell equity, debt securities and warrants to purchase any of such

securities, either individually or in units to raise capital to fund the continued development of our product candidates, the commercialization of our products or for other general corporate purposes.

Our existing cash, cash equivalents and marketable securities may not be adequate to fund our operations until we become profitable, if ever. We cannot be certain that additional financing will be available when needed or, if available, financing will be obtained on favorable terms. If we are unable to raise sufficient funds, we may need to delay, scale back or eliminate some or all of our research and development programs, delay the launch of our product candidates, if approved, and/or restructure our operations. If we raise additional funds by issuing equity securities, substantial dilution to existing stockholders could result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations, the issuance of warrants that may ultimately dilute existing stockholders when exercised and covenants that may restrict our ability to operate our business.

Cash Flows

Operating Activities

Net cash used in operations was $22.5 million for the three months ended March 31, 2017 compared to $13.0 million for the three months ended March 31, 2016. The $9.5 million increase in utilization of cash in operations was mainly due to an increase in operating loss and a reduction in working capital for the three months ended March 31, 2017 compared to the corresponding period in the prior year.

Investing Activities

Net cash provided by investing activities was $4.3 million for the three months ended March 31, 2017 compared to net cash used in investing activities of $105.6 million for the three months ended March 31, 2016. This change was due to net proceeds from maturities of marketable securities to provide cash to be used in operations in the current period, compared to net purchases of marketable securities in the three months ended March 31, 2016, using proceeds from financing activities.

Financing Activities

Net cash used in financing activities was $3.4 million for the three months ended March 31, 2017 compared to net cash provided by financing activities of $144.4 million for the three months ended March 31, 2016, when we drew net proceeds of $148.0 million on the Royalty-backed Loan.

Long-Term Debt

Royalty-backed Loan

In January 2016, through our wholly-owned subsidiary Halozyme Royalty LLC (Halozyme Royalty), we received a $150 million loan (the Royalty-backed Loan) pursuant to a credit agreement (the Credit Agreement) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the Royalty-backed Lenders). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (Collaboration Agreements). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the Royalty Payments). The Royalty-backed Loan bears interest at a per annum rate of 8.75% plus the three-month LIBOR rate. The three-month LIBOR rate is subject to a floor of 0.7% and a cap of 1.5%. The interest rate as of March 31, 2017 was 9.90%. The outstanding balance of the Royalty-backed Loan as of March 31, 2017 was $158.9 million, inclusive of payment-in-kind interest expense of $10.2 million and net of unamortized debt discount of $1.3 million.

The Credit Agreement provides that none of the Royalty Payments were required to be applied to the Royalty-backed Loan prior to January 1, 2017, 50% of the Royalty Payments are required to be applied to the Royalty-backed Loan between January 1, 2017 and January 1, 2018 and thereafter all Royalty Payments must be applied to the Royalty-backed Loan. However, the amounts available to repay the Royalty-backed Loan are subject to caps of $13.75 million per quarter in 2017, $18.75 million per quarter in 2018, $21.25 million per quarter in 2019 and $22.5 million per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first, to pay interest and second, to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date. Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps.

The final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050. Currently, we estimate that the loan will be repaid in the first quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January 1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to 105% of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan.

Oxford and SVB Loan and Security Agreement

In June 2016, we entered into a Loan and Security Agreement (the Loan Agreement) with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB) (collectively, the Lenders), providing a senior secured loan facility of up to an aggregate principal amount of $70 million, comprising a $55.0 million draw in June 2016 and an additional $15.0 million tranche, which we have the option to draw during the second quarter of 2017. The proceeds were partially used to pay the outstanding principal and final payment owed on a previous loan agreement with the Lenders. The remaining proceeds, including any drawdown of the additional $15.0 million available to us, are to be used for working capital and general business requirements. The remaining $15 million tranche is subject to an annual interest rate equal to the then-current prime rate as reported in The Wall Street Journal on the drawn-down date plus 4.75%. The Loan Agreement repayment schedule provides for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of January 1, 2021. The Loan Agreement provides for a final payment equal to 5.50% of the initial $55 million principal amount and, if we exercise our option to draw an additional $15 million in 2017, 7.25% of the principal amount of the second draw. The final payment is due when the Loan Agreement becomes due or upon the prepayment of the facility. We have the option to prepay the outstanding balance of the Loan Agreement in full, subject to a prepayment fee of 2% in the first year and 1% in the second year of the term loan. The outstanding term loan balance was $55.1 million as of March 31, 2017, inclusive of $0.1 million of accretion of the final payment and net of unamortized debt discount of $2.9 million.

The Loan Agreement is secured by substantially all of the assets of the Company and its subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc. and any intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same; and make any voluntary prepayment of or modify certain terms of the Royalty-backed Loan. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our domestic subsidiary.

The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in our business, operations or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, a material impairment in the perfection or priority of the Lender’s lien in the collateral or in the value of such collateral or the occurrence of an event of default under the Royalty-backed Loan. In the event of default by us under the Loan Agreement, the Lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Loan Agreement, which could harm our financial condition.

Off-Balance Sheet Arrangements

As of March 31, 2017, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we did not engage in trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. We review our estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Please see our audited consolidated financial statements and notes thereto included in Part II, Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2016 (2016 Form 10-K), which contain our critical accounting policies and other disclosures required by U.S. GAAP. There were no material changes from those policies and disclosures included in our 2016 Form 10-K.

Recent Accounting Pronouncements

Refer to Note 2, Summary of Significant Accounting Policies, of our condensed consolidated financial statements for a discussion of recent accounting pronouncements and their effect, if any.

Risk Factors

Risks Related To Our Business

We have generated only limited revenues from product sales to date; we have a history of net losses and negative cash flows, and we may never achieve or maintain profitability.

Relative to expenses incurred in our operations, we have generated only limited revenues from product sales, royalties, licensing fees, milestone payments, bulk rHuPH20 supply payments and research reimbursements to date and we may never generate sufficient revenues from future product sales, licensing fees and milestone payments to offset expenses. Even if we ultimately do achieve significant revenues from product sales, royalties, licensing fees, research reimbursements, bulk rHuPH20 supply payments and/or milestone payments, we expect to incur significant operating losses over the next few years. We have never been profitable, and we may never become profitable. Through March 31, 2017, we have incurred aggregate net losses of $618.2 million.

If our product candidates do not receive and maintain regulatory approvals, or if approvals are not obtained in a timely manner, such failure or delay would substantially impair our ability to generate revenues.

Approval from the FDA or equivalent health authorities is necessary to manufacture and market pharmaceutical products in the U.S. and the other countries in which we anticipate doing business have similar requirements. The process for obtaining FDA and other regulatory approvals is extensive, time-consuming, risky and costly, and there is no guarantee that the FDA or other regulatory bodies will approve any applications that may be filed with respect to any of our product candidates, or that the timing of any such approval will be appropriate for the desired product launch schedule for a product candidate. We and our collaborators attempt to provide guidance as to the timing for the filing and acceptance of such regulatory approvals, but such filings and approvals may not occur when we or our collaborators expect, or at all. The FDA or other foreign regulatory agency may refuse or delay approval of our product candidates for failure to collect sufficient clinical or animal safety data and require us or our collaborators to conduct additional clinical or animal safety studies which may cause lengthy delays and increased costs to our programs. For example, the approval of Baxalta’s HYQVIA BLA in the U.S. was delayed until we and Baxalta provided additional preclinical data sufficient to address concerns regarding non-neutralizing antibodies to rHuPH20 that were detected in the registration trial. Although these antibodies have not been associated with any known adverse clinical effects, and the HYQVIA BLA was approved by the FDA in September 2014, we cannot assure you that they will not arise and have an adverse impact on future development of products which include rHuPH20, future sales of Hylenex recombinant, our ability to enter into collaborations, or be raised by the FDA or other health authorities in connection with testing or approval of products including rHuPH20.

We and our collaborators may not be successful in obtaining approvals for any additional potential products in a timely manner, or at all. Refer to the risk factor titled “Our proprietary and collaboration product candidates or companion diagnostic assays may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns” for additional information relating to the approval of product candidates.

Additionally, even with respect to products which have been approved for commercialization, in order to continue to manufacture and market pharmaceutical products, we or our collaborators must maintain our regulatory approvals. If we or any of our collaborators are unsuccessful in maintaining our regulatory approvals, our ability to generate revenues would be adversely affected.

We will likely need to raise additional capital in the future and there can be no assurance that we will be able to obtain such funds.

We will likely need to raise additional capital in the future to continue the development of our product candidates or for other current corporate purposes. Our current cash reserves and expected revenues during the next few years will not be sufficient for us to continue the development of our proprietary product candidates, to fund general operations and conduct our business at the level desired. In addition, if we engage in acquisitions of companies, products or technologies in order to execute our business

strategy, we may need to raise additional capital. We may raise additional capital in the future through one or more financing vehicles that may be available to us including (i) the public offering of securities; (ii) new collaborative agreements; (iii) expansions or revisions to existing collaborative relationships; (iv) private financings; (v) other equity or debt financings; and/or (vi) monetizing assets.

In view of our stage of development, business prospects, the nature of our capital structure and general market conditions, if we are required to raise additional capital in the future, the additional financing may not be available on favorable terms, or at all. If additional capital is not available on favorable terms when needed, we will be required to raise capital on adverse terms or significantly reduce operating expenses through the restructuring of our operations or deferral of one or more product development programs. If we raise additional capital, a substantial number of additional shares may be issued, which may negatively affect our stock price and and these additional shares will dilute the ownership interest of our current investors.

Use of our product candidates or those of our collaborators could be associated with side effects or adverse events.

As with most pharmaceutical products, use of our product candidates or those of our collaborators could be associated with side effects or adverse events which can vary in severity (from minor reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our product candidates or those of our collaborators may be observed at any time, including in clinical trials or when a product is commercialized, and any such side effects or adverse events may negatively affect our or our collaborators’ ability to obtain or maintain regulatory approval or market our product candidates. Side effects such as toxicity or other safety issues associated with the use of our product candidates or those of our collaborators could require us or our collaborators to perform additional studies or halt development or commercialization of these product candidates or expose us to product liability lawsuits which will harm our business. We or our collaborators may be required by regulatory agencies to conduct additional animal or human studies regarding the safety and efficacy of our pharmaceutical product candidates which we have not planned or anticipated. Furthermore, there can be no assurance that we or our collaborators will resolve any issues related to any product related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition. For example, in April 2014, a clinical hold was placed on patient enrollment and dosing of PEGPH20 in Study 202 as a result of a possible difference in the TE event rate that had been observed at that time in the trial between the group of patients treated with PEGPH20 versus the group of patients treated without PEGPH20. The clinical hold was lifted by the FDA in June 2014, and we have completed enrollment and continue to monitor ongoing patients who remain either on treatment or in follow-up on Study 202 under a revised clinical protocol.

If our contract manufacturers are unable to manufacture and supply to us bulk rHuPH20 or other raw materials in the quantity and quality required by us or our collaborators for use in our products and product candidates, our product development and commercialization efforts could be delayed or stopped and our collaborations could be damaged.

We have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (Avid) and Cook Pharmica LLC (Cook) to produce bulk rHuPH20. These manufacturers each produce bulk rHuPH20 under cGMP for clinical uses. Cook currently produces bulk rHuPH20 for use in Hylenex recombinant, product candidates and collaboration product candidates. Avid currently produces bulk rHuPH20 for use in collaboration products. In addition to supply obligations, Avid and Cook will also provide support for the chemistry, manufacturing and controls sections for FDA and other regulatory filings. We rely on their ability to successfully manufacture these batches according to product specifications. If either Avid or Cook: (i) is unable to retain its status as an FDA approved manufacturing facility; (ii) is unable to otherwise successfully scale up bulk rHuPH20 production to meet corporate or regulatory authority quality standards; or (iii) fails to manufacture and supply bulk rHuPH20 in the quantity and quality required by us or our collaborators for use in our proprietary and collaboration products and product candidates for any other reason, our business will be adversely affected. In addition, a significant change in such parties’ or other third party manufacturers’ business or financial condition could adversely affect their abilities to fulfill their contractual obligations to us. We have not established, and may not be able to establish, favorable arrangements with additional bulk rHuPH20 manufacturers and suppliers of the ingredients necessary to manufacture bulk rHuPH20 should the existing manufacturers and suppliers become unavailable or in the event that our existing manufacturers and suppliers are unable to adequately perform their responsibilities. We have attempted to mitigate the impact of a potential supply interruption through

the establishment of excess bulk rHuPH20 inventory where possible, but there can be no assurances that this safety stock will be maintained or that it will be sufficient to address any delays, interruptions or other problems experienced by Avid and/or Cook. Any delays, interruptions or other problems regarding the ability of Avid and/or Cook to supply bulk rHuPH20 or the ability of other third party manufacturers, to supply other raw materials or ingredients necessary to produce our products on a timely basis could: (i) cause the delay of clinical trials or otherwise delay or prevent the regulatory approval of proprietary or collaboration product candidates; (ii) delay or prevent the effective commercialization of proprietary or collaboration products; and/or (iii) cause us to breach contractual obligations to deliver bulk rHuPH20 to our collaborators. Such delays would likely damage our relationship with our collaborators, and they would have a material adverse effect on royalties and thus our business and financial condition.

If we or any party to a key collaboration agreement fail to perform material obligations under such agreement, or if a key collaboration agreement, is terminated for any reason, our business could significantly suffer.

We have entered into multiple collaboration agreements under which we may receive significant future payments in the form of milestone payments, target designation fees, maintenance fees and royalties. We are dependent on our collaborators to develop and commercialize product candidates subject to our collaborations in order for us to realize any financial benefits from these collaborations. Our collaborators may not devote the attention and resources to such efforts that we would ourselves, change their clinical development plans, promotional efforts or simultaneously develop and commercialize products in competition to those products we have licensed to them. Any of these actions could not be visible to us immediately and could negatively impact the benefits and revenue we receive from such collaboration. In addition, in the event that a party fails to perform under a key collaboration agreement, or if a key collaboration agreement is terminated, the reduction in anticipated revenues could delay or suspend our product development activities for some of our product candidates, as well as our commercialization efforts for some or all of our products. Specifically, the termination of a key collaboration agreement by one of our collaborators could materially impact our ability to enter into additional collaboration agreements with new collaborators on favorable terms, if at all. In certain circumstances, the termination of a key collaboration agreement would require us to revise our corporate strategy going forward and reevaluate the applications and value of our technology.

Most of our current proprietary and collaboration products and product candidates rely on the rHuPH20 enzyme, and any adverse development regarding rHuPH20 could substantially impact multiple areas of our business, including current and potential collaborations, as well as proprietary programs.

rHuPH20 is a key technological component of ENHANZE Technology and our most advanced proprietary and collaboration products and product candidates, including the current and future products and product candidates under our Roche, Pfizer, Janssen, Baxalta, AbbVie and Lilly collaborations, our PEGPH20 program, and Hylenex recombinant. If there is an adverse development for rHuPH20 (e.g., an adverse regulatory determination relating to rHuPH20, if we are unable to obtain sufficient quantities of rHuPH20, if we are unable to obtain or maintain material proprietary rights to rHuPH20 or if we discover negative characteristics of rHuPH20), multiple areas of our business, including current and potential collaborations, as well as proprietary programs would be substantially impacted. For example, elevated anti-rHuPH20 antibody titers were detected in the registration trial for Baxalta’s HYQVIA product as well as in a former collaborator’s product in a Phase 2 clinical trial with rHuPH20, but have not been associated, in either case, with any adverse events. We monitor for antibodies to rHuPH20 in our collaboration and proprietary programs, and although we do not believe at this time that the incidence of non-neutralizing anti-rHuPH20 antibodies in either the HYQVIA program or the former collaborator’s program will have a significant impact on our other proprietary and other collaboration product candidates, there can be no assurance that there will not be other such occurrences in the foregoing programs or our other programs or that concerns regarding these antibodies will not also be raised by the FDA or other health authorities in the future, which could result in delays or discontinuations of our development or commercialization activities or deter entry into additional collaborations with third parties.

We routinely evaluate, and may modify, our business strategy and our strategic focus to only a few fields or applications of our technology which may increase the risk for potential negative impact from adverse developments.

We routinely evaluate our business strategy, and may modify this strategy in the future in light of our assessment of unmet medical needs, growth potential, resource requirements, regulatory issues, competition, risks and other factors. As a result of these strategic evaluations, we may focus our resources and efforts on one or a few programs or fields and may suspend or reduce our efforts on other programs and fields. For example, in the third quarter of 2014, we decided to focus our resources on advancing PEGPH20 and expanding utilization of our ENHANZE platform. While we believe these are applications with the greatest potential value, we have reduced the diversification of our programs and increased our dependence on the success of the areas we are pursuing. By focusing on one or a few areas, we increase the potential impact on us if one of those programs or product candidates does not successfully complete clinical trials, achieve commercial acceptance or meet expectations regarding sales and revenue. Our decision to focus on one or a few programs may also reduce the value of programs that are no longer within our principal strategic focus, which could impair our ability to pursue collaborations or other strategic alternatives for those programs we are not pursuing.

Our proprietary and collaboration product candidates or companion diagnostic assays may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns.

Clinical testing of pharmaceutical products is a long, expensive and uncertain process, and the failure or delay of a clinical trial can occur at any stage, including the patient enrollment stage. Even if initial results of preclinical and nonclinical studies or clinical trial results are promising, we or our collaborators may obtain different results in subsequent trials or studies that fail to show the desired levels of safety and efficacy, or we may not, or our collaborators may not, obtain applicable regulatory approval for a variety of other reasons. Preclinical, nonclinical, and clinical trials for any of our proprietary or collaboration product candidates or development of any collaboration companion diagnostic assays could be unsuccessful, which would delay or preclude regulatory approval and commercialization of the product candidates or companion diagnostic assays. In the U.S. and other jurisdictions, regulatory approval can be delayed, limited or not granted for many reasons, including, among others:


•	clinical results may not meet prescribed endpoints for the studies or otherwise provide sufficient data to support the efficacy of our product candidates;

•

clinical and nonclinical test results may reveal side effects, adverse events or unexpected safety issues associated with the use of our product candidates; for example, in April 2014, a clinical hold was placed on patient enrollment and dosing of PEGPH20 in Study 202 as a result of a possible difference in the TE event rate that had been observed at that time in the trial between the group of patients treated with PEGPH20 versus the group of patients treated without PEGPH20. The clinical hold was lifted by the FDA in June 2014, and we have completed enrollment and continue to monitor ongoing patients who remain either on treatment or in follow-up on Study 202 under a revised clinical protocol;


•	completion of clinical trials may be delayed for a variety of reasons including the amount of time it may take to identify and enroll patients with high levels of HA in our target population, and the ability to procure drug supply required in clinical trial protocols;


•	third parties, such as contract research organizations, upon whom we rely to help conduct and manage our clinical trials may not perform satisfactorily, fulfill their contractual obligations to us, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols;


•	regulatory review may not find a product candidate safe or effective enough to merit either continued testing or final approval;


•	regulatory review may not find that the data from preclinical testing and clinical trials justifies approval;


•	regulatory authorities may require that we change our studies or conduct additional studies which may significantly delay or make continued pursuit of approval commercially unattractive;


•	a regulatory agency may reject our trial data or disagree with our interpretations of either clinical trial data or applicable regulations;


•	a regulatory agency may approve only a narrow use of our product or may require additional safety monitoring and reporting through Risk Evaluation and Mitigation Strategies or conditions to assure safe use programs;


•	the cost of clinical trials required for product approval may be greater than what we originally anticipate, and we may decide to not pursue regulatory approval for such a product;


•	a regulatory agency may not approve our manufacturing processes or facilities, or the processes or facilities of our collaborators, our contract manufacturers or our raw material suppliers;


•	a regulatory agency may identify problems or other deficiencies in our existing manufacturing processes or facilities, or the existing processes or facilities of our collaborators, our contract manufacturers or our raw material suppliers;


•	a regulatory agency may change its formal or informal approval requirements and policies, act contrary to previous guidance, adopt new regulations or raise new issues or concerns late in the approval process; or


•	a product candidate may be approved only for indications that are narrow or under conditions that place the product at a competitive disadvantage, which may limit the sales and marketing activities for such product candidate or otherwise adversely impact the commercial potential of a product.

If a proprietary or collaboration product candidate or companion diagnostic assay is not approved in a timely fashion or obtained on commercially viable terms, or if development of any product candidate or a companion diagnostic assay is terminated due to difficulties or delays encountered in the regulatory approval process, it could have a material adverse impact on our business, and we would become more dependent on the development of other proprietary or collaboration product candidates and/or our ability to successfully acquire other products and technologies. There can be no assurances that any proprietary or collaboration product candidate or companion diagnostic assay will receive regulatory approval in a timely manner, or at all. There can be no assurance that we will be able to gain clarity as to the FDA’s requirements or that the requirements may be satisfied in a commercially feasible way, in which case our ability to enter into collaborations with third parties or explore other strategic alternatives to exploit this opportunity will be limited or may not be possible.

We anticipate that certain proprietary and collaboration products will be marketed, and perhaps manufactured, in foreign countries. The process of obtaining regulatory approvals in foreign countries is subject to delay and failure for the reasons set forth above, as well as for reasons that vary from jurisdiction to jurisdiction. The approval process varies among countries and jurisdictions and can involve additional testing. The time required to obtain approval may differ from that required to obtain FDA approval. Foreign regulatory agencies may not provide approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or jurisdictions or by the FDA.

Our third party collaborators are responsible for providing certain proprietary materials that are essential components of our collaboration products and product candidates, and any failure to supply these materials could delay the development and commercialization efforts for these collaboration products and product candidates and/or damage our collaborations.

Our development and commercialization collaborators are responsible for providing certain proprietary materials that are essential components of our collaboration products and product candidates. For example, Roche is responsible for producing the Herceptin and MabThera required for its subcutaneous products and Baxalta is responsible for producing the GAMMAGARD LIQUID for its product HYQVIA. If a collaborator, or any applicable third party service provider of a collaborator, encounters difficulties in the manufacture, storage, delivery, fill, finish or packaging of the collaboration product or product candidate or component of such product or product candidate, such difficulties could (i) cause the delay of clinical trials or otherwise delay or prevent the regulatory approval of collaboration product candidates; and/or (ii) delay or prevent the effective commercialization of collaboration products. Such delays could have a material adverse effect on our business and financial condition.

We rely on third parties to manufacture, prepare, fill, finish and package our products and product candidates, and if such third parties should fail to perform, our commercialization and development efforts for our products and product candidates could be delayed or stopped.

We rely on third parties to manufacture, prepare, fill, finish, package, store and ship our products and product candidates on our behalf. If we are unable to locate third parties to perform these functions on terms that are acceptable to us, or if the third

parties we identify fail to perform their obligations, the progress of clinical trials could be delayed or even suspended and the commercialization of approved product candidates could be delayed or prevented. In addition, we are scaling up our manufacturing of PEGPH20 with third party suppliers to support additional clinical trials, including the Phase 3 trial, and ultimately, if approved, potential commercial supply. If our contract manufacturers are unable to successfully manufacture and supply PEGPH20, the progress of our clinical trials could be delayed or halted for a period of time.

If we are unable to sufficiently develop our sales, marketing and distribution capabilities or enter into successful agreements with third parties to perform these functions, we will not be able to fully commercialize our products.

We may not be successful in marketing and promoting our approved product, Hylenex recombinant, or any other products we develop or acquire in the future. Our sales, marketing and distribution capabilities are very limited. In order to commercialize any products successfully, we must internally develop substantial sales, marketing and distribution capabilities or establish collaborations or other arrangements with third parties to perform these services. We do not have extensive experience in these areas, and we may not be able to establish adequate in-house sales, marketing and distribution capabilities or engage and effectively manage relationships with third parties to perform any or all of such services. To the extent that we enter into co-promotion or other licensing arrangements, our product revenues are likely to be lower than if we directly marketed and sold our products, and any revenues we receive will depend upon the efforts of third parties, whose efforts may not meet our expectations or be successful. These third parties would be largely responsible for the speed and scope of sales and marketing efforts, and may not dedicate the resources necessary to maximize product opportunities. Our ability to cause these third parties to increase the speed and scope of their efforts may also be limited. In addition, sales and marketing efforts could be negatively impacted by the delay or failure to obtain additional supportive clinical trial data for our products. In some cases, third party collaborators are responsible for conducting these additional clinical trials, and our ability to increase the efforts and resources allocated to these trials may be limited.

If we or our collaborators fail to comply with regulatory requirements applicable to promotion, sale and manufacturing of approved products, regulatory agencies may take action against us or them, which could significantly harm our business.

Any approved products, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for these products, are subject to continual requirements and review by the FDA, state and foreign regulatory bodies. Regulatory authorities subject a marketed product, its manufacturer and the manufacturing facilities to continual review and periodic inspections. We, our collaborators and our respective contractors, suppliers and vendors, will be subject to ongoing regulatory requirements, including complying with regulations and laws regarding advertising, promotion and sales of drug products, required submissions of safety and other post-market information and reports, registration requirements, cGMP regulations (including requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation), and the requirements regarding the distribution of samples to physicians and recordkeeping requirements. Regulatory agencies may change existing requirements or adopt new requirements or policies. We, our collaborators and our respective contractors, suppliers and vendors, may be slow to adapt or may not be able to adapt to these changes or new requirements.

In particular, regulatory requirements applicable to pharmaceutical products make the substitution of suppliers and manufacturers costly and time consuming. We have minimal internal manufacturing capabilities and are, and expect to be in the future, entirely dependent on contract manufacturers and suppliers for the manufacture of our products and for their active and other ingredients. The disqualification of these manufacturers and suppliers through their failure to comply with regulatory requirements could negatively impact our business because the delays and costs in obtaining and qualifying alternate suppliers (if such alternative suppliers are available, which we cannot assure) could delay clinical trials or otherwise inhibit our ability to bring approved products to market, which would have a material adverse effect on our business and financial condition. Likewise, if we, our collaborators and our respective contractors, suppliers and vendors involved in sales and promotion of our products do not comply with applicable laws and regulations, for example off-label or false or misleading promotion, this could materially harm our business and financial condition.

Failure to comply with regulatory requirements may result in any of the following:


•	restrictions on our products or manufacturing processes;


•	warning letters;


•	withdrawal of the products from the market;


•	voluntary or mandatory recall;


•	fines;


•	suspension or withdrawal of regulatory approvals;


•	suspension or termination of any of our ongoing clinical trials;


•	refusal to permit the import or export of our products;


•	refusal to approve pending applications or supplements to approved applications that we submit;


•	product seizure;


•	injunctions; or


•	imposition of civil or criminal penalties.

We currently have significant debt and failure by us to fulfill our obligations under the applicable loan agreements may cause the repayment obligations to accelerate.

In December 2015, our subsidiaries, Halozyme, Inc. (Halozyme) and Halozyme Royalty LLC (Halozyme Royalty) entered into a credit agreement (the Credit Agreement) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the Royalty-backed Lenders) pursuant to which we borrowed $150 million through Halozyme Royalty (the Royalty-backed Loan). The Royalty-backed Loan will be repaid primarily from a specified percentage of the royalty payments we receive under our collaboration agreements with Roche and Baxalta (the Royalty Payments).

The obligations of Halozyme Royalty under the Credit Agreement to repay the Royalty-backed Loan may be accelerated upon the occurrence of certain events of default under the Credit Agreement, including but not limited to:


•	if any payment of principal is not made within three days of when such payment is due and payable or otherwise made in accordance with the terms of the Credit Agreement;


•	if any representations or warranties made in the Credit Agreement or any other transaction document proves to be incorrect or misleading in any material respect when made;


•	if there occurs a default in the performance of affirmative and negative covenants set forth in the Credit Agreement or any other transaction document;


•	the failure by either Baxalta or Roche to pay material amounts owed under our collaboration agreements because of an actual breach or default by us under the collaboration agreements;


•	the voluntary or involuntary commencement of bankruptcy proceedings by either Halozyme or Halozyme Royalty and other insolvency related defaults;


•	any materially adverse effect on the binding nature of any of the transaction documents or the collaboration agreements with Baxalta and Roche; or


•	Halozyme ceases to own, of record and beneficially, 100% of the equity interests in Halozyme Royalty.

The Credit Agreement also contains covenants applicable to Halozyme and Halozyme Royalty, including certain visitation, information and audits rights granted to the collateral agent and the lenders and restrictions on the conduct of business, including continued compliance with the Baxalta and Roche collaboration agreements and specified affirmative actions regarding the escrow account established to facilitate payment of Royalty Payments to the Royalty-backed Lenders or other specified parties. The Credit Agreement also contains covenants solely applicable to Halozyme Royalty, including restrictions on incurring indebtedness, creating or granting liens, making acquisitions and making specified restricted payments. These covenants could make it more difficult for us to execute our business strategy.

In connection with the Royalty-backed Loan, Halozyme Royalty granted a first priority lien and security interest (subject only to permitted liens) in all of its assets and all real, intangible and personal property, including all of its right, title and interest in and to the Royalty Payments.

In June 2016, we entered into a Loan and Security Agreement (the Loan Agreement) with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB) (collectively, the Lenders), providing a senior secured loan facility of up to an aggregate principal amount of $70 million, comprising a $55.0 million draw in June 2016 and an additional $15.0 million tranche, which we have the option to draw during the second quarter of 2017. The initial proceeds were partially used to pay the outstanding principal and final payment owed on our previous loan agreement with the Lenders. The remaining proceeds, including any drawdown of the additional $15.0 million, are to be used for working capital and general business requirements. The Loan Agreement is secured by substantially all of the assets of the Company and its subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc., any intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; and enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our domestic subsidiary. Complying with these covenants may make it more difficult for us to successfully execute our business strategy.

Our ability to make payments on our debt will depend on our future operating performance and ability to generate cash and may also depend on our ability to obtain additional debt or equity financing. We will need to use cash to pay principal and interest on our debt, thereby reducing the funds available to fund our research and development programs, strategic initiatives and working capital requirements. If we are unable to generate sufficient cash to service our debt obligation, an event of default may occur. In the event of default by us under the Credit Agreement or the Loan Agreement, the lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Credit Agreement or the Loan Agreement which could harm our financial condition.

If proprietary or collaboration product candidates are approved for marketing but do not gain market acceptance, our business may suffer and we may not be able to fund future operations.

Assuming that our proprietary or collaboration product candidates obtain the necessary regulatory approvals for commercial sale, a number of factors may affect the market acceptance of these existing product candidates or any other products which are developed or acquired in the future, including, among others:


•	the price of products relative to other therapies for the same or similar treatments;


•	the perception by patients, physicians and other members of the health care community of the effectiveness and safety of these products for their prescribed treatments relative to other therapies for the same or similar treatments;


•	our ability to fund our sales and marketing efforts and the ability and willingness of our collaborators to fund sales and marketing efforts;


•	the degree to which the use of these products is restricted by the approved product label;


•	the effectiveness of our sales and marketing efforts and the effectiveness of the sales and marketing efforts of our collaborators;


•	the introduction of generic competitors; and


•	the extent to which reimbursement for our products and related treatments will be available from third party payors including government insurance programs (Medicare and Medicaid) and private insurers.

If these products do not gain market acceptance, we may not be able to fund future operations, including the development or acquisition of new product candidates and/or our sales and marketing efforts for our approved products, which would cause our business to suffer.

In addition, our proprietary and collaboration product candidates will be restricted to the labels approved by FDA and applicable regulatory bodies, and these restrictions may limit the marketing and promotion of the ultimate products. If the approved labels are restrictive, the sales and marketing efforts for these products may be negatively affected.

Developing and marketing pharmaceutical products for human use involves significant product liability risks for which we currently have limited insurance coverage.

The testing, marketing and sale of pharmaceutical products involves the risk of product liability claims by consumers and other third parties. Although we maintain product liability insurance coverage, product liability claims can be high in the pharmaceutical industry, and our insurance may not sufficiently cover our actual liabilities. If product liability claims were to be made against us, it is possible that the liabilities may exceed the limits of our insurance policy, or our insurance carriers may deny, or attempt to deny, coverage in certain instances. If a lawsuit against us is successful, then the lack or insufficiency of insurance coverage could materially and adversely affect our business and financial condition. Furthermore, various distributors of pharmaceutical products require minimum product liability insurance coverage before purchase or acceptance of products for distribution. Failure to satisfy these insurance requirements could impede our ability to achieve broad distribution of our proposed products, and higher insurance requirements could impose additional costs on us. In addition, since many of our collaboration product candidates include the pharmaceutical products of a third party, we run the risk that problems with the third party pharmaceutical product will give rise to liability claims against us.

Our inability to attract, hire and retain key management and scientific personnel could negatively affect our business.

Our success depends on the performance of key management and scientific employees with relevant experience. For example, in order to pursue our current business strategy, we will need to recruit and retain personnel experienced in oncology drug development which is a highly competitive market for talent. We depend substantially on our ability to hire, train, motivate and retain high quality personnel, especially our scientists and management team. Particularly in view of the small number of employees on our staff to cover our numerous programs and key functions, if we are unable to retain existing personnel or identify or hire additional personnel, we may not be able to research, develop, commercialize or market our products and product candidates as expected or on a timely basis and we may not be able to adequately support current and future alliances with strategic collaborators. Our use of domestic and international third-party contractors, consultants and staffing agencies also subjects us to potential co-employment liability claims.

Furthermore, if we were to lose key management personnel, we would likely lose some portion of our institutional knowledge and technical know-how, potentially causing a substantial delay in one or more of our development programs until adequate replacement personnel could be hired and trained. We currently have a severance policy applicable to all employees and a change in control policy applicable to senior executives.

We do not have key man life insurance policies on the lives of any of our employees.

Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.

Our operations, including laboratories, offices and other research facilities, are located in four buildings in San Diego, California. In addition, we have a satellite office in South San Francisco, California. We depend on our facilities and on our collaborators, contractors and vendors for the continued operation of our business. Natural disasters or other catastrophic events, interruptions in the supply of natural resources, political and governmental changes, wildfires and other fires, floods, explosions, actions of animal rights activists, earthquakes and civil unrest could disrupt our operations or those of our collaborators, contractors and vendors. Even though we believe we carry commercially reasonable business interruption and liability insurance, and our contractors may carry liability insurance that protect us in certain events, we may suffer losses as a result of business interruptions that exceed the coverage available under our and our contractors’ insurance policies or for which we or our contractors do not have coverage. Any natural disaster or catastrophic event could have a significant negative impact on our operations and financial results. Moreover, any such event could delay our research and development programs.

If we or our collaborators do not achieve projected development, clinical, regulatory or sales goals in the timeframes we publicly announce or otherwise expect, the commercialization of our products and the development of our product candidates may be delayed and, as a result, our stock price may decline, and we may face lawsuits relating to such declines.

From time to time, we or our collaborators may publicly articulate the estimated timing for the accomplishment of certain scientific, clinical, regulatory and other product development goals. The accomplishment of any goal is typically based on numerous assumptions, and the achievement of a particular goal may be delayed for any number of reasons both within and outside of our control. If scientific, regulatory, strategic or other factors cause us to not meet a goal, regardless of whether that goal has been publicly articulated or not, our stock price may decline rapidly. For example, the announcement in April 2014 of the temporary halting of our Phase 2 clinical trial for PEGPH20 caused a rapid decline in our stock price. Stock price declines may also trigger direct or derivative shareholder lawsuits. As with any litigation proceeding, the eventual outcome of any legal action is difficult to predict. If any such lawsuits occur, we will incur expenses in connection with the defense of these lawsuits, and we may have to pay substantial damages or settlement costs in connection with any resolution thereof. Although we have insurance coverage against which we may claim recovery against some of these expenses and costs, the amount of coverage may not be adequate to cover the full amount or certain expenses and costs may be outside the scope of the policies we maintain. In the event of an adverse outcome or outcomes, our business could be materially harmed from depletion of cash resources, negative impact on our reputation, or restrictions or changes to our governance or other processes that may result from any final disposition of the lawsuit. Moreover, responding to and defending pending litigation significantly diverts management’s attention from our operations.

In addition, the consistent failure to meet publicly announced milestones may erode the credibility of our management team with respect to future milestone estimates.

Future acquisitions could disrupt our business and harm our financial condition.

In order to augment our product pipeline or otherwise strengthen our business, we may decide to acquire additional businesses, products and technologies. As we have limited experience in evaluating and completing acquisitions, our ability as an organization to make such acquisitions is unproven. Acquisitions could require significant capital infusions and could involve many risks, including, but not limited to, the following:


•	we may have to issue convertible debt or equity securities to complete an acquisition, which would dilute our stockholders and could adversely affect the market price of our common stock;


•	an acquisition may negatively impact our results of operations because it may require us to amortize or write down amounts related to goodwill and other intangible assets, or incur or assume substantial debt or liabilities, or it may cause adverse tax consequences, substantial depreciation or deferred compensation charges;


•	we may encounter difficulties in assimilating and integrating the business, products, technologies, personnel or operations of companies that we acquire;


•	certain acquisitions may impact our relationship with existing or potential collaborators who are competitive with the acquired business, products or technologies;


•	acquisitions may require significant capital infusions and the acquired businesses, products or technologies may not generate sufficient value to justify acquisition costs;


•	we may take on liabilities from the acquired company such as debt, legal liabilities or business risk which could be significant;


•	an acquisition may disrupt our ongoing business, divert resources, increase our expenses and distract our management;


•	acquisitions may involve the entry into a geographic or business market in which we have little or no prior experience; and


•	key personnel of an acquired company may decide not to work for us.

If any of these risks occurred, it could adversely affect our business, financial condition and operating results. There is no assurance that we will be able to identify or consummate any future acquisitions on acceptable terms, or at all. If we do pursue any acquisitions, it is possible that we may not realize the anticipated benefits from such acquisitions or that the market will not view such acquisitions positively.

Security breaches may disrupt our operations and harm our operating results.

The wrongful use, theft, deliberate sabotage or any other type of security breach with respect to any of our information technology storage and access systems could result in the disruption of our ability to use such systems or disclosure or dissemination of our proprietary and confidential information that is electronically stored, including research or clinical data, resulting in a material adverse impact on our business, operating results and financial condition. Our security and data recovery measures may not be adequate to protect against computer viruses, break-ins, and similar disruptions from unauthorized tampering with our electronic storage systems. Furthermore, any physical break-in or trespass of our facilities could result in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data or damage to our research and development equipment and assets. Such adverse effects could be material and irrevocable to our business, operating results and financial condition.

Risks Related To Ownership of Our Common Stock

Our stock price is subject to significant volatility.

We participate in a highly dynamic industry which often results in significant volatility in the market price of common stock irrespective of company performance. The high and low sales prices of our common stock during the twelve months ended March 31, 2017 were $15.20 and $7.70, respectively. We expect our stock price to continue to be subject to significant volatility and, in addition to the other risks and uncertainties described elsewhere in this Quarterly Report on Form 10-Q and all other risks and uncertainties that are either not known to us at this time or which we deem to be immaterial, any of the following factors may lead to a significant drop in our stock price:


•	the presence of competitive products to those being developed by us;


•	failure (actual or perceived) of our collaborators to devote attention or resources to the development or commercialization of product candidates licensed to such collaborator;


•	a dispute regarding our failure, or the failure of one of our third party collaborators, to comply with the terms of a collaboration agreement;


•	the termination, for any reason, of any of our collaboration agreements;


•	the sale of common stock by any significant stockholder, including, but not limited to, direct or indirect sales by members of management or our Board of Directors;


•	the resignation, or other departure, of members of management or our Board of Directors;


•	general negative conditions in the healthcare industry;


•	general negative conditions in the financial markets;


•	the cost associated with obtaining regulatory approval for any of our proprietary or collaboration product candidates;


•	the failure, for any reason, to secure or defend our intellectual property position;


•	for those products that are not yet approved for commercial sale, the failure or delay of applicable regulatory bodies to approve such products;


•	identification of safety or tolerability issues;


•	failure of clinical trials to meet efficacy endpoints;


•	suspensions or delays in the conduct of clinical trials or securing of regulatory approvals;


•	adverse regulatory action with respect to our and our collaborators’ products and product candidates such as clinical holds, imposition of onerous requirements for approval or product recalls;


•	our failure, or the failure of our third party collaborators, to successfully commercialize products approved by applicable regulatory bodies such as the FDA;


•	our failure, or the failure of our third party collaborators, to generate product revenues anticipated by investors;


•	disruptions in our clinical or commercial supply chains, including disruptions caused by problems with a bulk rHuPH20 contract manufacturer or a fill and finish manufacturer for any product or product candidate;


•	the sale of additional debt and/or equity securities by us;


•	our failure to obtain financing on acceptable terms or at all; or


•	a restructuring of our operations.

Future transactions where we raise capital may negatively affect our stock price.

We are currently a “Well-Known Seasoned Issuer” and may file automatic shelf registration statements at any time with the SEC. In February 2017, we filed an automatic shelf registration statement on Form S-3 (Registration No. 333-216315) with the SEC. Sales of substantial amounts of shares of our common stock or other securities under our current or future shelf registration statements could lower the market price of our common stock and impair our ability to raise capital through the sale of equity securities.

Anti-takeover provisions in our charter documents and Delaware law may make an acquisition of us more difficult.

Anti-takeover provisions in our charter documents and Delaware law may make an acquisition of us more difficult. First, our board of directors is classified into three classes of directors. Under Delaware law, directors of a corporation with a classified board may be removed only for cause unless the corporation’s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation, as amended, does not provide otherwise. In addition, our bylaws limit who may call special meetings of stockholders, permitting only stockholders holding at least 50% of our outstanding shares to call a special meeting of stockholders. Our amended and restated certificate of incorporation, as amended, does not include a provision for cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient percentage of a class of shares may be able to ensure the election of one or more directors. Finally, our bylaws establish procedures, including advance notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals.

These provisions may discourage potential takeover attempts, discourage bids for our common stock at a premium over market price or adversely affect the market price of, and the voting and other rights of the holders of, our common stock. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors other than the candidates nominated by our board of directors.

In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit large stockholders from consummating a merger with, or acquisition of, us.

These provisions may deter an acquisition of us that might otherwise be attractive to stockholders.

Risks Related to Our Industry

Our products must receive regulatory approval before they can be sold, and compliance with the extensive government regulations is expensive and time consuming and may result in the delay or cancellation of product sales, introductions or modifications.

Extensive industry regulation has had, and will continue to have, a significant impact on our business. All pharmaceutical companies, including ours, are subject to extensive, complex, costly and evolving regulation by the health regulatory agencies including the FDA (and with respect to controlled drug substances, the U.S. Drug Enforcement Administration (DEA)) and equivalent foreign regulatory agencies and state and local/regional government agencies. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other domestic and foreign statutes and regulations govern or influence the testing, manufacturing, packaging, labeling, storing, recordkeeping, safety, approval, advertising, promotion, sale and distribution of our products. We are dependent on receiving FDA and other governmental approvals, including regulatory approvals in jurisdictions outside the United States, prior to manufacturing, marketing and shipping our products. Consequently, there is always a risk that the FDA or other applicable governmental authorities, including those outside the United States, will not approve our products or may impose onerous, costly and time-consuming requirements such as additional clinical or animal testing. Regulatory authorities may require that we change our studies or conduct additional studies, which may significantly delay or make continued pursuit of approval commercially unattractive. For example, the approval of Baxalta’s HYQVIA BLA was delayed by the FDA until we and Baxalta provided additional preclinical data sufficient to address concerns regarding non-neutralizing antibodies to rHuPH20 that were detected in the registration trial. Although these antibodies have not been associated with any known adverse clinical effects, and the HYQVIA BLA was approved by the FDA in September 2014, the FDA or other foreign regulatory agency may, at any time, halt our and our collaborators’ development and commercialization activities due to safety concerns. In addition, even if our products are approved, regulatory agencies may also take post-approval action limiting or revoking our ability to sell our products. Any of these regulatory actions may adversely affect the economic benefit we may derive from our products and therefore harm our financial condition.

Under certain of these regulations, we and our contract suppliers and manufacturers are subject to periodic inspection of our or their respective facilities, procedures and operations and/or the testing of products by the FDA, the DEA and other authorities, which conduct periodic inspections to confirm that we and our contract suppliers and manufacturers are in compliance with all applicable regulations. The FDA also conducts pre-approval and post-approval reviews and plant inspections to determine whether our systems, or our contract suppliers’ and manufacturers’ processes, are in compliance with cGMP and other FDA regulations. If we, or our contract supplier, fail these inspections, we may not be able to commercialize our product in a timely manner without incurring significant additional costs, or at all.

In addition, the FDA imposes a number of complex regulatory requirements on entities that advertise and promote pharmaceuticals including, but not limited to, standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the internet.

We may be subject, directly or indirectly, to various broad federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.

Our business operations and activities may be directly, or indirectly, subject to various broad federal and state healthcare laws, including without limitation, anti-kickback laws, the Foreign Corrupt Practices Act, false claims laws, civil monetary penalty laws, data privacy and security laws, tracing and tracking laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as sales, marketing and education programs. Many states have similar healthcare fraud and abuse laws, some of which may be broader in scope and may not be limited to items or services for which payment is made by a government health care program.

Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While we have adopted a healthcare corporate compliance program, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.

In addition, any sales of products outside the U.S. will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.

We may be required to initiate or defend against legal proceedings related to intellectual property rights, which may result in substantial expense, delay and/or cessation of the development and commercialization of our products.

We primarily rely on patents to protect our intellectual property rights. The strength of this protection, however, is uncertain. For example, it is not certain that:


•	we will be able to obtain patent protection for our products and technologies;


•	the scope of any of our issued patents will be sufficient to provide commercially significant exclusivity for our products and technologies;


•	others will not independently develop similar or alternative technologies or duplicate our technologies and obtain patent protection before we do; and


•	any of our issued patents, or patent pending applications that result in issued patents, will be held valid, enforceable and infringed in the event the patents are asserted against others.

We currently own or license several patents and also have pending patent applications applicable to rHuPH20 and other proprietary materials. There can be no assurance that our existing patents, or any patents issued to us as a result of our pending patent applications, will provide a basis for commercially viable products, will provide us with any competitive advantages, or will not face third party challenges or be the subject of further proceedings limiting their scope or enforceability. Any weaknesses or limitations in our patent portfolio could have a material adverse effect on our business and financial condition. In addition, if any of our pending patent applications do not result in issued patents, or result in issued patents with narrow or limited claims, this could result in us having no or limited protection against generic or biosimilar competition against our product candidates which would have a material adverse effect on our business and financial condition.

We may become involved in interference proceedings in the U.S. Patent and Trademark Office, or other proceedings in other jurisdictions, to determine the priority, validity or enforceability of our patents. In addition, costly litigation could be necessary to protect our patent position.

We also rely on trademarks to protect the names of our products (e.g. Hylenex recombinant). We may not be able to obtain trademark protection for any proposed product names we select. In addition, product names for pharmaceutical products must be approved by health regulatory authorities such as the FDA in addition to meeting the legal standards required for trademark protection and product names we propose may not be timely approved by regulatory agencies which may delay product launch. In addition, our trademarks may be challenged by others. If we enforce our trademarks against third parties, such enforcement proceedings may be expensive.

We also rely on trade secrets, unpatented proprietary know-how and continuing technological innovation that we seek to protect with confidentiality agreements with employees, consultants and others with whom we discuss our business. Disputes may arise concerning the ownership of intellectual property or the applicability or enforceability of these agreements, and we might not be able to resolve these disputes in our favor.

In addition to protecting our own intellectual property rights, third parties may assert patent, trademark or copyright infringement or other intellectual property claims against us. If we become involved in any intellectual property litigation, we may be required to pay substantial damages, including but not limited to treble damages, attorneys’ fees and costs, for past infringement if it is ultimately determined that our products infringe a third party’s intellectual property rights. Even if infringement claims against us are without merit, defending a lawsuit takes significant time, may be expensive and may divert management’s attention from other business concerns. Further, we may be stopped from developing, manufacturing or selling our products until we obtain a license from the owner of the relevant technology or other intellectual property rights. If such a license is available at all, it may require us to pay substantial royalties or other fees.

Patent protection for protein-based therapeutic products and other biotechnology inventions is subject to a great deal of uncertainty, and if patent laws or the interpretation of patent laws change, our competitors may be able to develop and commercialize products based on our discoveries.

Patent protection for protein-based therapeutic products is highly uncertain and involves complex legal and factual questions. In recent years, there have been significant changes in patent law, including the legal standards that govern the scope of protein and biotechnology patents. Standards for patentability of full-length and partial genes, and their corresponding proteins, are changing. Recent court decisions have made it more difficult to obtain patents, by making it more difficult to satisfy the patentable subject matter requirement and the requirement of non-obviousness, have decreased the availability of injunctions against infringers, and have increased the likelihood of challenging the validity of a patent through a declaratory judgment action. Taken together, these decisions could make it more difficult and costly for us to obtain, license and enforce our patents. In addition, the Leahy-Smith America Invents Act (HR 1249) was signed into law in September 2011, which among other changes to the U.S. patent laws, changes patent priority from “first to invent” to “first to file,” implements a post-grant opposition system for patents and provides for a prior user defense to infringement. These judicial and legislative changes have introduced significant uncertainty in the patent law landscape and may potentially negatively impact our ability to procure, maintain and enforce patents to provide exclusivity for our products.

There also have been, and continue to be, policy discussions concerning the scope of patent protection awarded to biotechnology inventions. Social and political opposition to biotechnology patents may lead to narrower patent protection within the biotechnology industry. Social and political opposition to patents on genes and proteins and recent court decisions concerning patentability of isolated genes may lead to narrower patent protection, or narrower claim interpretation, for isolated genes, their corresponding proteins and inventions related to their use, formulation and manufacture. Patent protection relating to biotechnology products is also subject to a great deal of uncertainty outside the U.S., and patent laws are evolving and undergoing revision in many countries. Changes in, or different interpretations of, patent laws worldwide may result in our inability to obtain or enforce patents, and may allow others to use our discoveries to develop and commercialize competitive products, which would impair our business.

If third party reimbursement and customer contracts are not available, our products may not be accepted in the market.

Our ability to earn sufficient returns on our products will depend in part on the extent to which reimbursement for our products and related treatments will be available from government health administration authorities, private health insurers, managed care organizations and other healthcare providers.

Third-party payors are increasingly attempting to limit both the coverage and the level of reimbursement of new drug products to contain costs. Consequently, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. Third party payors may not establish adequate levels of reimbursement for the products that we commercialize, which could limit their market acceptance and result in a material adverse effect on our revenues and financial condition.

Customer contracts, such as with group purchasing organizations and hospital formularies, will often not offer contract or formulary status without either the lowest price or substantial proven clinical differentiation. If our products are compared to animal-derived hyaluronidases by these entities, it is possible that neither of these conditions will be met, which could limit market acceptance and result in a material adverse effect on our revenues and financial condition.

The rising cost of healthcare and related pharmaceutical product pricing has led to cost containment pressures that could cause us to sell our products at lower prices, resulting in less revenue to us.

Any of the proprietary or collaboration products that have been, or in the future are, approved by the FDA may be purchased or reimbursed by state and federal government authorities, private health insurers and other organizations, such as health maintenance organizations and managed care organizations. Such third party payors increasingly challenge pharmaceutical product pricing. The trend toward managed healthcare in the U.S., the growth of such organizations, and various legislative proposals and enactments to reform healthcare and government insurance programs, including the Medicare Prescription Drug Modernization Act of 2003, could significantly influence the manner in which pharmaceutical products are prescribed and purchased, resulting in lower prices and/or a reduction in demand. Such cost containment measures and healthcare reforms could adversely affect our ability to sell our products.

In March 2010, the U.S. adopted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (the PPACA). This law substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The PPACA contains a number of provisions that are expected to impact our business and operations, in some cases in ways we cannot currently predict. Changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, fraud and abuse and enforcement. These changes will impact existing government healthcare programs and will result in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program.

Additional provisions of the PPACA may negatively affect our revenues in the future. For example, the PPACA imposes a non-deductible excise tax on pharmaceutical manufacturers or importers that sell branded prescription drugs to U.S. government programs that we believe will impact our revenues from our products. In addition, as part of the PPACA’s provisions closing a funding gap that currently exists in the Medicare Part D prescription drug program, we will also be required to provide a 50% discount on branded prescription drugs dispensed to beneficiaries under this prescription drug program. Recently, Congress and the new administration have proposed and taken various steps to revise, repeal or delay implementation of, various aspects of the Heathcare Reform Act. We expect that the PPACA, as it may be amended, and other healthcare reform measures that may be

adopted in the future could have a material adverse effect on our industry generally and on our ability to maintain or increase our product sales or successfully commercialize our product candidates and could limit or eliminate our future spending on development projects.

Furthermore, individual states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third party payors or other restrictions could negatively and materially impact our revenues and financial condition. We anticipate that we will encounter similar regulatory and legislative issues in most other countries outside the U.S.

We face intense competition and rapid technological change that could result in the development of products by others that are superior to our proprietary and collaboration products under development.

Our proprietary and collaboration products have numerous competitors in the U.S. and abroad including, among others, major pharmaceutical and specialized biotechnology firms, universities and other research institutions that have developed competing products. The competitors for Hylenex recombinant include, but are not limited to, Valeant Pharmaceuticals International, Inc.’s FDA-approved product, Vitrase^®, an ovine (ram) hyaluronidase, and Amphastar Pharmaceuticals, Inc.’s product, Amphadase^®, a bovine (bull) hyaluronidase. For our PEGPH20 product candidate, such competitors may include major pharmaceutical and specialized biotechnology firms. These competitors may develop technologies and products that are more effective, safer, or less costly than our current or future proprietary and collaboration product candidates or that could render our technologies and product candidates obsolete or noncompetitive. Many of these competitors have substantially more resources and product development, manufacturing and marketing experience and capabilities than we do. In addition, many of our competitors have significantly greater experience than we do in undertaking preclinical testing and clinical trials of pharmaceutical product candidates and obtaining FDA and other regulatory approvals of products and therapies for use in healthcare.


Item 3.	Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in our market risks during the quarter ended March 31, 2017.

As of March 31, 2017, our cash equivalents and marketable securities consisted of investments in money market funds, U.S. Treasury securities, corporate debt obligations and commercial paper. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments that we invest in could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. Based on our current investment portfolio as of March 31, 2017, we do not believe that our results of operations would be materially impacted by an immediate change of 10% in interest rates.

We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and marketable securities have significant risk of default or illiquidity. We made this determination based on discussions with our investment advisors and a review of our holdings. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. All of our cash equivalents and marketable securities are recorded at fair market value.


Item 4.	Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decision regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.

Changes in Internal Control Over Financial Reporting

There have been no significant changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION


Item 1.	Legal Proceedings


Item 1A.	Risk Factors

We have provided updated Risk Factors in the section labeled “Risk Factors” in Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. The “Risk Factors” section provides updated information in certain areas, particularly with respect to the risks and uncertainties regarding the regulatory approval of proprietary and collaboration product candidates. We do not believe the updates have materially changed the type or magnitude of risks we face in comparison to the disclosure provided in our most recent Annual Report on Form 10-K.


Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds

None.


Item 3.	Defaults Upon Senior Securities

Not applicable.


Item 4.	Mine Safety Disclosures

Not applicable.


Item 5.	Other Information

None.


Item 6.	Exhibits



3.1		Composite Certificate of Incorporation (1)

3.2		Bylaws, as amended (2)

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended

31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended

32		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		Instance Document

101.SCH		Taxonomy Extension Schema Document

101.CAL		Taxonomy Extension Calculation Linkbase Document

101.DEF		Taxonomy Extension Definition Linkbase Document

101.LAB		Taxonomy Extension Label Linkbase Document

101.PRE		Taxonomy Extension Presentation Linkbase Document


(1)	Incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q, filed August 7, 2013 (File No. 001-32335).


(2)	Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed December 19, 2016 (File No. 001-32335).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



		Halozyme Therapeutics, Inc., a Delaware corporation
		Halozyme Therapeutics, Inc., a Delaware corporation

Dated:	May 9, 2017	/s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.
		Helen I. Torley, M.B. Ch.B., M.R.C.P. President and Chief Executive Officer (Principal Executive Officer)



Dated:	May 9, 2017	/s/ Laurie D. Stelzer
		Laurie D. Stelzer Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 ex311q12017.htm EXHIBIT 31.1 Exhibit

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of Halozyme Therapeutics, Inc. certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;


4.	The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:


a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)	evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)	disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and


5.	The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):


a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and


b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

EX-31.2 3 ex312q12017.htm EXHIBIT 31.2 Exhibit

EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Laurie D. Stelzer, Chief Financial Officer of Halozyme Therapeutics, Inc. certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;


4.	The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:


a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)	evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)	disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and


5.	The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):


a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and


b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

EX-32 4 ex32q12017.htm EXHIBIT 32 Exhibit

EXHIBIT 32

CERTIFICATION OF

CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the “Registrant”) on Form 10-Q for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and


(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the “Registrant”) on Form 10-Q for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Laurie D. Stelzer, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and


(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

EX-101.INS 5 halo-20170331.xml XBRL INSTANCE DOCUMENT 0001159036 2017-01-01 2017-03-31 0001159036 halo:OthercollaboratorsMember 2017-01-01 2017-03-31 0001159036 halo:RocheMember 2017-01-01 2017-03-31 0001159036 2017-05-01 0001159036 2017-03-31 0001159036 2016-12-31 0001159036 2016-01-01 2016-03-31 0001159036 2016-03-31 0001159036 2015-12-31 0001159036 halo:HylenexRecombinantMember 2017-03-31 0001159036 us-gaap:MaximumMember 2017-01-01 2017-03-31 0001159036 halo:InlicensetechnologiesMember 2017-01-01 2017-03-31 0001159036 halo:HylenexRecombinantMember 2016-12-31 0001159036 2016-01-01 2016-12-31 0001159036 halo:BulkrHuPH20Member 2017-03-31 0001159036 us-gaap:MinimumMember 2017-01-01 2017-03-31 0001159036 halo:BulkrHuPH20Member 2016-12-31 0001159036 us-gaap:FairValueInputsLevel3Member 2016-12-31 0001159036 us-gaap:MoneyMarketFundsMember 2016-12-31 0001159036 us-gaap:FairValueInputsLevel2Member 2017-03-31 0001159036 us-gaap:FairValueInputsLevel1Member 2017-03-31 0001159036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2017-03-31 0001159036 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2017-03-31 0001159036 us-gaap:FairValueInputsLevel1Member 2016-12-31 0001159036 us-gaap:CommercialPaperMember 2016-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2016-12-31 0001159036 us-gaap:FairValueInputsLevel2Member 2016-12-31 0001159036 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001159036 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2017-03-31 0001159036 us-gaap:USTreasurySecuritiesMember 2016-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember 2017-03-31 0001159036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2017-03-31 0001159036 us-gaap:USTreasurySecuritiesMember 2017-03-31 0001159036 us-gaap:CommercialPaperMember 2017-03-31 0001159036 us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0001159036 us-gaap:MoneyMarketFundsMember 2017-03-31 0001159036 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2016-12-31 0001159036 us-gaap:USTreasurySecuritiesMember 2016-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0001159036 us-gaap:CommercialPaperMember 2016-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember 2017-03-31 0001159036 us-gaap:USTreasurySecuritiesMember 2017-03-31 0001159036 us-gaap:CommercialPaperMember 2017-03-31 0001159036 us-gaap:FairValueInputsLevel3Member 2017-03-31 0001159036 halo:RocheMember 2017-03-31 0001159036 halo:BaxaltaMember 2017-03-31 0001159036 halo:AbbVieMember 2017-01-01 2017-03-31 0001159036 halo:JanssenMember 2017-01-01 2017-03-31 0001159036 halo:LillyMember 2017-01-01 2017-03-31 0001159036 halo:RocheMember 2017-03-31 0001159036 halo:PfizerMember 2016-01-01 2016-12-31 0001159036 halo:BaxaltaMember 2017-01-01 2017-03-31 0001159036 halo:LillyMember 2017-03-31 0001159036 halo:AbbVieMember 2017-03-31 0001159036 halo:PfizerMember 2017-01-01 2017-03-31 0001159036 halo:PfizerMember 2017-03-31 0001159036 halo:JanssenMember 2017-03-31 0001159036 halo:PfizerJanssenandAbbVieMember 2017-01-01 2017-03-31 0001159036 halo:RocheMember 2016-12-31 0001159036 halo:BaxaltaMember 2017-03-31 0001159036 halo:PfizerJanssenandAbbVieMember 2016-01-01 2016-03-31 0001159036 halo:BaxaltaMember 2016-12-31 0001159036 halo:OthercollaboratorsMember 2017-03-31 0001159036 halo:RocheMember 2016-01-01 2016-03-31 0001159036 halo:BaxaltaMember 2016-01-01 2016-03-31 0001159036 us-gaap:MachineryAndEquipmentMember 2016-12-31 0001159036 us-gaap:MachineryAndEquipmentMember 2017-03-31 0001159036 us-gaap:LeaseholdImprovementsMember 2017-03-31 0001159036 halo:ResearchEquipmentMember 2017-03-31 0001159036 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001159036 halo:ResearchEquipmentMember 2016-12-31 0001159036 us-gaap:CollaborativeArrangementMember 2017-03-31 0001159036 us-gaap:ResearchAndDevelopmentArrangementMember 2017-03-31 0001159036 us-gaap:CollaborativeArrangementMember 2016-12-31 0001159036 halo:InlicensetechnologiesMember 2017-03-31 0001159036 us-gaap:ResearchAndDevelopmentArrangementMember 2016-12-31 0001159036 halo:InlicensetechnologiesMember 2016-12-31 0001159036 us-gaap:SecuredDebtMember 2017-03-31 0001159036 us-gaap:SeniorLoansMember 2017-03-31 0001159036 us-gaap:SecuredDebtMember 2017-01-01 2017-03-31 0001159036 halo:RoyaltybackedLoanMember 2017-01-01 2017-03-31 0001159036 us-gaap:SeniorLoansMember 2017-01-01 2017-03-31 0001159036 halo:RoyaltybackedLoanMember 2017-03-31 0001159036 halo:A2017Member halo:RoyaltybackedLoanMember 2017-01-01 2017-03-31 0001159036 us-gaap:SecuredDebtMember 2016-12-31 0001159036 halo:RoyaltybackedLoanMember 2016-01-01 2016-03-31 0001159036 halo:RoyaltybackedLoanMember us-gaap:MaximumMember 2017-01-01 2017-03-31 0001159036 halo:A2016Member halo:RoyaltybackedLoanMember 2017-01-01 2017-03-31 0001159036 halo:A2020QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2017-01-01 2017-03-31 0001159036 us-gaap:SeniorLoansMember us-gaap:MaximumMember 2017-03-31 0001159036 halo:A2017QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2017-01-01 2017-03-31 0001159036 us-gaap:SecuredDebtMember 2016-01-01 2016-03-31 0001159036 us-gaap:SeniorLoansMember 2016-06-01 2016-06-30 0001159036 us-gaap:SeniorLoansMember us-gaap:MinimumMember 2017-03-31 0001159036 halo:A2019QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2017-01-01 2017-03-31 0001159036 us-gaap:SecuredDebtMember 2013-12-01 2013-12-31 0001159036 halo:A2018QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2017-01-01 2017-03-31 0001159036 halo:RoyaltybackedLoanMember us-gaap:MinimumMember 2017-01-01 2017-03-31 0001159036 halo:A2018andthereafterMember halo:RoyaltybackedLoanMember 2017-01-01 2017-03-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0001159036 us-gaap:RestrictedStockMember 2017-03-31 0001159036 us-gaap:EmployeeStockOptionMember 2017-03-31 0001159036 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0001159036 us-gaap:RestrictedStockMember 2017-01-01 2017-03-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2017-03-31 0001159036 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001159036 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0001159036 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-03-31 0001159036 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-03-31 0001159036 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0001159036 halo:RSURSAandPRSUawardsMember 2017-01-01 2017-03-31 0001159036 halo:RSURSAandPRSUawardsMember 2016-01-01 2016-03-31 0001159036 us-gaap:MinimumMember 2016-01-01 2016-03-31 0001159036 us-gaap:MaximumMember 2016-01-01 2016-03-31 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-03-31 0001159036 us-gaap:RestrictedStockMember 2016-01-01 2016-03-31 iso4217:USD xbrli:pure iso4217:USD xbrli:shares xbrli:shares halo:Compound halo:Segment false --12-31 Q1 2017 2017-03-31 10-Q 0001159036 129840030 Large Accelerated Filer HALOZYME THERAPEUTICS INC. HALO 6151000 2921000 2234000 2090000 7854000 8023000 100000 9522000 11970000 17000 26000 3225000 3670000 62500000 12000000 559000 582000 23000000 4000000 15000000 10200000 43792000 69593000 67264000 45688000 13000000 P10Y 1.05 0.02 0.01 43900000 P10Y P10Y P10Y P10Y P10Y P10Y 0.0725 0.085 0.055 23000000 10000000 15300000 33000000 12500000 20000000 9 4 2 2 10 1 1 5 8 9 5 5 6 13 1 3 2 2 1 P90D P30D P90D P90D P60D P30D 8613000 8345000 29000000 17000000 15250000 33000000 93750000 16500000 79000000 3000000 8000000 4100000 0 0.5 1

3578000

3079000

16239000

13034000

15680000

12452000

-213000

-16000

28838000

24961000

28821000

24935000

11919000

12482000

-6000

-49000

552737000

559659000

5817000

2109000

3708000

2584000

3233000

7315000

2566000

4749000

3274000

4041000

1054000

487000

13000000

16400000

261515000

226767000

256532000

222354000

199133000

154926000

44207000

172611000

104788000

67823000

25000

1000

24000

1000

31000

15000

16000

47000

18000

29000

138217000

4000000

40207000

94010000

4000000

40207000

94010000

133797000

30683000

33140000

69974000

30683000

33140000

69974000

138223000

4000000

40221000

94002000

133843000

30683000

33158000

70002000

138217000

133797000

124800000

66764000

45188000

60916000

4000000

34814000

25801000

-21576000

0.001

200000000

129502000

129822000

129502000

129822000

130000

-19629000

-32940000

7762000

7544000

58668000

57094000

0.015

0.007

in compliance

8.75% plus the three-month LIBOR rate

150000000

50000000

70000000

1500000

700000

20000000

0.0755

0.0825

2016-06-07

2016-01-26

2050-12-31

2018-01-01

2021-01-01

final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050

interest only payments for the first 18 months

13750000

18750000

21250000

22500000

4250000

1300000

2900000

15000000

prime rate as reported in The Wall Street Journal on the draw-down date plus 4.75%

0.099

400000

44618000

8200000

43918000

35709000

35700000

8209000

700000

42895000

8000000

42895000

34900000

34877000

8018000

4793000

4093000

39825000

38802000

800000

200000

800000

500000

600000

489000

602000

-0.16

-0.26

11539000

5045000

53470000

7281000

22742000

P2Y11M

P2Y1M

P3Y4M

1000

-44000

-19816000

-32687000

210000

-4565000

-4413000

-6867000

-3228000

856000

-333000

2522000

-4668000

1900000

3876000

5448000

2600000

1300000

4000000

1400000

1012000

537000

14623000

12300000

2300000

14290000

12600000

1700000

761000

868000

12850000

12885000

261515000

226767000

54585000

61708000

18172000

4152000

199228000

184430000

17393000

29601000

144446000

-3382000

-105622000

4265000

-13023000

-22459000

-19816000

-32897000

500000

-16169000

-27526000

4552000

4276000

1100000

400000

1530000

602000

4000

187000

-40000

358000

326000

5000

70000

114000

229000

287000

1661000

1525000

1890000

700000

1700000

126431000

54830000

1099000

99000

0.001

20000000

21467000

16799000

21248000

16627000

219000

172000

9663000

6327000

148046000

285000

-393000

21908000

59194000

1000000

600000

16183000

10479000

2331000

3373000

16223000

10483000

2345000

3395000

4264000

3741000

1524000

1723000

3885000

2989000

40100000

36935000

500000

-585342000

-618239000

6000000

42499000

29568000

11387000

13982000

12940000

11434000

158900000

55100000

55000000

10806000

12615000

5817000

7315000

0.000

0.0173

0.0194

0.0127

0.0192

0.691

0.675

0.717

0.710

2800000

2200000

12500000

15500000

6.22

7.78

P5Y5M

P5Y7M

70288

79499

807036

106389

252305

156185

74522

-32481000

-58499000

127615000

128615000

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,002</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,974</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,683</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,683</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,002</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,010</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on February 28, 2017. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC and Halozyme Switzerland GmbH. All intercompany accounts and transactions have been eliminated. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fees and event-based payments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reimbursement for research and development services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,793</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,825</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes, by major security type, our cash equivalents and marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,814</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,814</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   securities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,683</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,683</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,823</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,611</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,926</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,002</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,974</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,683</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,683</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,002</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,010</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$124.8 million</font><font style="font-family:inherit;font-size:10pt;"> of our available-for-sale marketable securities were scheduled to mature within the next 12 months. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;"> available-for-sale marketable securities were in a gross unrealized loss position, all of which had been in such position for less than 12 months. Based on our review of these marketable securities, we believe we had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> other-than-temporary impairments on these securities as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes, by major security type, our cash equivalents and marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,814</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,814</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   securities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,683</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,683</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,823</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,611</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,926</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> transfers between Level 1 and Level 2 of the fair value hierarchy during the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. We have </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> instruments that were classified within Level 3 as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders’ deficit. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the condensed consolidated statements of operations.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption and Pending Adoption of Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, Inventory: Simplifying the Measurement of Inventory.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance requires that for entities that measure inventory using the first-in, first-out method, inventory should be measured at the lower of cost or net realizable value. Topic 330, Inventory, currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximate normal profit margin. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2017. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The adoption did not have a material impact on our condensed consolidated financial position or results of operations.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.<br clear="none"/><br clear="none"/>In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current U.S. GAAP either is unclear or does not include specific guidance on the eight cash flow classification issues included in ASU 2016-15. The new guidance is an improvement to U.S. GAAP and is intended to reduce the current and potential future diversity in practice. ASU 2016-18 provides additional classification guidance for restricted cash, which requires that restricted cash be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2018. We have elected to early adopt as of January1, 2017. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at the beginning-of-period and end-of-period total amounts in the Condensed Consolidated Statements of Cash Flows have been adjusted to include $0.5 million of restricted cash for each of the periods presented. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall; Recognition and Measurement of Financial Assets and Financial Liabilities.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities to be measured at fair value with changes in the fair value recognized through net income. The new guidance requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2018. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently do not hold equity securities, and we are evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). In March, April, May and December 2016, the FASB issued additional guidance related to Topic 606.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new standard will supersede nearly all existing revenue recognition guidance. Under Topic 606, an entity is required to recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. Topic 606 defines a five-step process in order to achieve this core principle, which may require the use of judgment and estimates, and also requires expanded qualitative and quantitative disclosures relating to the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers, including significant judgments and estimates used. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized. The new standard permits adoption either by using (i) a full retrospective approach for all periods presented in the period of adoption or (ii) a modified retrospective approach where the new standard is applied in the financial statements starting with the year of adoption. Under both approaches, cumulative impact of the adoption is reflected as an adjustment to retained earnings (accumulated deficit) as of the earliest date presented in accordance with the new standard.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2018. Early adoption is permitted. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We plan to implement the new guidance on January 1, 2018. We currently plan to adopt using the modified retrospective approach; however, a final decision regarding the adoption method has not been finalized at this time. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. However, we anticipate an impact to the timing of recognition of payments related to certain of our license and collaboration agreements </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:10pt;">and the timing of recognition of our sales-based royalties.</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) </sup></font><font style="font-family:inherit;font-size:10pt;">We anticipate that this standard will have a material impact on our consolidated financial statements. Additional areas of impact may be identified as we continue our evaluation. We cannot reasonably estimate additional quantitative information related to the impact of the new standard on our consolidated financial statements at this time.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance requires lessees to recognize assets and liabilities for most leases and provides enhanced disclosures.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2019. Early adoption is permitted.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. However, we anticipate recognition of additional assets and corresponding liabilities related to our leases on our consolidated balance sheet. </font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,483</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,345</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,331</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,482</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,919</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,741</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</font><font style="font-family:inherit;font-size:8pt;"> </font><font style="font-family:inherit;font-size:10pt;">After receiving approval from the FDA or comparable regulatory agencies in foreign countries for a product, costs related to purchases and manufacturing of bulk rHuPH20 for such product are capitalized as inventory. The manufacturing costs of bulk rHuPH20 for the collaboration products, Herceptin SC, MabThera SC and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of <br clear="none"/>March 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront license fee payment for the application of rHuPH20 to the initial exclusive target</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulatory milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales-based milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments received</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of <br clear="none"/>March 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Election of additional exclusive targets and annual license maintenance fees for the right to </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   designate the remaining targets as exclusive targets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Clinical development milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulatory milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Sales-based milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments received</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of <br clear="none"/>March 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lilly</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AbbVie</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pfizer</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total payments received</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generate revenues from product sales and payments received under collaborative agreements. Collaborative agreement payments may include nonrefundable fees at the inception of the agreements, license fees, milestone and event-based payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk rHuPH20, and/or royalties on sales of products resulting from collaborative arrangements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenues in accordance with the authoritative guidance for revenue recognition. We recognize revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Sales,</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Hylenex </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recombinant</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers provide for selling prices that are fixed on the date of sale, although we offer discounts to certain group purchasing organizations (“GPOs”), hospitals and government programs. The wholesalers take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have developed sufficient historical experience and data to reasonably estimate future returns and chargebacks of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant. As a result, we recognize </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant product sales and related cost of product sales at the time title transfers to the wholesalers.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon recognition of revenue from product sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant, we record certain sales reserves and allowances as a reduction to gross revenue. These reserves and allowances include amounts for product returns (based primarily on an analysis of historical return patterns), distribution fees, prompt payment discounts, and GPO fees and other discounts and fees. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize product sales reserves and allowances as a reduction of product sales in the same period the related revenue is recognized. Because of the shelf life of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. If actual product return results differ from our estimates, we will be required to make adjustments to these allowances in the future, which could have an effect on product sales revenue and earnings in the period of adjustments. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Bulk rHuPH20</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries, sales of bulk rHuPH20 for use in collaboration commercial products are recognized as product sales when the materials have met all the specifications required for the customer’s acceptance and title and risk of loss have transferred to the customer. Following the receipt of European marketing approvals of Roche’s Herceptin SC product in August 2013 and MabThera</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> SC product in March 2014 and Baxalta’s HYQVIA product in May 2013, revenue from the sales of bulk rHuPH20 for these collaboration products has been recognized as product sales.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues under Collaborative Agreements</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into license and collaboration agreements under which our collaborators obtained worldwide rights for the use of our proprietary rHuPH20 enzyme in the development and commercialization of their biologic compounds identified as targets. These agreements may also contain other elements. Pursuant to the terms of these agreements, collaborators could be required to make various payments to us for each target, including nonrefundable upfront license fees, exclusivity fees, payments based on achievement of specified milestones designated in the collaborative agreements, annual maintenance fees, reimbursements of research and development services, payments for supply of bulk rHuPH20 used by the collaborator and/or royalties on sales of products resulting from collaborative agreements. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to account for the multiple-element arrangements, we identify the deliverables included within the collaborative agreement and evaluate which deliverables represent units of accounting. We then determine the appropriate method of revenue recognition for each unit based on the nature and timing of the delivery process. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The deliverables under our collaborative agreements include (i) the license to our rHuPH20 technology, (ii) at the collaborator’s request, research and development services which are reimbursed at contractually determined rates, and (iii) at the collaborator’s request, supply of bulk rHuPH20 which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. We base this determination on the collaborators’ ability to use the delivered items on their own without us supplying undelivered items, which we determine taking into consideration factors such as the research capabilities of the collaborator, the availability of research expertise in this field in the general marketplace, and the ability to procure the supply of bulk rHuPH20 from the marketplace. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (“VSOE”) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are not contingent upon the delivery of additional items or meeting other specified performance conditions. The consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonrefundable upfront license fees are recognized upon delivery of the license if facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of bulk rHuPH20, the relative selling price allocation of the license is equal to or exceeds the upfront license fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable and collectibility is reasonably assured. Upfront license fees are deferred if facts and circumstances dictate that the license does not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When collaborators have rights to elect additional targets, the rights are assessed as to whether they represent deliverables at the inception of the arrangement. In assessing these contingent deliverables, we consider whether the right is a substantive option. We consider a right to be a substantive option if the election of the additional targets is not essential to the functionality of the other elements in the arrangement and if we are truly at risk of the right being exercised. If the right is determined to be a substantive option, we further consider whether the right is priced at a significant and incremental discount that should be accounted for as an element of the arrangement. If a right is determined to be a substantive option and is not priced at a significant and incremental discount, it is not treated as a deliverable in the arrangement and receives no allocation at the inception of the arrangement of the original arrangement consideration. The right is then accounted for when and if it is exercised.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our collaborative agreements provide for milestone payments upon achievement of development and regulatory events and/or specified sales volumes of commercialized products by the collaborator. We account for milestone payments in accordance with the provisions of ASU No. 2010-17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition - Milestone Method </font><font style="font-family:inherit;font-size:10pt;">(“Milestone Method of Accounting”). We recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration relates solely to past performance; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the vendor.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reimbursements of research and development services are recognized as revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Revenue from the manufacture of bulk rHuPH20 is recognized when the materials have met all specifications required for the collaborator’s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control when any collaborator will request research and development services or supply of bulk rHuPH20; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of bulk rHuPH20. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since we receive royalty reports 60 days after quarter end, royalty revenue from sales of collaboration products by our collaborators is recognized in the quarter following the quarter in which the corresponding sales occurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaborative agreements typically provide the collaborators the right to terminate such agreement in whole or on a product-by-product or target-by-target basis at any time upon </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> prior written notice to us. There are no performance, cancellation, termination or refund provisions in any of our collaborative agreements that contain material financial consequences to us.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from product sales to collaborators</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from other product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,090</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,234</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from revenues under collaborative agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,921</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,034</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for distribution fees and discounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,680</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced research and development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and payroll taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,045</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced manufacturing expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,276</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,552</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total accrued expenses, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,821</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense by type of share-based award (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSAs, RSUs and PRSUs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,566</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,315</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,817</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,041</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,233</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,315</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,817</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid manufacturing expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,345</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">602</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total prepaid expenses and other assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,799</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total prepaid expenses and other assets, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,627</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The assumptions used in the Black-Scholes model were as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71.0-71.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.5-69.1%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average expected term (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92-1.94%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.27-1.73%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</font></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrecognized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Recognition Period</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,470</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.9</font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSAs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,281</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate our business in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on February 28, 2017. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC and Halozyme Switzerland GmbH. All intercompany accounts and transactions have been eliminated. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Marketable Securities </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, our cash equivalents consisted of money market funds and commercial paper.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders’ deficit. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the condensed consolidated statements of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, restricted cash of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> was pledged as collateral for the letters of credit.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consist of corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to receiving marketing approval from the U.S. Food and Drug Administration (“FDA”) or comparable regulatory agencies in foreign countries, costs related to purchases of bulk rHuPH20 and raw materials and the manufacturing of the product candidates are recorded as research and development expense. All direct manufacturing costs incurred after receiving marketing approval are capitalized as inventory. Inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, inventories consisted of </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant inventory, net, and </font><font style="font-family:inherit;font-size:10pt;">$12.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of bulk rHuPH20 for use in the manufacture of Baxalta’s and Roche’s collaboration products.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generate revenues from product sales and payments received under collaborative agreements. Collaborative agreement payments may include nonrefundable fees at the inception of the agreements, license fees, milestone and event-based payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk rHuPH20, and/or royalties on sales of products resulting from collaborative arrangements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenues in accordance with the authoritative guidance for revenue recognition. We recognize revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Sales,</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Hylenex </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recombinant</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers provide for selling prices that are fixed on the date of sale, although we offer discounts to certain group purchasing organizations (“GPOs”), hospitals and government programs. The wholesalers take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have developed sufficient historical experience and data to reasonably estimate future returns and chargebacks of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant. As a result, we recognize </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant product sales and related cost of product sales at the time title transfers to the wholesalers.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon recognition of revenue from product sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant, we record certain sales reserves and allowances as a reduction to gross revenue. These reserves and allowances include amounts for product returns (based primarily on an analysis of historical return patterns), distribution fees, prompt payment discounts, and GPO fees and other discounts and fees. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize product sales reserves and allowances as a reduction of product sales in the same period the related revenue is recognized. Because of the shelf life of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. If actual product return results differ from our estimates, we will be required to make adjustments to these allowances in the future, which could have an effect on product sales revenue and earnings in the period of adjustments. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Bulk rHuPH20</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries, sales of bulk rHuPH20 for use in collaboration commercial products are recognized as product sales when the materials have met all the specifications required for the customer’s acceptance and title and risk of loss have transferred to the customer. Following the receipt of European marketing approvals of Roche’s Herceptin SC product in August 2013 and MabThera</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> SC product in March 2014 and Baxalta’s HYQVIA product in May 2013, revenue from the sales of bulk rHuPH20 for these collaboration products has been recognized as product sales.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues under Collaborative Agreements</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into license and collaboration agreements under which our collaborators obtained worldwide rights for the use of our proprietary rHuPH20 enzyme in the development and commercialization of their biologic compounds identified as targets. These agreements may also contain other elements. Pursuant to the terms of these agreements, collaborators could be required to make various payments to us for each target, including nonrefundable upfront license fees, exclusivity fees, payments based on achievement of specified milestones designated in the collaborative agreements, annual maintenance fees, reimbursements of research and development services, payments for supply of bulk rHuPH20 used by the collaborator and/or royalties on sales of products resulting from collaborative agreements. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to account for the multiple-element arrangements, we identify the deliverables included within the collaborative agreement and evaluate which deliverables represent units of accounting. We then determine the appropriate method of revenue recognition for each unit based on the nature and timing of the delivery process. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The deliverables under our collaborative agreements include (i) the license to our rHuPH20 technology, (ii) at the collaborator’s request, research and development services which are reimbursed at contractually determined rates, and (iii) at the collaborator’s request, supply of bulk rHuPH20 which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. We base this determination on the collaborators’ ability to use the delivered items on their own without us supplying undelivered items, which we determine taking into consideration factors such as the research capabilities of the collaborator, the availability of research expertise in this field in the general marketplace, and the ability to procure the supply of bulk rHuPH20 from the marketplace. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (“VSOE”) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are not contingent upon the delivery of additional items or meeting other specified performance conditions. The consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nonrefundable upfront license fees are recognized upon delivery of the license if facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of bulk rHuPH20, the relative selling price allocation of the license is equal to or exceeds the upfront license fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable and collectibility is reasonably assured. Upfront license fees are deferred if facts and circumstances dictate that the license does not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When collaborators have rights to elect additional targets, the rights are assessed as to whether they represent deliverables at the inception of the arrangement. In assessing these contingent deliverables, we consider whether the right is a substantive option. We consider a right to be a substantive option if the election of the additional targets is not essential to the functionality of the other elements in the arrangement and if we are truly at risk of the right being exercised. If the right is determined to be a substantive option, we further consider whether the right is priced at a significant and incremental discount that should be accounted for as an element of the arrangement. If a right is determined to be a substantive option and is not priced at a significant and incremental discount, it is not treated as a deliverable in the arrangement and receives no allocation at the inception of the arrangement of the original arrangement consideration. The right is then accounted for when and if it is exercised.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our collaborative agreements provide for milestone payments upon achievement of development and regulatory events and/or specified sales volumes of commercialized products by the collaborator. We account for milestone payments in accordance with the provisions of ASU No. 2010-17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition - Milestone Method </font><font style="font-family:inherit;font-size:10pt;">(“Milestone Method of Accounting”). We recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration relates solely to past performance; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the vendor.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reimbursements of research and development services are recognized as revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Revenue from the manufacture of bulk rHuPH20 is recognized when the materials have met all specifications required for the collaborator’s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control when any collaborator will request research and development services or supply of bulk rHuPH20; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of bulk rHuPH20. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since we receive royalty reports 60 days after quarter end, royalty revenue from sales of collaboration products by our collaborators is recognized in the quarter following the quarter in which the corresponding sales occurred.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaborative agreements typically provide the collaborators the right to terminate such agreement in whole or on a product-by-product or target-by-target basis at any time upon </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> prior written notice to us. There are no performance, cancellation, termination or refund provisions in any of our collaborative agreements that contain material financial consequences to us.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to Note 4, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Agreements</font><font style="font-family:inherit;font-size:10pt;">, for further discussion on our collaborative arrangements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Product Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and bulk rHuPH20 for use in approved collaboration products. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</font><font style="font-family:inherit;font-size:8pt;"> </font><font style="font-family:inherit;font-size:10pt;">After receiving approval from the FDA or comparable regulatory agencies in foreign countries for a product, costs related to purchases and manufacturing of bulk rHuPH20 for such product are capitalized as inventory. The manufacturing costs of bulk rHuPH20 for the collaboration products, Herceptin SC, MabThera SC and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> in-licensed technologies that have alternative future uses in research and development projects or otherwise.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make payments in connection with our clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record compensation expense associated with stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and RSUs with performance conditions (“PRSUs”) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. While we have begun to utilize certain of our net operating losses, we have not yet established a track record of profitability. Accordingly, valuation allowances have been recorded to reduce our net deferred tax assets to </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> until such time we can demonstrate an ability to realize them.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. Because of our net loss, outstanding common stock equivalents totaling approximately </font><font style="font-family:inherit;font-size:10pt;">16.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">13.0 million</font><font style="font-family:inherit;font-size:10pt;"> were excluded from the calculation of diluted net loss per common share for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, because their effect was anti-dilutive.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate our business in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment. Our long-lived assets located in foreign countries had minimal book value as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption and Pending Adoption of Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, Inventory: Simplifying the Measurement of Inventory.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance requires that for entities that measure inventory using the first-in, first-out method, inventory should be measured at the lower of cost or net realizable value. Topic 330, Inventory, currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximate normal profit margin. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2017. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The adoption did not have a material impact on our condensed consolidated financial position or results of operations.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.<br clear="none"/><br clear="none"/>In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current U.S. GAAP either is unclear or does not include specific guidance on the eight cash flow classification issues included in ASU 2016-15. The new guidance is an improvement to U.S. GAAP and is intended to reduce the current and potential future diversity in practice. ASU 2016-18 provides additional classification guidance for restricted cash, which requires that restricted cash be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2018. We have elected to early adopt as of January1, 2017. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at the beginning-of-period and end-of-period total amounts in the Condensed Consolidated Statements of Cash Flows have been adjusted to include $0.5 million of restricted cash for each of the periods presented. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall; Recognition and Measurement of Financial Assets and Financial Liabilities.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities to be measured at fair value with changes in the fair value recognized through net income. The new guidance requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2018. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently do not hold equity securities, and we are evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). In March, April, May and December 2016, the FASB issued additional guidance related to Topic 606.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new standard will supersede nearly all existing revenue recognition guidance. Under Topic 606, an entity is required to recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. Topic 606 defines a five-step process in order to achieve this core principle, which may require the use of judgment and estimates, and also requires expanded qualitative and quantitative disclosures relating to the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers, including significant judgments and estimates used. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized. The new standard permits adoption either by using (i) a full retrospective approach for all periods presented in the period of adoption or (ii) a modified retrospective approach where the new standard is applied in the financial statements starting with the year of adoption. Under both approaches, cumulative impact of the adoption is reflected as an adjustment to retained earnings (accumulated deficit) as of the earliest date presented in accordance with the new standard.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2018. Early adoption is permitted. </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We plan to implement the new guidance on January 1, 2018. We currently plan to adopt using the modified retrospective approach; however, a final decision regarding the adoption method has not been finalized at this time. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. However, we anticipate an impact to the timing of recognition of payments related to certain of our license and collaboration agreements </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:10pt;">and the timing of recognition of our sales-based royalties.</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) </sup></font><font style="font-family:inherit;font-size:10pt;">We anticipate that this standard will have a material impact on our consolidated financial statements. Additional areas of impact may be identified as we continue our evaluation. We cannot reasonably estimate additional quantitative information related to the impact of the new standard on our consolidated financial statements at this time.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance requires lessees to recognize assets and liabilities for most leases and provides enhanced disclosures.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2019. Early adoption is permitted.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. However, we anticipate recognition of additional assets and corresponding liabilities related to our leases on our consolidated balance sheet. </font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_______________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the new standard, we are required to assess whether licenses granted under our collaboration and license agreements are distinct from other performance obligations and functional when granted. We expect that license-related amounts, including upfront payments, exclusive designation fees, annual license maintenance fees and sales-based milestones will be recognized, generally, when earned. Currently, these amounts related to certain of our license and collaboration agreements are being amortized over the term of the collaboration agreement. For example, during the year ended December 31, 2016, we recognized revenue from amortization of license payments of </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;">, and total deferred revenue related to license payments under collaboration agreements as of December 31, 2016 was </font><font style="font-family:inherit;font-size:10pt;">$43.9 million</font><font style="font-family:inherit;font-size:10pt;">. While we have not completed our evaluation at this time, we anticipate a potential reduction or elimination of our associated deferred revenue balances upon adoption of Topic 606.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the new standard, we expect sales-based royalties will be recognized in the quarter they are earned based on estimates, with true-up to actual results following in the subsequent quarter. Sales-based royalty revenue earned under our collaboration and license agreements is presently recognized when the royalty reports are made available. Upon adoption of Topic 606, we will evaluate and reduce our accumulated deficit and increase our accounts receivable, net, by the amount earned but not yet reported in our consolidated balance sheet at the time of adoption. We are establishing a process to estimate sales-based royalty revenues in the quarter in which the sales occur.</font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certain Balance Sheet Items</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from product sales to collaborators</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from other product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,090</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,234</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from revenues under collaborative agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,921</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,034</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for distribution fees and discounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,680</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,885</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">537</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,012</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total inventories</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,290</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid manufacturing expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,345</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">602</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total prepaid expenses and other assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,799</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total prepaid expenses and other assets, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,627</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid manufacturing expenses include slot reservation fees and other amounts paid to contract manufacturing organizations. Such amounts are reclassified to work-in-process inventory once the manufacturing process has commenced.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,483</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,345</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,331</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,482</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,919</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,741</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:9pt;"> </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense totaled </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced research and development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and payroll taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,045</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced manufacturing expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,276</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,552</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total accrued expenses, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,821</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fees and event-based payments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reimbursement for research and development services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,793</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,825</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

EX-101.SCH 6 halo-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2407402 - Disclosure - Certain Balance Sheet Items - Accounts receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2407407 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2407408 - Disclosure - Certain Balance Sheet Items - Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Certain Balance Sheet Items - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Certain Balance Sheet Items (Notes) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Certain Balance Sheet Items - Prepaid expenses and other assets (Details) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2407406 - Disclosure - Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Certain Balance Sheet Items (Tables) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Collaborative Agreements Collaborative Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Collaborative Agreements Collaborative Agreements tables (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Collaborative Agreements Collaborative Agreements Textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Collaborative Agreements (Notes) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Fair Value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Fair Value Measurement Fair Value Measures (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Fair Value Measurement (Notes) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Fair Value Measurement Textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Long-Term Debt, Net Long-Term Debt Textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Long-Term Debt, Net (Notes) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Share-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Share-based Compensation (Notes) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Share-based Compensation Share-based compensation textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Share-based Compensation Share-based compensation, unrecognized (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Share-based Compensation Share-based compensation, valuation (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Stockholders' Deficit (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402410 - Disclosure - Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2402407 - Disclosure - Summary of Significant Accounting Policies Income tax (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Summary of Significant Accounting Policies Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2402408 - Disclosure - Summary of Significant Accounting Policies Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Summary of Significant Accounting Policies Research and development (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of Significant Accounting Policies Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Summary of Significant Accounting Policies Revenue recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2402409 - Disclosure - Summary of Significant Accounting Policies Segment information (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 halo-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 halo-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 halo-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Property, Plant and Equipment [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization [Abstract] Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Fair Value Disclosures [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Money Market Funds [Member] Money Market Funds [Member] Commercial Paper [Member] Commercial Paper [Member] Corporate Debt Securities [Member] Corporate Debt Securities [Member] US Treasury Securities [Member] US Treasury Securities [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalents, Fair Value Disclosure Available-for-sale Securities Available-for-sale Securities Assets, Fair Value Disclosure Assets, Fair Value Disclosure Investments, Fair Value Disclosure Investments, Fair Value Disclosure Share-based Compensation [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Stock options Employee Stock Option [Member] RSAs Restricted Stock [Member] RSUs Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Compensation Cost Not yet Recognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Compensation Cost Not yet Recognized, Period for Recognition Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Income Tax Disclosure [Abstract] Deferred Tax Assets, Net Deferred Tax Assets, Net Income Tax Expense Income Tax Expense (Benefit) Statement of Financial Position [Abstract] Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Schedule of Property and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Research equipment Research Equipment [Member] Research equipment. Computer and office equipment Machinery and Equipment [Member] Leasehold improvements Leasehold Improvements [Member] Statement [Line Items] Statement [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net Deferred Revenue Disclosure [Abstract] Collaborative Agreements Collaborative Arrangement Disclosure [Text Block] Collaborative Agreements Disclosure [Abstract] Collaborative Agreements Disclosure [Abstract] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Collaborative Arrangements and Non-collaborative Arrangements [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Roche [Member] Roche [Member] Roche Baxalta [Member] Baxalta [Member] Baxalta [Member] Lilly [Member] Lilly [Member] Lilly [Member] AbbVie [Member] AbbVie [Member] AbbVie [Member] Janssen [Member] Janssen [Member] Janssen Collaboration [Member] Pfizer [Member] Pfizer [Member] Pfizer [Member] Pfizer, Janssen and AbbVie Pfizer, Janssen and AbbVie [Member] Pfizer, Janssen and AbbVie [Member] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Domain] Deferred Revenue [Domain] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Agreements Terms Collaborative Agreements Terms [Abstract] Collaborative Agreements Terms [Abstract] Number of product compound combinations licensed to develop Number of Product Compound Combinations Licensed to Develop Number of Product Compound Combinations Licensed to Develop Number of exclusive right targets Number of exclusive right targets Number of exclusive right targets Number of targets elected Number of Targets Elected Number of Targets Elected Number of Returned Targets Number of Returned Targets Number of Returned Targets Number of targets elected, additional exclusive targets Number of targets elected, additional exclusive targets Number of targets elected, additional exclusive targets Number of additional targets, optional Number of Additional Target, Optional Number of Additional Target, Optional Collaborative agreement target selection period Collaborative agreement target selection period Collaborative agreement target selection period Number of targets elected, additional semi-exclusive targets Number of targets elected, additional semi-exclusive targets Number of targets elected, additional semi-exclusive targets Duration of royalty receivable Duration of Royalty Receivable Duration of royalty receivable. Notification period for termination Period for Termination Period for termination. Collaborative Agreements (Textual) Collaborative Agreements (Textual) [Abstract] Collaborative agreements. Deferred revenue, revenue recognized Deferred Revenue, Revenue Recognized Revenue Recognition, Event-based or Milestone, Revenue Recognized Revenue Recognition, Milestone Method, Revenue Recognized Additional maximum proceeds receivable from collaborators of license and collaborative agreement upon achievement of clinical development milestones for elected targets Additional Maximum Proceeds Receivable from Collaborator of License and Collaborative Agreement Upon Achievement of Clinical Development Milestones Additional maximum proceeds receivable from collaborator of license and collaborative agreement upon achievement of clinical development milestones for elected targets. Sales-based payment to be received upon the first commercial sale Additional maximum cash payments receivable upon achievement of regulatory milestones for elected targets Additional maximum cash payments receivable upon achievement of regulatory milestones for elected targets. Deferred Revenue (Textual) [Abstract] Deferred Revenue (Textual) [Abstract] Deferred revenue. Deferred revenue relating to upfront payment license fees and annual maintenance fees Deferred Revenue Inventory Disclosure [Abstract] Inventory, Current [Table] Inventory, Current [Table] Inventory [Axis] Inventory [Axis] Inventory [Domain] Inventory [Domain] Hylenex recombinant Hylenex Recombinant [Member] Hylenex Recombinant [Member] bulk rHuPH20 bulk rHuPH20 [Member] bulk rHuPH20 for use in collaboration products Inventory [Line Items] Inventory [Line Items] Inventory, Net Inventory, Net Available-for-sale securities maturities, next twelve months Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Number of available-for-sale securities in unrealized loss position, less than one year Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year Other than Temporary Impairment Losses, Marketable Securities Other than Temporary Impairment Losses, Investments, Available-for-sale Securities Available-for-sale marketable securities Available-for-sale Securities [Table Text Block] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Revenue Recognition [Abstract] Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Period prior to expiration Minimum [Member] Period after expiration Maximum [Member] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Collaborative agreements termination notification Revenue from External Customer [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Revenue Recognition, Multiple-deliverable Arrangements [Table] Revenue Recognition, Multiple-deliverable Arrangements [Table] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Roche [Member] Other collaborators [Member] Other collaborators [Member] Other collaborators [Member] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block] Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block] Schedule of Share-based Compensation Arrangements Valuation Inputs [Table] Schedule of Share-based Compensation Arrangements Valuation Inputs [Table] Schedule of Share-based Compensation Arrangements Valuation Inputs [Table] Minimum [Member] Maximum [Member] Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items] Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items] [Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table] Fair Value Assumptions, Weighted Average Volatility Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Fair Value Assumptions, Weighted Average Expected Term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Fair Value Assumptions, Expected Dividend Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Fair Value Assumptions, Risk Free Interest Rate, Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Fair Value Assumptions, Risk Free Interest Rate, Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities, available-for-sale Available-for-sale Securities, Current Accounts receivable, net Accounts Receivable, Net, Current Inventories Prepaid expenses and other assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Prepaid expenses and other assets Prepaid Expense and Other Assets, Noncurrent Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Deferred revenue, current portion Deferred Revenue, Current Current portion of long-term debt, net Long-term Debt, Current Maturities Total current liabilities Liabilities, Current Deferred revenue, net of current portion Deferred Revenue, Noncurrent Long-term debt, net Long-term Debt Other long-term liabilities Other Liabilities, Noncurrent Commitments and contingencies (Note 9) Commitments and Contingencies Stockholders' deficit: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Common stock - $0.001 par value; 200,000 shares authorized; 129,822 and 129,502 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' deficit Stockholders' Equity Attributable to Parent Total liabilities and stockholders' deficit Liabilities and Equity Debt Disclosure [Abstract] Long-term Debt Long-term Debt [Text Block] Segment Reporting [Abstract] Number of Operating Segments Number of Operating Segments Accounting Policies [Abstract] Basis of Presentation Basis of Presentation and Significant Accounting Policies [Text Block] Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Marketable Securities Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Cost of Product Sales Cost of Sales, Policy [Policy Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Clinical Trial Expenses Disclosure of Accounting Policy for Clinical Trial Expenses [Policy Text Block] Disclosure of accounting policy for clinical trial expenses. Share-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Segment Information Segment Reporting, Policy [Policy Text Block] Adoption and Pending Adoption of Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Schedule of Available-for-sale Securities Schedule of Available-for-sale Securities [Line Items] Amortized cost Available-for-sale Securities, Amortized Cost Basis Gross Unrealized Gains Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax Estimated fair value Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Balance Sheet Related Disclosures [Abstract] Certain Balance Sheet Items Supplemental Balance Sheet Disclosures [Text Block] EX-101.PRE 10 halo-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 slide1a28.jpg begin 644 slide1a28.jpg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end GRAPHIC 12 slide2a23.jpg begin 644 slide2a23.jpg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൥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�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end GRAPHIC 13 slide3a22.jpg begin 644 slide3a22.jpg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end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1

Document and Entity Information - shares
3 Months Ended

Mar. 31, 2017

May 01, 2017

Document Information [Line Items]

Entity Registrant Name HALOZYME THERAPEUTICS INC.

Trading Symbol HALO

Entity Central Index Key 0001159036

Document Type 10-Q

Document Period End Date Mar. 31, 2017

Amendment Flag false

Document Fiscal Year Focus 2017

Document Fiscal Period Focus Q1

Current Fiscal Year End Date --12-31

Entity Filer Category Large Accelerated Filer

Entity Common Stock, Shares Outstanding 129,840,030

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 15 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands

Mar. 31, 2017

Dec. 31, 2016

Current assets:

Cash and cash equivalents $ 45,188 $ 66,764

Marketable securities, available-for-sale 133,797 138,217

Accounts receivable, net 12,452 15,680

Inventories 14,290 14,623

Prepaid expenses and other assets 16,627 21,248

Total current assets 222,354 256,532

Property and equipment, net 3,741 4,264

Prepaid expenses and other assets 172 219

Restricted cash 500 500

Total assets 226,767 261,515

Current liabilities:

Accounts payable 3,079 3,578

Accrued expenses 24,935 28,821

Deferred revenue, current portion 4,093 4,793

Current portion of long-term debt, net 29,601 17,393

Total current liabilities 61,708 54,585

Deferred revenue, net of current portion 38,802 39,825

Long-term debt, net 184,430 199,228

Other long-term liabilities 326 358

Commitments and contingencies (Note 9)

Stockholders' deficit:

Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding 0 0

Common stock - $0.001 par value; 200,000 shares authorized; 129,822 and 129,502 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively 130 130

Additional paid-in capital 559,659 552,737

Accumulated other comprehensive loss (49) (6)

Accumulated deficit (618,239) (585,342)

Total stockholders' deficit (58,499) (32,481)

Total liabilities and stockholders' deficit $ 226,767 $ 261,515

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669686-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26626-111562
+ Details

Name: us-gaap_AvailableForSaleSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(10))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
shares in Thousands

Mar. 31, 2017

Dec. 31, 2016

Statement of Financial Position [Abstract]

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 20,000 20,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 200,000 200,000

Common stock, shares issued 129,822 129,502

Common stock, shares outstanding 129,822 129,502

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 17 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Revenues:

Product sales, net $ 11,434 $ 12,940

Royalties 13,982 11,387

Revenues under collaborative agreements 4,152 18,172

Total revenues 29,568 42,499

Operating expenses:

Cost of product sales 7,544 7,762

Research and development 36,935 40,100

Selling, general and administrative 12,615 10,806

Total operating expenses 57,094 58,668

Operating loss (27,526) (16,169)

Other income (expense):

Investment and other income, net 287 229

Interest expense (5,448) (3,876)

Net loss before income taxes (32,687) (19,816)

Income Tax Expense 210 0

Net loss $ (32,897) $ (19,816)

Basic and diluted net loss per share $ (0.26) $ (0.16)

Shares used in computing basic and diluted net loss per share 128,615 127,615

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Income Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6515339
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 18 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Statement of Comprehensive Income [Abstract]

Net loss $ (32,897) $ (19,816)

Other comprehensive (loss) income:

Unrealized (loss) gain on marketable securities (40) 187

Foreign currency translation adjustment (4) 0

Unrealized gain on foreign currency 1 0

Total comprehensive loss $ (32,940) $ (19,629)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30690-110894

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30700-110894

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossUnrealized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Operating activities:

Net loss $ (32,897) $ (19,816)

Adjustments to reconcile net loss to net cash used in operating activities:

Share-based compensation 7,315 5,817

Depreciation and amortization 602 489

Non-cash interest expense 487 1,054

Payment-in-kind Interest expense on long-term debt 0 1,890

Amortization of premiums on marketable securities, net 16 213

Loss on disposal of equipment 44 0

Recognition of Deferred Revenue (1,723) (1,524)

Recognition of deferred rent (114) (70)

Other (5) 0

Changes in operating assets and liabilities:

Accounts receivable, net 3,228 6,867

Inventories 333 (856)

Prepaid expenses and other assets 4,668 (2,522)

Accounts payable and accrued expenses (4,413) (4,565)

Net cash used in operating activities (22,459) (13,023)

Investing activities:

Purchases of marketable securities (54,830) (126,431)

Proceeds from maturities of marketable securities 59,194 21,908

Purchases of property and equipment (99) (1,099)

Net cash provided by (used in) investing activities 4,265 (105,622)

Financing activities:

Proceeds from issuance of long-term debt, net 0 148,046

Repayment of long-term debt (2,989) (3,885)

Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement (393) 285

Net cash (used in) provided by financing activities (3,382) 144,446

Net (decrease) increase in cash, cash equivalents and restricted cash (21,576) 25,801

Cash, cash equivalents, and restricted cash at beginning of period 67,264 43,792

Cash, cash equivalents, and restricted cash at end of period $ 45,688 $ 69,593

X

- Definition
Cash, cash equivalents, and restricted cash
+ References
No definition available.
+ Details

Name: halo_Cashcashequivalentsandrestrictedcash

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of amortization expense attributable to debt issuance costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(8))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(8))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income or gain included in net income that result in no cash inflow (outflow), classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherNoncashIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherNoncashIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_PaidInKindInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26853-111562
+ Details

Name: us-gaap_PaymentsToAcquireAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_RecognitionOfDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_RepaymentsOfSecuredDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 20 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1

Organization and Business
3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Business
Organization and Business
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.
Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators’ proprietary compounds.
The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex^® recombinant, and it works by temporarily breaking down hyaluronan (or “HA”), a naturally occurring complex carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE^™ Technology. We license the ENHANZE Technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.
We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), and Eli Lilly and Company (“Lilly”). We receive royalties from two of these collaborations, including royalties from sales of one product approved in both the United States and outside the United States from the Baxalta collaboration and from sales of two products approved for marketing outside the United States from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.
Our proprietary development pipeline consists primarily of pre-clinical and clinical stage product candidates in oncology. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 has been demonstrated in animal models to work by temporarily degrading HA surrounding cancer cells resulting in reduced pressure and increased blood flow to the tumor thereby enabling increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. Through our efforts and efforts of our partners and collaborators, we are currently in Phase 3 clinical testing for PEGPH20 with ABRAXANE^®(nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (“PDA”) (Study 109-301), in Phase 1b clinical testing for PEGPH20 with KEYTRUDA^®(pembrolizumab) in non-small cell lung cancer and gastric cancer (Study 107-101) and in Phase 1b/2 clinical testing for PEGPH20 with HALAVEN^® (eribulin) in patients treated with up to two lines of prior therapy for HER2-negative metastatic breast cancer.
Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC and Halozyme Switzerland GmbH.

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6003-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 2A
-URI http://asc.fasb.org/extlink&oid=64851502&loc=SL51803626-108592
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1

Summary of Significant Accounting Policies
3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
Summary of Significant Accounting Policies
Basis of Presentation
The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on February 28, 2017. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.
The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC and Halozyme Switzerland GmbH. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.
Cash Equivalents and Marketable Securities
Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of March 31, 2017, our cash equivalents consisted of money market funds and commercial paper.
Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders’ deficit. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the condensed consolidated statements of operations.
Restricted Cash
Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At March 31, 2017 and December 31, 2016, restricted cash of $0.5 million was pledged as collateral for the letters of credit.
Fair Value of Financial Instruments
The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.
Available-for-sale marketable securities consist of corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.
Inventories
Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.
Prior to receiving marketing approval from the U.S. Food and Drug Administration (“FDA”) or comparable regulatory agencies in foreign countries, costs related to purchases of bulk rHuPH20 and raw materials and the manufacturing of the product candidates are recorded as research and development expense. All direct manufacturing costs incurred after receiving marketing approval are capitalized as inventory. Inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials.
As of March 31, 2017 and December 31, 2016, inventories consisted of $1.7 million and $2.3 million, respectively, of Hylenex recombinant inventory, net, and $12.6 million and $12.3 million, respectively, of bulk rHuPH20 for use in the manufacture of Baxalta’s and Roche’s collaboration products.
Revenue Recognition
We generate revenues from product sales and payments received under collaborative agreements. Collaborative agreement payments may include nonrefundable fees at the inception of the agreements, license fees, milestone and event-based payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk rHuPH20, and/or royalties on sales of products resulting from collaborative arrangements.
We recognize revenues in accordance with the authoritative guidance for revenue recognition. We recognize revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured.
Product Sales, Net
Hylenex Recombinant
We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers provide for selling prices that are fixed on the date of sale, although we offer discounts to certain group purchasing organizations (“GPOs”), hospitals and government programs. The wholesalers take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales.
We have developed sufficient historical experience and data to reasonably estimate future returns and chargebacks of Hylenex recombinant. As a result, we recognize Hylenex recombinant product sales and related cost of product sales at the time title transfers to the wholesalers.
Upon recognition of revenue from product sales of Hylenex recombinant, we record certain sales reserves and allowances as a reduction to gross revenue. These reserves and allowances include amounts for product returns (based primarily on an analysis of historical return patterns), distribution fees, prompt payment discounts, and GPO fees and other discounts and fees.
We recognize product sales reserves and allowances as a reduction of product sales in the same period the related revenue is recognized. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. If actual product return results differ from our estimates, we will be required to make adjustments to these allowances in the future, which could have an effect on product sales revenue and earnings in the period of adjustments.
Bulk rHuPH20
Subsequent to receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries, sales of bulk rHuPH20 for use in collaboration commercial products are recognized as product sales when the materials have met all the specifications required for the customer’s acceptance and title and risk of loss have transferred to the customer. Following the receipt of European marketing approvals of Roche’s Herceptin SC product in August 2013 and MabThera^® SC product in March 2014 and Baxalta’s HYQVIA product in May 2013, revenue from the sales of bulk rHuPH20 for these collaboration products has been recognized as product sales.
Revenues under Collaborative Agreements
We have entered into license and collaboration agreements under which our collaborators obtained worldwide rights for the use of our proprietary rHuPH20 enzyme in the development and commercialization of their biologic compounds identified as targets. These agreements may also contain other elements. Pursuant to the terms of these agreements, collaborators could be required to make various payments to us for each target, including nonrefundable upfront license fees, exclusivity fees, payments based on achievement of specified milestones designated in the collaborative agreements, annual maintenance fees, reimbursements of research and development services, payments for supply of bulk rHuPH20 used by the collaborator and/or royalties on sales of products resulting from collaborative agreements.
In order to account for the multiple-element arrangements, we identify the deliverables included within the collaborative agreement and evaluate which deliverables represent units of accounting. We then determine the appropriate method of revenue recognition for each unit based on the nature and timing of the delivery process. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The deliverables under our collaborative agreements include (i) the license to our rHuPH20 technology, (ii) at the collaborator’s request, research and development services which are reimbursed at contractually determined rates, and (iii) at the collaborator’s request, supply of bulk rHuPH20 which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. We base this determination on the collaborators’ ability to use the delivered items on their own without us supplying undelivered items, which we determine taking into consideration factors such as the research capabilities of the collaborator, the availability of research expertise in this field in the general marketplace, and the ability to procure the supply of bulk rHuPH20 from the marketplace.
Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (“VSOE”) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are not contingent upon the delivery of additional items or meeting other specified performance conditions. The consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement.
Nonrefundable upfront license fees are recognized upon delivery of the license if facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of bulk rHuPH20, the relative selling price allocation of the license is equal to or exceeds the upfront license fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable and collectibility is reasonably assured. Upfront license fees are deferred if facts and circumstances dictate that the license does not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period.
When collaborators have rights to elect additional targets, the rights are assessed as to whether they represent deliverables at the inception of the arrangement. In assessing these contingent deliverables, we consider whether the right is a substantive option. We consider a right to be a substantive option if the election of the additional targets is not essential to the functionality of the other elements in the arrangement and if we are truly at risk of the right being exercised. If the right is determined to be a substantive option, we further consider whether the right is priced at a significant and incremental discount that should be accounted for as an element of the arrangement. If a right is determined to be a substantive option and is not priced at a significant and incremental discount, it is not treated as a deliverable in the arrangement and receives no allocation at the inception of the arrangement of the original arrangement consideration. The right is then accounted for when and if it is exercised.
Certain of our collaborative agreements provide for milestone payments upon achievement of development and regulatory events and/or specified sales volumes of commercialized products by the collaborator. We account for milestone payments in accordance with the provisions of ASU No. 2010-17, Revenue Recognition - Milestone Method (“Milestone Method of Accounting”). We recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:
1.
The consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone;
2.
The consideration relates solely to past performance; and
3.
The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.
A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the vendor.
Reimbursements of research and development services are recognized as revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Revenue from the manufacture of bulk rHuPH20 is recognized when the materials have met all specifications required for the collaborator’s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control when any collaborator will request research and development services or supply of bulk rHuPH20; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of bulk rHuPH20.
Since we receive royalty reports 60 days after quarter end, royalty revenue from sales of collaboration products by our collaborators is recognized in the quarter following the quarter in which the corresponding sales occurred.
The collaborative agreements typically provide the collaborators the right to terminate such agreement in whole or on a product-by-product or target-by-target basis at any time upon 30 to 90 days prior written notice to us. There are no performance, cancellation, termination or refund provisions in any of our collaborative agreements that contain material financial consequences to us.
Refer to Note 4, Collaborative Agreements, for further discussion on our collaborative arrangements.
Cost of Product Sales
Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of Hylenex recombinant and bulk rHuPH20 for use in approved collaboration products. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.
Research and Development Expenses
Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses. After receiving approval from the FDA or comparable regulatory agencies in foreign countries for a product, costs related to purchases and manufacturing of bulk rHuPH20 for such product are capitalized as inventory. The manufacturing costs of bulk rHuPH20 for the collaboration products, Herceptin SC, MabThera SC and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory.
We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.
Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have no in-licensed technologies that have alternative future uses in research and development projects or otherwise.
Clinical Trial Expenses
We make payments in connection with our clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.
Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.
Share-Based Compensation
We record compensation expense associated with stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and RSUs with performance conditions (“PRSUs”) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.
Income Taxes
We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. While we have begun to utilize certain of our net operating losses, we have not yet established a track record of profitability. Accordingly, valuation allowances have been recorded to reduce our net deferred tax assets to zero until such time we can demonstrate an ability to realize them.
Net Loss Per Share
Basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. Because of our net loss, outstanding common stock equivalents totaling approximately 16.4 million and 13.0 million were excluded from the calculation of diluted net loss per common share for the three months ended March 31, 2017 and 2016, respectively, because their effect was anti-dilutive.
Segment Information
We operate our business in one segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of Hylenex recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment. Our long-lived assets located in foreign countries had minimal book value as of March 31, 2017 and December 31, 2016.
Adoption and Pending Adoption of Recent Accounting Pronouncements
The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:
Standard

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters

In July 2015, the FASB issued ASU 2015-11, Inventory: Simplifying the Measurement of Inventory.

The new guidance requires that for entities that measure inventory using the first-in, first-out method, inventory should be measured at the lower of cost or net realizable value. Topic 330, Inventory, currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximate normal profit margin. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.

January 1, 2017.

The adoption did not have a material impact on our condensed consolidated financial position or results of operations.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash.

Current U.S. GAAP either is unclear or does not include specific guidance on the eight cash flow classification issues included in ASU 2016-15. The new guidance is an improvement to U.S. GAAP and is intended to reduce the current and potential future diversity in practice. ASU 2016-18 provides additional classification guidance for restricted cash, which requires that restricted cash be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows.

January 1, 2018. We have elected to early adopt as of January1, 2017.

Cash and cash equivalents at the beginning-of-period and end-of-period total amounts in the Condensed Consolidated Statements of Cash Flows have been adjusted to include $0.5 million of restricted cash for each of the periods presented.

Standard

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters
In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall; Recognition and Measurement of Financial Assets and Financial Liabilities.

The new guidance supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities to be measured at fair value with changes in the fair value recognized through net income. The new guidance requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement.

January 1, 2018.

We currently do not hold equity securities, and we are evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.

Standard

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). In March, April, May and December 2016, the FASB issued additional guidance related to Topic 606.

The new standard will supersede nearly all existing revenue recognition guidance. Under Topic 606, an entity is required to recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. Topic 606 defines a five-step process in order to achieve this core principle, which may require the use of judgment and estimates, and also requires expanded qualitative and quantitative disclosures relating to the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers, including significant judgments and estimates used. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized. The new standard permits adoption either by using (i) a full retrospective approach for all periods presented in the period of adoption or (ii) a modified retrospective approach where the new standard is applied in the financial statements starting with the year of adoption. Under both approaches, cumulative impact of the adoption is reflected as an adjustment to retained earnings (accumulated deficit) as of the earliest date presented in accordance with the new standard.

January 1, 2018. Early adoption is permitted.

We plan to implement the new guidance on January 1, 2018. We currently plan to adopt using the modified retrospective approach; however, a final decision regarding the adoption method has not been finalized at this time. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. However, we anticipate an impact to the timing of recognition of payments related to certain of our license and collaboration agreements ⁽¹⁾and the timing of recognition of our sales-based royalties.⁽²⁾We anticipate that this standard will have a material impact on our consolidated financial statements. Additional areas of impact may be identified as we continue our evaluation. We cannot reasonably estimate additional quantitative information related to the impact of the new standard on our consolidated financial statements at this time.

In February 2016, the FASB issued ASU 2016-02, Leases.

The new guidance requires lessees to recognize assets and liabilities for most leases and provides enhanced disclosures.

January 1, 2019. Early adoption is permitted.

We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. However, we anticipate recognition of additional assets and corresponding liabilities related to our leases on our consolidated balance sheet.

_______________
(1)
Under the new standard, we are required to assess whether licenses granted under our collaboration and license agreements are distinct from other performance obligations and functional when granted. We expect that license-related amounts, including upfront payments, exclusive designation fees, annual license maintenance fees and sales-based milestones will be recognized, generally, when earned. Currently, these amounts related to certain of our license and collaboration agreements are being amortized over the term of the collaboration agreement. For example, during the year ended December 31, 2016, we recognized revenue from amortization of license payments of $4.1 million, and total deferred revenue related to license payments under collaboration agreements as of December 31, 2016 was $43.9 million. While we have not completed our evaluation at this time, we anticipate a potential reduction or elimination of our associated deferred revenue balances upon adoption of Topic 606.
(2)
Under the new standard, we expect sales-based royalties will be recognized in the quarter they are earned based on estimates, with true-up to actual results following in the subsequent quarter. Sales-based royalty revenue earned under our collaboration and license agreements is presently recognized when the royalty reports are made available. Upon adoption of Topic 606, we will evaluate and reduce our accumulated deficit and increase our accounts receivable, net, by the amount earned but not yet reported in our consolidated balance sheet at the time of adoption. We are establishing a process to estimate sales-based royalty revenues in the quarter in which the sales occur.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18854-107790
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1

Fair Value Measurement (Notes)
3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]
Fair Value Measurement
Available-for-sale marketable securities consisted of the following (in thousands):

March 31, 2017

Amortized Cost

Gross Unrealized Gains

Gross Unrealized Losses

Estimated Fair Value
Corporate debt securities

$
33,158

$
—

$
(18
)

$
33,140

U.S. Treasury securities

70,002

1

(29
)

69,974

Commercial paper

30,683

—

—

30,683

$
133,843

$
1

$
(47
)

$
133,797

December 31, 2016

Amortized Cost

Gross Unrealized Gains

Gross Unrealized Losses

Estimated Fair Value
Corporate debt securities

$
40,221

$
1

$
(15
)

$
40,207

U.S. Treasury securities

94,002

24

(16
)

94,010

Commercial paper

$
4,000

$
—

$
—

$
4,000

$
138,223

$
25

$
(31
)

$
138,217

As of March 31, 2017, $124.8 million of our available-for-sale marketable securities were scheduled to mature within the next 12 months. As of March 31, 2017, eight available-for-sale marketable securities were in a gross unrealized loss position, all of which had been in such position for less than 12 months. Based on our review of these marketable securities, we believe we had no other-than-temporary impairments on these securities as of March 31, 2017 because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.
The following table summarizes, by major security type, our cash equivalents and marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):

March 31, 2017

December 31, 2016

Level 1

Level 2

Total estimated fair value

Level 1

Level 2

Total estimated fair value
Cash equivalents:

Money market funds

$
34,814

$
—

$
34,814

$
60,916

$
—

$
60,916

Commercial paper

4,000

4,000

—

—

—

Available-for-sale marketable
   securities:

Corporate debt securities

—

33,140

33,140

—

40,207

40,207

U.S. Treasury securities

69,974

—

69,974

94,010

—

94,010

Commercial paper

—

30,683

30,683

—

4,000

4,000

$
104,788

$
67,823

$
172,611

$
154,926

$
44,207

$
199,133

There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the three months ended March 31, 2017. We have no instruments that were classified within Level 3 as of March 31, 2017 and December 31, 2016.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1

Collaborative Agreements (Notes)
3 Months Ended

Mar. 31, 2017

Deferred Revenue Disclosure [Abstract]

Collaborative Agreements
Collaborative Agreements
Roche Collaboration
In December 2006, we and Roche entered into a collaboration and license agreement, under which Roche obtained a worldwide license to develop and commercialize product combinations of rHuPH20 and up to thirteen Roche target compounds (the “Roche Collaboration”). Roche initially had the exclusive right to apply rHuPH20 to three pre-defined Roche biologic targets with the option to develop and commercialize rHuPH20 with ten additional targets. Roche had the right to exercise this option to identify additional targets for ten years. As of the ten year anniversary in December 2016, Roche had elected a total of eight targets, two of which are exclusive.
In August 2013, Roche received European marketing approval for its collaboration product, Herceptin SC, for the treatment of patients with HER2-positive breast cancer and launched Herceptin SC in the European Union (“EU”) in September 2013. In March 2014, Roche received European marketing approval for its collaboration product, MabThera SC, for the treatment of patients with common forms of non-Hodgkin lymphoma (“NHL”). In June 2014, Roche launched MabThera SC in the EU. In May 2016, Roche announced that the EMA approved Mabthera SC to treat patients with chronic lymphocytic leukemia (“CLL”). In November 2016, the FDA accepted Genentech’s (a member of the Roche Group) Biologics License Application (“BLA”) for a subcutaneous formulation of rituximab for CLL and NHL. This is a co-formulation with rHuPH20, which is approved and marketed under the MabThera SC brand in countries outside the U.S. In March 2017, an Oncologic Drug Advisory Committee of the FDA voted 11 to 0 that the benefit/risk of rituximab SC was favorable for patients in the proposed indications in CLL and two types of NHL, follicular lymphoma and diffuse large B-cell lymphoma. The FDA action date is June 26, 2017.
Roche assumes all development, manufacturing, clinical, regulatory, sales and marketing costs under the Roche Collaboration, while we are responsible for the supply of bulk rHuPH20. We are entitled to receive reimbursements for providing research and development services and supplying bulk rHuPH20 to Roche at its request.
Under the terms of the Roche Collaboration, Roche pays us a royalty on each product commercialized under the agreement consisting of a mid-single digit percent of the net sales of such product. Unless terminated earlier in accordance with its terms, the Roche Collaboration continues in effect until the expiration of Roche’s obligation to pay royalties. Roche has the obligation to pay royalties to us with respect to each product commercialized in each country, during the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the Roche Collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term.
Payments received from Roche, excluding royalties and reimbursements for providing research and development services and supplying bulk rHuPH20, since inception of the collaboration agreement are as follows (in thousands):

As of
March 31, 2017
Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets
$
20,000

Election of additional exclusive targets and annual license maintenance fees for the right to
   designate the remaining targets as exclusive targets
23,000

Clinical development milestone payments
13,000

Regulatory milestone payments
8,000

Sales-based milestone payments
15,000

Total payments received
$
79,000

Due to our continuing involvement obligations (for example, support activities associated with rHuPH20), revenues from the upfront payment, exclusive designation fees, annual license maintenance fees and sales-based milestone payments were deferred and are being amortized over the remaining term of the Roche Collaboration.
For each of the three months ended March 31, 2017 and 2016, we recognized $0.8 million of Roche deferred revenues, excluding reimbursements for providing research and development services and supplying bulk rHuPH20, as revenues under collaborative agreements. Total Roche deferred revenues, excluding deferred revenues related to reimbursements for providing research and development services and supplying bulk rHuPH20, were $34.9 million and $35.7 million as of March 31, 2017 and December 31, 2016, respectively.
Baxalta Collaboration
In September 2007, we and Baxalta entered into a collaboration and license agreement, under which Baxalta obtained a worldwide, exclusive license to develop and commercialize HYQVIA, a combination of Baxalta’s current product GAMMAGARD LIQUID^™ and our patented rHuPH20 enzyme (the “Baxalta Collaboration”). In 2013, the European Commission granted Baxalta marketing authorization in all EU Member States for the use of HYQVIA (solution for subcutaneous use), a combination of GAMMAGARD LIQUID and rHuPH20 in dual vial units, as replacement therapy for adult patients with primary and secondary immunodeficiencies, and Baxalta launched HYQVIA in the EU. In 2014, Baxalta launched HYQVIA in the U.S following the FDA’s approval of HYQVIA for treatment of adult patients with primary immunodeficiency. In May 2016, Baxalta announced that HYQVIA received a marketing authorization from the European Commission for a pediatric indication, which is being launched in Europe to treat primary and certain secondary immunodeficiencies.
The Baxalta Collaboration is applicable to both kit and formulation combinations. Baxalta assumes all development, manufacturing, clinical, regulatory, sales and marketing costs under the Baxalta Collaboration, while we are responsible for the supply of bulk rHuPH20. We perform research and development activities and supply bulk rHuPH20 at the request of Baxalta, and are reimbursed by Baxalta under the terms of the Baxalta Collaboration. In addition, Baxalta has certain product development and commercialization obligations in major markets identified in the Baxalta Collaboration.
Under the terms of the Baxalta Collaboration, Baxalta pays us a royalty consisting of a mid-single digit percent of the net sales of HYQVIA. Unless terminated earlier in accordance with its terms, the Baxalta Collaboration continues in effect until the expiration of Baxalta’s obligation to pay royalties to us. Baxalta has the obligation to pay royalties to us, with respect to each product commercialized in each country, during the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the Baxalta Collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term.
Payments received from Baxalta, excluding royalties and reimbursements for providing research and development services and supplying bulk rHuPH20, since inception of the collaboration agreement are as follows (in thousands):

As of
March 31, 2017
Upfront license fee payment for the application of rHuPH20 to the initial exclusive target
$
10,000

Regulatory milestone payments
3,000

Sales-based milestone payments
4,000

Total payments received
$
17,000

Due to our continuing involvement obligations (for example, support activities associated with rHuPH20 enzyme), the upfront license fee and sales-based milestone payments were deferred and are being recognized over the term of the Baxalta Collaboration.
For each of the three months ended March 31, 2017 and 2016, we recognized $0.2 million of Baxalta deferred revenues, excluding reimbursements for providing research and development services and supplying bulk rHuPH20, as revenues under collaborative agreements. Total Baxalta deferred revenues, excluding reimbursements for providing research and development services and supplying bulk rHuPH20, were $8.0 million and $8.2 million as of March 31, 2017 and December 31, 2016, respectively.
Other Collaborations
In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Lilly proprietary biologics directed at up to five targets (the “Lilly Collaboration”). Targets, once selected, will be on an exclusive, global basis, with the exception of one semi-exclusive target. As of March 31, 2017, Lilly has elected two specified exclusive targets and one specified semi-exclusive target. Lilly has the right to elect up to two additional targets for additional fees. The upfront license payment may be followed by event-based payments subject to Lilly’s achievement of specified development, regulatory and sales-based milestones. In addition, Lilly will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Lilly Collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Lilly Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. Lilly may terminate the agreement prior to expiration for any reason in its entirety upon 60 days prior written notice to us. Upon any such termination, the license granted to Lilly (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.
In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with AbbVie proprietary biologics directed at up to nine targets (the “AbbVie Collaboration”). Targets, once selected, will be on an exclusive, global basis. As of March 31, 2017, AbbVie has elected one specified exclusive target, and subsequently returned the target. AbbVie has the right to elect up to nine additional targets for additional fees. The upfront license payment may be followed by event-based payments subject to AbbVie’s achievement of specified development, regulatory and sales-based milestones. In addition, AbbVie will pay tiered royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the AbbVie Collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the AbbVie Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. AbbVie may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis upon 90 days prior written notice to us. Upon any such termination, the license granted to AbbVie (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.
In December 2014, we and Janssen entered into a collaboration and license agreement, under which Janssen has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Janssen proprietary biologics directed at up to five targets (the “Janssen Collaboration”). Targets, once selected, will be on an exclusive, global basis. As of March 31, 2017, Janssen has elected one specified exclusive target. Janssen has the right to elect four additional targets in the future upon payment of additional fees. In addition, Janssen will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Janssen Collaboration continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Janssen Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. In the event such valid claims expire, the royalty rate is reduced for the remaining royalty term. Janssen may terminate the agreement prior to expiration for any reason in its entirety or on a product-by-product basis upon 90 days prior written notice to us. Upon any such termination, the license granted to Janssen (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.
In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our patented rHuPH20 enzyme with Pfizer proprietary biologics directed at up to six targets (the “Pfizer Collaboration”). Targets may be selected on an exclusive or non-exclusive basis. As of March 31, 2017, Pfizer has elected five specified exclusive targets. In December 2016, Pfizer returned one of its elected targets. Pfizer has the right to elect two additional targets in the future upon payment of additional fees. In addition, Pfizer will pay royalties to us if products under the collaboration are commercialized. Unless terminated earlier in accordance with its terms, the Pfizer Collaboration continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Pfizer Collaboration, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. Royalties are subject to adjustment as set forth in the agreement. Pfizer may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis upon 30 days prior written notice to us. Upon any such termination, the license granted to Pfizer (in total or with respect to the terminated target, as applicable) will terminate, provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.
Payments received from other collaborators for upfront license fees, license fees for the election of additional targets, maintenance fees and event-based payments since inception of the collaboration agreements are as follows (in thousands):

As of
March 31, 2017
Lilly
$
33,000

AbbVie
29,000

Janssen
15,250

Pfizer
16,500

Total payments received
$
93,750

At the inception of the Pfizer, Janssen, AbbVie and Lilly arrangements, we identified the deliverables in each arrangement to include the license, research and development services and supply of bulk rHuPH20. We have determined that the license, research and development services and supply of bulk rHuPH20 individually represent separate units of accounting, because each deliverable has standalone value. We determined that the rights to elect additional targets in the future upon the payment of additional license fees are substantive options that are not priced at a significant and incremental discount. Therefore, we determined for each collaboration that the rights to elect additional targets are not deliverables at the inception of the arrangement. The estimated selling prices for the units of accounting we identified were determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous collaborative agreements, our pricing practices and pricing objectives. The arrangement consideration was allocated to the deliverables based on the relative selling price method and the nature of the research and development services to be performed for the collaborator.
The amount allocable to the delivered unit or units of accounting is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions (non-contingent amount). As such, we excluded from the allocable arrangement consideration the event-based payments, milestone payments, annual exclusivity fees and royalties regardless of the probability of receipt. Based on the results of our analysis, we allocated the $12.5 million license fees from Pfizer, the $15.3 million license fee from Janssen, the $23.0 million upfront license fee from AbbVie and the $33.0 million license fees from Lilly to the license fee deliverable under each of the arrangements. We determined that the upfront payments were earned upon the granting of the worldwide, exclusive right to our technology to the collaborators in these arrangements. As a result, we recognized the $12.5 million license fees under the Pfizer Collaboration, the $15.3 million license fee under the Janssen Collaboration, the $23.0 million upfront license fee under the AbbVie Collaboration, and the $33.0 million license fees under the Lilly Collaboration as revenues under collaborative agreements in the period when such license fees were earned. We recognized no revenue for the three months ended March 31, 2017 and $6.0 million for the three months ended March 31, 2016 related to event-based payments or milestone payments under these collaborations.
The collaborators are each solely responsible for the development, manufacturing and marketing of any products resulting from their respective collaborations. We are entitled to receive payments for research and development services and supply of bulk rHuPH20 if requested by any collaborator. We recognize amounts allocated to research and development services as revenues under collaborative agreements as the related services are performed. We recognize amounts allocated to the sales of bulk rHuPH20 as revenues under collaborative agreements or product sales, as appropriate, when such bulk rHuPH20 has met all required specifications by the collaborators and the related title and risk of loss and damages have passed to the collaborators. We cannot predict the timing of delivery of research and development services and bulk rHuPH20 as they are at the collaborators’ requests.
Pursuant to the terms of our collaboration agreements with Roche and Pfizer, certain future payments meet the definition of a milestone in accordance with the Milestone Method of Accounting. We are entitled to receive additional milestone payments under our collaboration agreements with Roche and Pfizer for the successful development of the elected targets in the aggregate of up to $62.5 million upon achievement of specified clinical development milestone events and up to $12.0 million upon achievement of specified regulatory milestone events in connection with specified regulatory filings and receipt of marketing approvals.

X

- Definition
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434
+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1

Certain Balance Sheet Items (Notes)
3 Months Ended

Mar. 31, 2017

Balance Sheet Related Disclosures [Abstract]

Certain Balance Sheet Items
Certain Balance Sheet Items
Accounts receivable, net consisted of the following (in thousands):

March 31,
2017

December 31,
2016
Accounts receivable from product sales to collaborators

$
8,023

$
7,854

Accounts receivable from other product sales

2,090

2,234

Accounts receivable from revenues under collaborative agreements

2,921

6,151

     Subtotal

13,034

16,239

Allowance for distribution fees and discounts

(582
)

(559
)
     Total accounts receivable, net

$
12,452

$
15,680

Inventories consisted of the following (in thousands):

March 31,
2017

December 31,
2016
Raw materials

$
868

$
761

Work-in-process

12,885

12,850

Finished goods

537

1,012

     Total inventories

$
14,290

$
14,623

Prepaid expenses and other assets consisted of the following (in thousands):

March 31,
2017

December 31,
2016
Prepaid manufacturing expenses

$
6,327

$
9,663

Prepaid research and development expenses

8,345

8,613

Other prepaid expenses

1,525

1,661

Other assets

602

1,530

     Total prepaid expenses and other assets

16,799

21,467

Less long-term portion

172

219

     Total prepaid expenses and other assets, current

$
16,627

$
21,248

Prepaid manufacturing expenses include slot reservation fees and other amounts paid to contract manufacturing organizations. Such amounts are reclassified to work-in-process inventory once the manufacturing process has commenced.
Property and equipment, net consisted of the following (in thousands):

March 31,
2017

December 31,
2016
Research equipment

$
10,483

$
10,479

Computer and office equipment

3,395

3,373

Leasehold improvements

2,345

2,331

     Subtotal

16,223

16,183

Accumulated depreciation and amortization

(12,482
)

(11,919
)
     Property and equipment, net

$
3,741

$
4,264

Depreciation and amortization expense totaled $0.6 million and $0.5 million for the three months ended March 31, 2017 and 2016, respectively.
Accrued expenses consisted of the following (in thousands):

March 31,
2017

December 31,
2016
Accrued outsourced research and development expenses

$
11,970

$
9,522

Accrued compensation and payroll taxes

5,045

11,539

Accrued outsourced manufacturing expenses

3,670

3,225

Other accrued expenses

4,276

4,552

     Total accrued expenses

24,961

28,838

Less long-term portion

26

17

     Total accrued expenses, current

$
24,935

$
28,821

Deferred revenue consisted of the following (in thousands):

March 31,
2017

December 31,
2016
Collaborative agreements

License fees and event-based payments:

Roche

$
34,877

$
35,709

Other

8,018

8,209

42,895

43,918

Reimbursement for research and development services

—

700

Total deferred revenue

42,895

44,618

Less current portion

4,093

4,793

Deferred revenue, net of current portion

$
38,802

$
39,825

X

- References
No definition available.
+ Details

Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.
+ References
No definition available.
+ Details

Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1

Long-Term Debt, Net (Notes)
3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Long-term Debt
Long-Term Debt, Net
Royalty-backed Loan
In January 2016, through our wholly-owned subsidiary Halozyme Royalty LLC (“Halozyme Royalty”), we received a $150 million loan (the “Royalty-backed Loan”) pursuant to a credit agreement (the “Credit Agreement”) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the “Royalty-backed Lenders”). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (“Collaboration Agreements”). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the “Royalty Payments”). The Royalty-backed Loan bears interest at a per annum rate of 8.75% plus the three-month LIBOR rate. The three-month LIBOR rate is subject to a floor of 0.7% and a cap of 1.5%. The interest rate as of March 31, 2017 was 9.9%.
The Credit Agreement provides that none of the Royalty Payments were required to be applied to the Royalty-backed Loan prior to January 1, 2017, 50% of the Royalty Payments are required to be applied to the Royalty-backed Loan between January 1, 2017 and January 1, 2018 and thereafter all Royalty Payments must be applied to the Royalty-backed Loan. However, the amounts available to repay the Royalty-backed Loan are subject to caps of $13.75 million per quarter in 2017, $18.75 million per quarter in 2018, $21.25 million per quarter in 2019 and $22.5 million per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first to pay interest and second to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date. Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps.
Because the repayment of the term loan is contingent upon the level of Royalty Payments received, the repayment term may be shortened or extended depending on the actual level of Royalty Payments. The final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050. Currently, we estimate that the loan will be repaid in the first quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January 1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to 105% of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan.
As of March 31, 2017, we were in compliance with all covenants under the Royalty-backed Loan and there was no material adverse change in our business, operations or financial condition.
During the three months ended March 31, 2016, accrued interest in the amount of $1.9 million was capitalized and added to the principal balance of the Royalty-backed Loan. We began making principal and interest payments against the Royalty-backed Loan in the first quarter of 2017 and therefore had no capitalized interest in the three months ended March 31, 2017. In addition, we recorded accrued interest, which is included in accrued expenses, of $0.7 million as of March 31, 2017 and December 31, 2016.
In connection with the Royalty-backed Loan, we paid the Royalty-backed Lenders a fee of $1.5 million and incurred additional debt issuance costs totaling $0.4 million, which includes expenses that we paid on behalf of the Royalty-backed Lenders and expenses incurred directly by us. Debt issuance costs and the lender fee have been netted against the debt as of March 31, 2017, and are being amortized over the estimated term of the debt using the effective interest method. For the three months ended March 31, 2017 and 2016, the Company recognized interest expense, including amortization of the debt discount, related to the Royalty-backed Loan of $4.0 million and $2.6 million, respectively. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. The outstanding balance of the Royalty-backed Loan as of March 31, 2017 was $158.9 million, inclusive of payment-in-kind interest expense of $10.2 million and net of unamortized debt discount of $1.3 million.
Oxford and SVB Loan and Security Agreement
In December 2013, we entered into an Amended and Restated Loan and Security Agreement (the “Original Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”) (collectively, the “Lenders”), amending and restating in its entirety our previous loan agreement with the Lenders, dated December 2012. The Original Loan Agreement provided for an additional $20 million principal amount of new term loan, bringing the total term loan balance to $50 million. The amended term loan facility was scheduled to mature on January 1, 2018.
In January 2015, we entered into the second amendment to the Original Loan Agreement with the Lenders, amending and restating the term loan repayment schedules of the Original Loan Agreement. The amended and restated term loan repayment schedule provided for interest only payments through January 2016, followed by consecutive equal monthly payments of principal and interest in arrears starting in February 2016 and continuing through the previously established maturity date of January 1, 2018. Consistent with the original loan, the amended Original Loan Agreement provided for a 7.55% interest rate on the term loan and a final payment equal to 8.5% of the original principal amount, or $4.25 million, which was due when the term loan became due or upon the prepayment of the facility.
In June 2016, we entered into a Loan and Security Agreement (the “Loan Agreement”) with the Lenders, providing a senior secured loan facility of up to an aggregate principal amount of $70.0 million, comprising a $55.0 million draw in June 2016 and an additional $15.0 million tranche, which we have the option to draw during the second quarter of 2017. The initial proceeds carry an interest rate of 8.25% and were partially used to pay the outstanding principal and final payment of $4.25 million owed on the previous loan agreement with the Lenders. The remaining proceeds, including any drawdown of the additional $15.0 million, are to be used for working capital and general business requirements. The remaining $15.0 million tranche is subject to an annual interest rate equal to the prime rate as reported in The Wall Street Journal on the draw-down date plus 4.75%. The repayment schedule provides for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of January 1, 2021. The Loan Agreement provides for a final payment equal to 5.50% of the initial $55.0 million principal amount and, if we exercise our option to draw an additional $15.0 million in 2017, 7.25% of the principal amount of the second draw. The final payment is due when the Loan Agreement becomes due or upon the prepayment of the facility. We have the option to prepay the outstanding balance of the Loan Agreement in full, subject to a prepayment fee of 2% in the first year and 1% in the second year of the Loan Agreement.
In connection with the Loan Agreement, the debt offering costs have been recorded as a debt discount in our condensed consolidated balance sheets which, together with the final payment and fixed interest rate payments, are being amortized and recorded as interest expense throughout the life of the loan using the effective interest rate method.
The Loan Agreement is secured by substantially all of the assets of the Company and our subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc., any of our intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same; and make any voluntary prepayment of or modify certain terms of the Royalty-backed Loan. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our subsidiary, Halozyme, Inc.
The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, a material impairment in the perfection or priority of the Lender’s lien in the collateral or in the value of such collateral or the occurrence of an event of default under the Royalty-backed Loan. In the event of default by us under the Loan Agreement, the Lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Loan Agreement, which could harm our financial condition.
As of March 31, 2017, we were in compliance with all covenants under the Loan Agreement and there was no material adverse change in our business, operations or financial condition.
Interest expense, including amortization of the debt discount, related to the Loan Agreement totaled $1.4 million and $1.3 million for the three months ended March 31, 2017 and 2016, respectively. Accrued interest, which is included in accrued expenses, was $0.4 million and $1.1 million as of March 31, 2017 and December 31, 2016, respectively. The outstanding term loan balance was $55.1 million as of March 31, 2017, inclusive of $0.1 million of accretion of the final payment and net of unamortized debt discount of $2.9 million.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1

Share-based Compensation (Notes)
3 Months Ended

Mar. 31, 2017

Share-based Compensation [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Share-based Compensation
Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):

Three Months Ended
March 31,

2017

2016
Research and development

$
3,274

$
2,584

Selling, general and administrative

4,041

3,233

Share-based compensation expense

$
7,315

$
5,817

Share-based compensation expense by type of share-based award (in thousands):

Three Months Ended
March 31,

2017

2016
Stock options

$
4,749

$
3,708

RSAs, RSUs and PRSUs

2,566

2,109

$
7,315

$
5,817

We granted stock options to purchase approximately 2.2 million and 2.8 million shares of common stock during the three months ended March 31, 2017 and 2016, respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (“Black-Scholes model”). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes model were as follows:

Three Months Ended
March 31,

2017

2016
Expected volatility

71.0-71.7%

67.5-69.1%
Average expected term (in years)

5.6

5.4
Risk-free interest rate

1.92-1.94%

1.27-1.73%
Expected dividend yield

—

—

Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):

March 31, 2017

Unrecognized
Expense

Remaining
Weighted-Average
Recognition Period
(years)
Stock options

$
53,470

2.9
RSAs

$
7,281

2.1
RSUs

$
22,742

3.3

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65895303&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1

Stockholders' Deficit
3 Months Ended

Mar. 31, 2017

Equity [Abstract]

Stockholders' Deficit
Stockholders’ Deficit
During the three months ended March 31, 2017 and 2016, we issued an aggregate of 74,522 and 156,185 shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $7.78 and $6.22 per share, respectively, for net proceeds of approximately $0.6 million and $1.0 million, respectively. For the three months ended March 31, 2017 and 2016, we issued 252,305 and 106,389 shares of common stock, respectively, upon vesting of certain RSUs for which the RSU holders surrendered 79,499 and 70,288 RSUs, respectively, to pay for minimum withholding taxes totaling approximately $1.7 million and $0.7 million, respectively. In addition, we issued zero and 807,036 shares of common stock in connection with the grants of RSAs during the three months ended March 31, 2017 and 2016, respectively. Stock options and unvested restricted units totaling approximately 15.5 million shares and 12.5 million shares of our common stock were outstanding as of March 31, 2017 and December 31, 2016, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1

Commitments and Contingencies
3 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Commitments and Contingencies
From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73718637&loc=d3e25287-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1

Summary of Significant Accounting Policies (Policies)
3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation
Basis of Presentation
The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on February 28, 2017. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.
The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC and Halozyme Switzerland GmbH. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.

Cash Equivalents
Cash Equivalents and Marketable Securities
Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of March 31, 2017, our cash equivalents consisted of money market funds and commercial paper.

Marketable Securities
Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders’ deficit. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the condensed consolidated statements of operations.

Restricted Cash
Restricted Cash
Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases.

Fair Value of Financial Instruments
Fair Value of Financial Instruments
The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.
Available-for-sale marketable securities consist of corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.

Inventories
Inventories
Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.
Prior to receiving marketing approval from the U.S. Food and Drug Administration (“FDA”) or comparable regulatory agencies in foreign countries, costs related to purchases of bulk rHuPH20 and raw materials and the manufacturing of the product candidates are recorded as research and development expense. All direct manufacturing costs incurred after receiving marketing approval are capitalized as inventory. Inventories used in clinical trials are expensed at the time the inventories are packaged for the clinical trials.

Revenue Recognition
Revenue Recognition
We generate revenues from product sales and payments received under collaborative agreements. Collaborative agreement payments may include nonrefundable fees at the inception of the agreements, license fees, milestone and event-based payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk rHuPH20, and/or royalties on sales of products resulting from collaborative arrangements.
We recognize revenues in accordance with the authoritative guidance for revenue recognition. We recognize revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured.
Product Sales, Net
Hylenex Recombinant
We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers provide for selling prices that are fixed on the date of sale, although we offer discounts to certain group purchasing organizations (“GPOs”), hospitals and government programs. The wholesalers take title to the product, bear the risk of loss of ownership and have economic substance to the inventory. Further, we have no significant obligations for future performance to generate pull-through sales.
We have developed sufficient historical experience and data to reasonably estimate future returns and chargebacks of Hylenex recombinant. As a result, we recognize Hylenex recombinant product sales and related cost of product sales at the time title transfers to the wholesalers.
Upon recognition of revenue from product sales of Hylenex recombinant, we record certain sales reserves and allowances as a reduction to gross revenue. These reserves and allowances include amounts for product returns (based primarily on an analysis of historical return patterns), distribution fees, prompt payment discounts, and GPO fees and other discounts and fees.
We recognize product sales reserves and allowances as a reduction of product sales in the same period the related revenue is recognized. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. If actual product return results differ from our estimates, we will be required to make adjustments to these allowances in the future, which could have an effect on product sales revenue and earnings in the period of adjustments.
Bulk rHuPH20
Subsequent to receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries, sales of bulk rHuPH20 for use in collaboration commercial products are recognized as product sales when the materials have met all the specifications required for the customer’s acceptance and title and risk of loss have transferred to the customer. Following the receipt of European marketing approvals of Roche’s Herceptin SC product in August 2013 and MabThera^® SC product in March 2014 and Baxalta’s HYQVIA product in May 2013, revenue from the sales of bulk rHuPH20 for these collaboration products has been recognized as product sales.
Revenues under Collaborative Agreements
We have entered into license and collaboration agreements under which our collaborators obtained worldwide rights for the use of our proprietary rHuPH20 enzyme in the development and commercialization of their biologic compounds identified as targets. These agreements may also contain other elements. Pursuant to the terms of these agreements, collaborators could be required to make various payments to us for each target, including nonrefundable upfront license fees, exclusivity fees, payments based on achievement of specified milestones designated in the collaborative agreements, annual maintenance fees, reimbursements of research and development services, payments for supply of bulk rHuPH20 used by the collaborator and/or royalties on sales of products resulting from collaborative agreements.
In order to account for the multiple-element arrangements, we identify the deliverables included within the collaborative agreement and evaluate which deliverables represent units of accounting. We then determine the appropriate method of revenue recognition for each unit based on the nature and timing of the delivery process. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. The deliverables under our collaborative agreements include (i) the license to our rHuPH20 technology, (ii) at the collaborator’s request, research and development services which are reimbursed at contractually determined rates, and (iii) at the collaborator’s request, supply of bulk rHuPH20 which is reimbursed at our cost plus a margin. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement. We base this determination on the collaborators’ ability to use the delivered items on their own without us supplying undelivered items, which we determine taking into consideration factors such as the research capabilities of the collaborator, the availability of research expertise in this field in the general marketplace, and the ability to procure the supply of bulk rHuPH20 from the marketplace.
Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (“VSOE”) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are not contingent upon the delivery of additional items or meeting other specified performance conditions. The consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement.
Nonrefundable upfront license fees are recognized upon delivery of the license if facts and circumstances dictate that the license has standalone value from the undelivered items, which generally include research and development services and the manufacture of bulk rHuPH20, the relative selling price allocation of the license is equal to or exceeds the upfront license fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable and collectibility is reasonably assured. Upfront license fees are deferred if facts and circumstances dictate that the license does not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period.
When collaborators have rights to elect additional targets, the rights are assessed as to whether they represent deliverables at the inception of the arrangement. In assessing these contingent deliverables, we consider whether the right is a substantive option. We consider a right to be a substantive option if the election of the additional targets is not essential to the functionality of the other elements in the arrangement and if we are truly at risk of the right being exercised. If the right is determined to be a substantive option, we further consider whether the right is priced at a significant and incremental discount that should be accounted for as an element of the arrangement. If a right is determined to be a substantive option and is not priced at a significant and incremental discount, it is not treated as a deliverable in the arrangement and receives no allocation at the inception of the arrangement of the original arrangement consideration. The right is then accounted for when and if it is exercised.
Certain of our collaborative agreements provide for milestone payments upon achievement of development and regulatory events and/or specified sales volumes of commercialized products by the collaborator. We account for milestone payments in accordance with the provisions of ASU No. 2010-17, Revenue Recognition - Milestone Method (“Milestone Method of Accounting”). We recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:
1.
The consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone;
2.
The consideration relates solely to past performance; and
3.
The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.
A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the vendor.
Reimbursements of research and development services are recognized as revenue during the period in which the services are performed as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Revenue from the manufacture of bulk rHuPH20 is recognized when the materials have met all specifications required for the collaborator’s acceptance and title and risk of loss have transferred to the collaborator. We do not directly control when any collaborator will request research and development services or supply of bulk rHuPH20; therefore, we cannot predict when we will recognize revenues in connection with research and development services and supply of bulk rHuPH20.
Since we receive royalty reports 60 days after quarter end, royalty revenue from sales of collaboration products by our collaborators is recognized in the quarter following the quarter in which the corresponding sales occurred.
The collaborative agreements typically provide the collaborators the right to terminate such agreement in whole or on a product-by-product or target-by-target basis at any time upon 30 to 90 days prior written notice to us. There are no performance, cancellation, termination or refund provisions in any of our collaborative agreements that contain material financial consequences to us.

Cost of Product Sales
Cost of Product Sales
Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of Hylenex recombinant and bulk rHuPH20 for use in approved collaboration products. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.

Research and Development Expenses
Research and Development Expenses
Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses. After receiving approval from the FDA or comparable regulatory agencies in foreign countries for a product, costs related to purchases and manufacturing of bulk rHuPH20 for such product are capitalized as inventory. The manufacturing costs of bulk rHuPH20 for the collaboration products, Herceptin SC, MabThera SC and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory.
We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.
Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred.

Clinical Trial Expenses
Clinical Trial Expenses
We make payments in connection with our clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.
Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.

Share-Based Compensation
Share-Based Compensation
We record compensation expense associated with stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and RSUs with performance conditions (“PRSUs”) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.

Income Taxes
Income Taxes
We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. While we have begun to utilize certain of our net operating losses, we have not yet established a track record of profitability. Accordingly, valuation allowances have been recorded to reduce our net deferred tax assets to zero until such time we can demonstrate an ability to realize them.

Net Loss Per Share
Net Loss Per Share
Basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive.

Segment Information
Segment Information
We operate our business in one segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of Hylenex recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.

Adoption and Pending Adoption of Recent Accounting Pronouncements
Adoption and Pending Adoption of Recent Accounting Pronouncements
The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:
Standard

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters

In July 2015, the FASB issued ASU 2015-11, Inventory: Simplifying the Measurement of Inventory.

The new guidance requires that for entities that measure inventory using the first-in, first-out method, inventory should be measured at the lower of cost or net realizable value. Topic 330, Inventory, currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximate normal profit margin. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.

January 1, 2017.

The adoption did not have a material impact on our condensed consolidated financial position or results of operations.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash.

Current U.S. GAAP either is unclear or does not include specific guidance on the eight cash flow classification issues included in ASU 2016-15. The new guidance is an improvement to U.S. GAAP and is intended to reduce the current and potential future diversity in practice. ASU 2016-18 provides additional classification guidance for restricted cash, which requires that restricted cash be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows.

January 1, 2018. We have elected to early adopt as of January1, 2017.

Cash and cash equivalents at the beginning-of-period and end-of-period total amounts in the Condensed Consolidated Statements of Cash Flows have been adjusted to include $0.5 million of restricted cash for each of the periods presented.

Standard

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters
In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall; Recognition and Measurement of Financial Assets and Financial Liabilities.

The new guidance supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities to be measured at fair value with changes in the fair value recognized through net income. The new guidance requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement.

January 1, 2018.

We currently do not hold equity securities, and we are evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.

Standard

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). In March, April, May and December 2016, the FASB issued additional guidance related to Topic 606.

The new standard will supersede nearly all existing revenue recognition guidance. Under Topic 606, an entity is required to recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. Topic 606 defines a five-step process in order to achieve this core principle, which may require the use of judgment and estimates, and also requires expanded qualitative and quantitative disclosures relating to the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers, including significant judgments and estimates used. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized. The new standard permits adoption either by using (i) a full retrospective approach for all periods presented in the period of adoption or (ii) a modified retrospective approach where the new standard is applied in the financial statements starting with the year of adoption. Under both approaches, cumulative impact of the adoption is reflected as an adjustment to retained earnings (accumulated deficit) as of the earliest date presented in accordance with the new standard.

January 1, 2018. Early adoption is permitted.

We plan to implement the new guidance on January 1, 2018. We currently plan to adopt using the modified retrospective approach; however, a final decision regarding the adoption method has not been finalized at this time. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. However, we anticipate an impact to the timing of recognition of payments related to certain of our license and collaboration agreements ⁽¹⁾and the timing of recognition of our sales-based royalties.⁽²⁾We anticipate that this standard will have a material impact on our consolidated financial statements. Additional areas of impact may be identified as we continue our evaluation. We cannot reasonably estimate additional quantitative information related to the impact of the new standard on our consolidated financial statements at this time.

In February 2016, the FASB issued ASU 2016-02, Leases.

The new guidance requires lessees to recognize assets and liabilities for most leases and provides enhanced disclosures.

January 1, 2019. Early adoption is permitted.

We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. However, we anticipate recognition of additional assets and corresponding liabilities related to our leases on our consolidated balance sheet.

X

- Definition
Disclosure of accounting policy for clinical trial expenses.
+ References
No definition available.
+ Details

Name: halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock

Namespace Prefix: halo_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586
+ Details

Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 50
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68069731&loc=d3e63676-111659

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790
+ Details

Name: us-gaap_CostOfSalesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e32280-109318
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investments in debt and equity securities that are classified as available-for-sale. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.M)
-URI http://asc.fasb.org/extlink&oid=65877573&loc=d3e87990-122713

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Research and Development
-URI http://asc.fasb.org/extlink&oid=6523717
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.B.Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790
+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1

Fair Value Measurement (Tables)
3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Available-for-sale marketable securities
Available-for-sale marketable securities consisted of the following (in thousands):

March 31, 2017

Amortized Cost

Gross Unrealized Gains

Gross Unrealized Losses

Estimated Fair Value
Corporate debt securities

$
33,158

$
—

$
(18
)

$
33,140

U.S. Treasury securities

70,002

1

(29
)

69,974

Commercial paper

30,683

—

—

30,683

$
133,843

$
1

$
(47
)

$
133,797

December 31, 2016

Amortized Cost

Gross Unrealized Gains

Gross Unrealized Losses

Estimated Fair Value
Corporate debt securities

$
40,221

$
1

$
(15
)

$
40,207

U.S. Treasury securities

94,002

24

(16
)

94,010

Commercial paper

$
4,000

$
—

$
—

$
4,000

$
138,223

$
25

$
(31
)

$
138,217

Fair Value, Assets Measured on Recurring Basis [Table Text Block]
The following table summarizes, by major security type, our cash equivalents and marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):

March 31, 2017

December 31, 2016

Level 1

Level 2

Total estimated fair value

Level 1

Level 2

Total estimated fair value
Cash equivalents:

Money market funds

$
34,814

$
—

$
34,814

$
60,916

$
—

$
60,916

Commercial paper

4,000

4,000

—

—

—

Available-for-sale marketable
   securities:

Corporate debt securities

—

33,140

33,140

—

40,207

40,207

U.S. Treasury securities

69,974

—

69,974

94,010

—

94,010

Commercial paper

—

30,683

30,683

—

4,000

4,000

$
104,788

$
67,823

$
172,611

$
154,926

$
44,207

$
199,133

X

- Definition
Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19190-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1

Collaborative Agreements Collaborative Agreements (Tables)
3 Months Ended

Mar. 31, 2017

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]

As of
March 31, 2017
Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets
$
20,000

Election of additional exclusive targets and annual license maintenance fees for the right to
   designate the remaining targets as exclusive targets
23,000

Clinical development milestone payments
13,000

Regulatory milestone payments
8,000

Sales-based milestone payments
15,000

Total payments received
$
79,000

Roche [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]

As of
March 31, 2017
Upfront license fee payment for the application of rHuPH20 to the initial exclusive target
$
10,000

Regulatory milestone payments
3,000

Sales-based milestone payments
4,000

Total payments received
$
17,000

Other collaborators [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]

As of
March 31, 2017
Lilly
$
33,000

AbbVie
29,000

Janssen
15,250

Pfizer
16,500

Total payments received
$
93,750

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement. This item includes certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68059916&loc=d3e50766-111635

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 25
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68059916&loc=SL6750900-111635
+ Details

Name: us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_RocheMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1

Certain Balance Sheet Items (Tables)
3 Months Ended

Mar. 31, 2017

Balance Sheet Related Disclosures [Abstract]

Summary of Accounts Receivable
Accounts receivable, net consisted of the following (in thousands):

March 31,
2017

December 31,
2016
Accounts receivable from product sales to collaborators

$
8,023

$
7,854

Accounts receivable from other product sales

2,090

2,234

Accounts receivable from revenues under collaborative agreements

2,921

6,151

     Subtotal

13,034

16,239

Allowance for distribution fees and discounts

(582
)

(559
)
     Total accounts receivable, net

$
12,452

$
15,680

Summary of Inventories
Inventories consisted of the following (in thousands):

March 31,
2017

December 31,
2016
Raw materials

$
868

$
761

Work-in-process

12,885

12,850

Finished goods

537

1,012

     Total inventories

$
14,290

$
14,623

Summary of Prepaid Expenses and Other Assets
Prepaid expenses and other assets consisted of the following (in thousands):

March 31,
2017

December 31,
2016
Prepaid manufacturing expenses

$
6,327

$
9,663

Prepaid research and development expenses

8,345

8,613

Other prepaid expenses

1,525

1,661

Other assets

602

1,530

     Total prepaid expenses and other assets

16,799

21,467

Less long-term portion

172

219

     Total prepaid expenses and other assets, current

$
16,627

$
21,248

Summary of Property and Equipment
Property and equipment, net consisted of the following (in thousands):

March 31,
2017

December 31,
2016
Research equipment

$
10,483

$
10,479

Computer and office equipment

3,395

3,373

Leasehold improvements

2,345

2,331

     Subtotal

16,223

16,183

Accumulated depreciation and amortization

(12,482
)

(11,919
)
     Property and equipment, net

$
3,741

$
4,264

Summary of Accrued Expenses
Accrued expenses consisted of the following (in thousands):

March 31,
2017

December 31,
2016
Accrued outsourced research and development expenses

$
11,970

$
9,522

Accrued compensation and payroll taxes

5,045

11,539

Accrued outsourced manufacturing expenses

3,670

3,225

Other accrued expenses

4,276

4,552

     Total accrued expenses

24,961

28,838

Less long-term portion

26

17

     Total accrued expenses, current

$
24,935

$
28,821

Summary of Deferred Revenue
Deferred revenue consisted of the following (in thousands):

March 31,
2017

December 31,
2016
Collaborative agreements

License fees and event-based payments:

Roche

$
34,877

$
35,709

Other

8,018

8,209

42,895

43,918

Reimbursement for research and development services

—

700

Total deferred revenue

42,895

44,618

Less current portion

4,093

4,793

Deferred revenue, net of current portion

$
38,802

$
39,825

X

- References
No definition available.
+ Details

Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765
+ Details

Name: us-gaap_DeferredRevenueByArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3,4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfOtherAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1

Share-based Compensation (Tables)
3 Months Ended

Mar. 31, 2017

Share-based Compensation [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):

Three Months Ended
March 31,

2017

2016
Research and development

$
3,274

$
2,584

Selling, general and administrative

4,041

3,233

Share-based compensation expense

$
7,315

$
5,817

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]
Share-based compensation expense by type of share-based award (in thousands):

Three Months Ended
March 31,

2017

2016
Stock options

$
4,749

$
3,708

RSAs, RSUs and PRSUs

2,566

2,109

$
7,315

$
5,817

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
The assumptions used in the Black-Scholes model were as follows:

Three Months Ended
March 31,

2017

2016
Expected volatility

71.0-71.7%

67.5-69.1%
Average expected term (in years)

5.6

5.4
Risk-free interest rate

1.92-1.94%

1.27-1.73%
Expected dividend yield

—

—

Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]
Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):

March 31, 2017

Unrecognized
Expense

Remaining
Weighted-Average
Recognition Period
(years)
Stock options

$
53,470

2.9
RSAs

$
7,281

2.1
RSUs

$
22,742

3.3

X

- Definition
Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the total compensation cost related to nonvested awards not yet recognized and the weighted-average period over which it is expected to be recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1

Summary of Significant Accounting Policies Restricted Cash (Details) - USD ($)
$ in Thousands

Mar. 31, 2017

Dec. 31, 2016

Restricted Cash and Investments, Current [Abstract]

Restricted cash $ 500 $ 500

X

- Definition
Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_RestrictedCashAndInvestmentsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1

Summary of Significant Accounting Policies Inventories (Details) - USD ($)
$ in Thousands

Mar. 31, 2017

Dec. 31, 2016

Inventory [Line Items]

Inventory, Net $ 14,290 $ 14,623

Hylenex recombinant

Inventory [Line Items]

Inventory, Net 1,700 2,300

bulk rHuPH20

Inventory [Line Items]

Inventory, Net $ 12,600 $ 12,300

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_InventoryLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=halo_HylenexRecombinantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=halo_BulkrHuPH20Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1

Summary of Significant Accounting Policies Revenue recognition (Details)
3 Months Ended

Mar. 31, 2017

Period prior to expiration

Collaborative agreements termination notification

Notification period for termination 30 days

Period after expiration

Collaborative agreements termination notification

Notification period for termination 90 days

X

- Definition
Period for termination.
+ References
No definition available.
+ Details

Name: halo_PeriodForTermination

Namespace Prefix: halo_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1

Summary of Significant Accounting Policies Research and development (Details) - USD ($)
3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research and Development Expense $ 36,935,000 $ 40,100,000

In-license technologies [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research and Development Expense $ 0

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=halo_InlicensetechnologiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1

Summary of Significant Accounting Policies Income tax (Details) - USD ($)
3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Income Tax Disclosure [Abstract]

Deferred Tax Assets, Net $ 0

Income Tax Expense $ 210,000 $ 0

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Income Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6515339
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 39 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1

Summary of Significant Accounting Policies Net Loss Per Share (Details) - shares
shares in Millions
3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Net loss per share (Textuals) [Abstract]

Shares excluded from calculation of diluted net loss, amount 16.4 13.0

X

- Definition
Net income (loss) per share (Textuals) [Abstract]
+ References
No definition available.
+ Details

Name: halo_NetincomelosspershareTextualsAbstract

Namespace Prefix: halo_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 40 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1

Summary of Significant Accounting Policies Segment information (Details)
3 Months Ended

Mar. 31, 2017

Segment

Segment Reporting [Abstract]

Number of Operating Segments 1

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1

Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Dec. 31, 2016

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Reclassification of restricted cash $ 0.5 $ 0.5

Revenue, amortization of license payments $ 4.1

Deferred Revenue Relating To Upfront Payment License Fees $ 43.9

X

- Definition
Deferred Revenue Relating To Upfront Payment License Fees
+ References
No definition available.
+ Details

Name: halo_DeferredRevenueRelatingToUpfrontPaymentLicenseFees

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Revenue, amortization of license payments
+ References
No definition available.
+ Details

Name: halo_Revenueamortizationoflicensepayments

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1

Fair Value Measurement (Details) - USD ($)
$ in Thousands

Mar. 31, 2017

Dec. 31, 2016

Schedule of Available-for-sale Securities

Amortized cost $ 133,843 $ 138,223

Gross Unrealized Gains 1 25

Gross Unrealized Losses (47) (31)

Estimated fair value 133,797 138,217

Corporate Debt Securities [Member]

Schedule of Available-for-sale Securities

Amortized cost 33,158 40,221

Gross Unrealized Gains 0 1

Gross Unrealized Losses (18) (15)

Estimated fair value 33,140 40,207

US Treasury Securities [Member]

Schedule of Available-for-sale Securities

Amortized cost 70,002 94,002

Gross Unrealized Gains 1 24

Gross Unrealized Losses (29) (16)

Estimated fair value 69,974 94,010

Commercial Paper [Member]

Schedule of Available-for-sale Securities

Amortized cost 30,683 4,000

Gross Unrealized Gains 0 0

Gross Unrealized Losses 0 0

Estimated fair value $ 30,683 $ 4,000

X

- Definition
Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26610-111562
+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AvailableForSaleSecuritiesAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1

Fair Value Measurement Textuals (Details)
$ in Millions
3 Months Ended

Mar. 31, 2017

USD ($)

Fair Value Disclosures [Abstract]

Available-for-sale securities maturities, next twelve months $ 124.8

Number of available-for-sale securities in unrealized loss position, less than one year 8

Other than Temporary Impairment Losses, Marketable Securities $ 0.0

X

- Definition
Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of investment positions in available-for-sale investments in a continuous unrealized loss position for less than one year or normal operating cycle, if longer, for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.
+ References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563
+ Details

Name: us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 44 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1

Fair Value Measurement Fair Value Measures (Details) - USD ($)
$ in Thousands

Mar. 31, 2017

Dec. 31, 2016

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $ 0 $ 0

Available-for-sale Securities 133,797 138,217

Assets, Fair Value Disclosure 172,611 199,133

Money Market Funds [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Cash and Cash Equivalents, Fair Value Disclosure 34,814 60,916

Commercial Paper [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Cash and Cash Equivalents, Fair Value Disclosure 4,000

Available-for-sale Securities 30,683 4,000

Corporate Debt Securities [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities 33,140 40,207

US Treasury Securities [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities 69,974 94,010

Fair Value, Inputs, Level 3 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Investments, Fair Value Disclosure 0 0

Fair Value, Inputs, Level 1 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets, Fair Value Disclosure 104,788 154,926

Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Cash and Cash Equivalents, Fair Value Disclosure 34,814 60,916

Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities 69,974 94,010

Fair Value, Inputs, Level 2 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets, Fair Value Disclosure 67,823 44,207

Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Cash and Cash Equivalents, Fair Value Disclosure 4,000

Available-for-sale Securities 30,683 4,000

Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities $ 33,140 $ 40,207

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26610-111562
+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016
+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Trading Securities
-URI http://asc.fasb.org/extlink&oid=6526789

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 35
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=27723805&loc=d3e24584-111560

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Available-for-Sale Securities
-URI http://asc.fasb.org/extlink&oid=6505594
+ Details

Name: us-gaap_InvestmentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1

Collaborative Agreements Collaborative Agreements Textuals (Details)
$ in Thousands
3 Months Ended 12 Months Ended

Mar. 31, 2017

USD ($)

Compound

Mar. 31, 2016

USD ($)

Dec. 31, 2016

USD ($)

Collaborative Agreements (Textual)

Additional maximum proceeds receivable from collaborators of license and collaborative agreement upon achievement of clinical development milestones for elected targets | $ $ 62,500

Sales-based payment to be received upon the first commercial sale | $ 12,000

Deferred Revenue (Textual) [Abstract]

Deferred revenue relating to upfront payment license fees and annual maintenance fees | $ 42,895 $ 44,618

Roche [Member]

Deferred Revenue (Textual) [Abstract]

Deferred revenue relating to upfront payment license fees and annual maintenance fees | $ 34,877 35,709

Baxalta [Member]

Deferred Revenue (Textual) [Abstract]

Deferred revenue relating to upfront payment license fees and annual maintenance fees | $ $ 8,000 $ 8,200

Roche [Member]

Collaborative Agreements Terms

Number of product compound combinations licensed to develop 13

Number of exclusive right targets 3

Number of targets elected 8

Number of targets elected, additional exclusive targets 2

Number of additional targets, optional 10

Collaborative agreement target selection period 10 years

Duration of royalty receivable 10 years

Collaborative Agreements (Textual)

Deferred revenue, revenue recognized | $ $ 800 $ 800

Baxalta [Member]

Collaborative Agreements Terms

Duration of royalty receivable 10 years

Collaborative Agreements (Textual)

Deferred revenue, revenue recognized | $ $ 200 200

Lilly [Member]

Collaborative Agreements Terms

Number of product compound combinations licensed to develop 5

Number of targets elected, additional exclusive targets 2

Number of additional targets, optional 2

Number of targets elected, additional semi-exclusive targets 1

Duration of royalty receivable 10 years

Notification period for termination 60 days

AbbVie [Member]

Collaborative Agreements Terms

Number of product compound combinations licensed to develop 9

Number of targets elected 1

Number of additional targets, optional 9

Duration of royalty receivable 10 years

Notification period for termination 90 days

Janssen [Member]

Collaborative Agreements Terms

Number of product compound combinations licensed to develop 5

Number of targets elected 1

Number of additional targets, optional 4

Duration of royalty receivable 10 years

Notification period for termination 90 days

Pfizer [Member]

Collaborative Agreements Terms

Number of product compound combinations licensed to develop 6

Number of targets elected 5

Number of Returned Targets 1

Number of additional targets, optional 2

Duration of royalty receivable 10 years

Notification period for termination 30 days

Pfizer, Janssen and AbbVie

Collaborative Agreements (Textual)

Revenue Recognition, Event-based or Milestone, Revenue Recognized | $ $ 0 $ 6,000

X

- Definition
Additional maximum proceeds receivable from collaborator of license and collaborative agreement upon achievement of clinical development milestones for elected targets.
+ References
No definition available.
+ Details

Name: halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Additional maximum cash payments receivable upon achievement of regulatory milestones for elected targets.
+ References
No definition available.
+ Details

Name: halo_Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Collaborative Agreements Terms [Abstract]
+ References
No definition available.
+ Details

Name: halo_CollaborativeAgreementsTermsAbstract

Namespace Prefix: halo_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Collaborative agreements.
+ References
No definition available.
+ Details

Name: halo_CollaborativeAgreementsTextualAbstract

Namespace Prefix: halo_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Collaborative agreement target selection period
+ References
No definition available.
+ Details

Name: halo_Collaborativeagreementtargetselectionperiod

Namespace Prefix: halo_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Deferred revenue.
+ References
No definition available.
+ Details

Name: halo_DeferredRevenueTextualAbstract

Namespace Prefix: halo_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Duration of royalty receivable.
+ References
No definition available.
+ Details

Name: halo_DurationOfRoyaltyReceivable

Namespace Prefix: halo_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of Additional Target, Optional
+ References
No definition available.
+ Details

Name: halo_NumberOfAdditionalTargetOptional

Namespace Prefix: halo_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of Targets Elected
+ References
No definition available.
+ Details

Name: halo_NumberOfTargetsElected

Namespace Prefix: halo_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of Product Compound Combinations Licensed to Develop
+ References
No definition available.
+ Details

Name: halo_NumberofProductCompoundCombinationsLicensedtoDevelop

Namespace Prefix: halo_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of Returned Targets
+ References
No definition available.
+ Details

Name: halo_NumberofReturnedTargets

Namespace Prefix: halo_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of exclusive right targets
+ References
No definition available.
+ Details

Name: halo_Numberofexclusiverighttargets

Namespace Prefix: halo_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of targets elected, additional exclusive targets
+ References
No definition available.
+ Details

Name: halo_Numberoftargetselectedadditionalexclusivetargets

Namespace Prefix: halo_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of targets elected, additional semi-exclusive targets
+ References
No definition available.
+ Details

Name: halo_Numberoftargetselectedadditionalsemiexclusivetargets

Namespace Prefix: halo_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Period for termination.
+ References
No definition available.
+ Details

Name: halo_PeriodForTermination

Namespace Prefix: halo_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized that was previously reported as deferred or unearned revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueRevenueRecognized1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of consideration recognized during the period for the milestone or milestones.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501
+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=halo_RocheMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=halo_BaxaltaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_RocheMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_BaxaltaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_LillyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_AbbVieMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_JanssenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_PfizerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_PfizerJanssenandAbbVieMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1

Collaborative Agreements Collaborative Agreements tables (Details)
$ in Thousands

Mar. 31, 2017

USD ($)

Roche [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets $ 20,000

Additional Exclusive Targets And Annual License Maintenance Fees 23,000

Clinical development milestone payments 13,000

Regulatory milestone payments 8,000

Sales-based milestone payments 15,000

Total Proceeds from Partner of License and Collaborative Agreement 79,000

Baxalta [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets 10,000

Regulatory milestone payments 3,000

Sales-based milestone payments 4,000

Total Proceeds from Partner of License and Collaborative Agreement 17,000

Lilly [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets 33,000

Total Proceeds from Partner of License and Collaborative Agreement 33,000

AbbVie [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets 23,000

Total Proceeds from Partner of License and Collaborative Agreement 29,000

Janssen [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets 15,300

Total Proceeds from Partner of License and Collaborative Agreement 15,250

Pfizer [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets 12,500

Total Proceeds from Partner of License and Collaborative Agreement 16,500

Other collaborators [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Total Proceeds from Partner of License and Collaborative Agreement $ 93,750

X

- Definition
Amount received from Roche for additional exclusive targets and annual license maintenance fees.
+ References
No definition available.
+ Details

Name: halo_AmountReceivedForAdditionalExclusiveTargetsAndAnnualLicenseMaintenanceFeesUnderCollaborativeAgreement

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount received for sales-based payment
+ References
No definition available.
+ Details

Name: halo_Amountreceivedforsalesbasedpayment

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Clinical development milestone payments received under collaborative agreement.
+ References
No definition available.
+ Details

Name: halo_ClinicalDevelopmentMilestonePaymentsReceivedUnderCollaborativeAgreement

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Nonrefundable upfront license fee payment received under collaborative agreement.
+ References
No definition available.
+ Details

Name: halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Proceeds from partner of license and collaborative agreement.
+ References
No definition available.
+ Details

Name: halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Regulatory milestone payments received under collaborative agreement.
+ References
No definition available.
+ Details

Name: halo_RegulatoryMilestonePaymentsReceivedUnderCollaborativeAgreement

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_RocheMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_BaxaltaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_LillyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_AbbVieMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_JanssenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_PfizerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1

Certain Balance Sheet Items - Accounts receivable (Details) - USD ($)
$ in Thousands

Mar. 31, 2017

Dec. 31, 2016

Accounts Receivable, Net, Current [Abstract]

Accounts receivable from product sales to collaborators $ 8,023 $ 7,854

Accounts receivable from other product sales 2,090 2,234

Accounts receivable from revenues under collaborative agreements 2,921 6,151

Accounts receivable, gross 13,034 16,239

Allowance for distribution fees and discounts (582) (559)

Total accounts receivable, net $ 12,452 $ 15,680

X

- Definition
Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.
+ References
No definition available.
+ Details

Name: halo_Accountsreceivablefromcollaborators

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accounts receivable from product sales
+ References
No definition available.
+ Details

Name: halo_Accountsreceivablefromproductsales

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accounts receivable from product sales to collaborators
+ References
No definition available.
+ Details

Name: halo_Accountsreceivablefromproductsalestocollaborators

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Allowance for Discount and Distribution Fees
+ References
No definition available.
+ Details

Name: halo_AllowanceforDistributionFeesandDiscounts

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(5))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_AccountsReceivableGrossCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccountsReceivableNetCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R35.htm IDEA: XBRL DOCUMENT v3.7.0.1

Certain Balance Sheet Items - Inventories (Details) - USD ($)
$ in Thousands

Mar. 31, 2017

Dec. 31, 2016

Inventory Disclosure [Abstract]

Inventory, Raw Materials $ 868 $ 761

Inventory, Work in Process 12,885 12,850

Inventory, Finished Goods 537 1,012

Summary of Inventories

Total inventories $ 14,290 $ 14,623

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729
+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729
+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729
+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 49 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1

Certain Balance Sheet Items - Prepaid expenses and other assets (Details) - USD ($)
$ in Thousands

Mar. 31, 2017

Dec. 31, 2016

Prepaid Expense and Other Assets, Current [Abstract]

Prepaid manufacturing expenses $ 6,327 $ 9,663

Prepaid research and development expenses 8,345 8,613

Other prepaid expenses 1,525 1,661

Other assets 602 1,530

Total prepaid expense and other assets 16,799 21,467

Less long-term portion 172 219

Total prepaid expense and other assets, current $ 16,627 $ 21,248

X

- Definition
Prepaid research and development
+ References
No definition available.
+ Details

Name: halo_Prepaidresearchanddevelopment

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(10))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765
+ Details

Name: us-gaap_OtherPrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.
+ References
No definition available.
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(10))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Assets
-URI http://asc.fasb.org/extlink&oid=6509628

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 50 R37.htm IDEA: XBRL DOCUMENT v3.7.0.1

Certain Balance Sheet Items - Property and Equipment (Details) - USD ($)
$ in Thousands

Mar. 31, 2017

Dec. 31, 2016

Property and equipment, gross $ 16,223 $ 16,183

Accumulated depreciation and amortization (12,482) (11,919)

Property and equipment, net 3,741 4,264

Research equipment

Property and equipment, gross 10,483 10,479

Computer and office equipment

Property and equipment, gross 3,395 3,373

Leasehold improvements

Property and equipment, gross $ 2,345 $ 2,331

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1

Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Depreciation and amortization

Depreciation and amortization expense $ 0.6 $ 0.5

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DepreciationAndAmortizationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R39.htm IDEA: XBRL DOCUMENT v3.7.0.1

Certain Balance Sheet Items - Accrued Expenses (Details) - USD ($)
$ in Thousands

Mar. 31, 2017

Dec. 31, 2016

Summary of Accrued Expenses

Accrued outsourced research and development $ 11,970 $ 9,522

Accrued compensation and payroll taxes 5,045 11,539

Accrued outsourced manufacturing expenses 3,670 3,225

Other accrued expenses 4,276 4,552

Total accrued expenses 24,961 28,838

Less long-term portion 26 17

Total accrued expenses, current $ 24,935 $ 28,821

X

- Definition
Accrued outsourced research and development expenses current.
+ References
No definition available.
+ Details

Name: halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued Outsourced Research and Development Expenses Long-Term
+ References
No definition available.
+ Details

Name: halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued manufacturing expenses
+ References
No definition available.
+ Details

Name: halo_Accruedmanufacturingexpenses

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 53 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1

Certain Balance Sheet Items - Deferred Revenue (Details) - USD ($)
$ in Thousands

Mar. 31, 2017

Dec. 31, 2016

Deferred revenue

Total deferred revenue $ 42,895 $ 44,618

Less current portion 4,093 4,793

Deferred revenue, net of current portion 38,802 39,825

Roche [Member]

Deferred revenue

Total deferred revenue 34,877 35,709

Other collaborative agreements

Deferred revenue

Total deferred revenue 8,018 8,209

License fees and event-based payments

Deferred revenue

Total deferred revenue 42,895 43,918

Research and Development Services

Deferred revenue

Total deferred revenue $ 0 $ 700

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueArrangementLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=halo_RocheMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_CollaborativeArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=halo_InlicensetechnologiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_ResearchAndDevelopmentArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R41.htm IDEA: XBRL DOCUMENT v3.7.0.1

Long-Term Debt, Net Long-Term Debt Textuals (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended

Jun. 30, 2016

Dec. 31, 2013

Mar. 31, 2017

Mar. 31, 2016

Dec. 31, 2016

Royalty-backed Loan

Debt Instrument [Line Items]

Issuance date Jan. 26, 2016

Total loan balance $ 150,000

Debt Instrument, Description of Variable Rate Basis 8.75% plus the three-month LIBOR rate

Debt, Interest Rate 9.90%

Debt Instrument, Maturity Date, Description final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050

Prepayment fee, percent 105.00%

Debt instrument, covenant in compliance in compliance

Interest Costs Capitalized $ 0 $ 1,900

Accrued Interest 700 700

Lender Fee 1,500

Debt Issuance Cost 400

Interest Expense, debt 4,000 2,600

Outstanding loan balance 158,900

Capitalized interest expense 10,200

Debt Instrument, Unamortized Discount $ 1,300

Maturity date Dec. 31, 2050

Royalty-backed Loan | 2016 [Member]

Debt Instrument [Line Items]

Royalty payments to be applied to debt instrument 0.00%

Royalty-backed Loan | 2017 [Member]

Debt Instrument [Line Items]

Royalty payments to be applied to debt instrument 50.00%

Royalty-backed Loan | 2018 and thereafter [Member]

Debt Instrument [Line Items]

Royalty payments to be applied to debt instrument 100.00%

Royalty-backed Loan | 2017 Quarterly Maximum Payment [Member]

Debt Instrument [Line Items]

Debt Instrument, Periodic Payment $ 13,750

Royalty-backed Loan | 2018 Quarterly Maximum Payment [Member]

Debt Instrument [Line Items]

Debt Instrument, Periodic Payment 18,750

Royalty-backed Loan | 2019 Quarterly Maximum Payment [Member]

Debt Instrument [Line Items]

Debt Instrument, Periodic Payment 21,250

Royalty-backed Loan | 2020 Quarterly Maximum Payment [Member]

Debt Instrument [Line Items]

Debt Instrument, Periodic Payment $ 22,500

Royalty-backed Loan | Minimum [Member]

Debt Instrument [Line Items]

Debt Instrument, Basis Spread on Variable Rate 0.70%

Royalty-backed Loan | Maximum [Member]

Debt Instrument [Line Items]

Debt Instrument, Basis Spread on Variable Rate 1.50%

Secured Debt

Debt Instrument [Line Items]

Total loan balance $ 50,000

Interest rate, stated percentage 7.55%

Interest Expense, debt $ 1,400 $ 1,300

Outstanding loan balance 55,100

Accretion of debt balloon payment 100

Debt Instrument, Unamortized Discount $ 2,900

Term loan, increase $ 20,000

Maturity date Jan. 01, 2018

Final payment $ 4,250

Final payment as percent of original principal 8.50%

Accrued interest, noncurrent $ 400 $ 1,100

Senior Loans [Member]

Debt Instrument [Line Items]

Issuance date Jun. 07, 2016

Total loan balance $ 70,000

Interest rate, stated percentage 8.25%

Debt instrument, covenant in compliance in compliance

Outstanding loan balance $ 55,000

Maturity date Jan. 01, 2021

Debt Instrument, interest only period interest only payments for the first 18 months

Debt Instrument, Unused Borrowing Capacity, Amount $ 15,000

Debt Instrument, Unused Borrowing Capacity, Description prime rate as reported in The Wall Street Journal on the draw-down date plus 4.75%

Final payment as percent of original principal 5.50%

Final payment as percent of additional draw 7.25%

Senior Loans [Member] | Minimum [Member]

Debt Instrument [Line Items]

Prepayment fee, percent 1.00%

Senior Loans [Member] | Maximum [Member]

Debt Instrument [Line Items]

Prepayment fee, percent 2.00%

X

- Definition
Accretion of debt balloon payment
+ References
No definition available.
+ Details

Name: halo_Accretionofdebtballoonpayment

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Capitalized interest expense
+ References
No definition available.
+ Details

Name: halo_Capitalizedinterestexpense

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Debt Instrument, Prepayment Fee,Percent
+ References
No definition available.
+ Details

Name: halo_DebtInstrumentPrepaymentFeePercent

Namespace Prefix: halo_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Final payment as percent of additional draw
+ References
No definition available.
+ Details

Name: halo_Finalpaymentaspercentofadditionaldraw

Namespace Prefix: halo_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Final payment as percent of original principal
+ References
No definition available.
+ Details

Name: halo_Finalpaymentaspercentoforiginalprincipal

Namespace Prefix: halo_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Royalty payments to be applied to debt instrument
+ References
No definition available.
+ Details

Name: halo_Royaltypaymentstobeappliedtodebtinstrument

Namespace Prefix: halo_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage points added to the reference rate to compute the variable rate on the debt instrument.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentCovenantCompliance

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentDescriptionOfVariableRateBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of the fee that accompanies borrowing money under the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentFeeAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Increase for accrued, but unpaid interest on the debt instrument for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_DebtInstrumentIncreaseAccruedInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net increase or decrease in the carrying amount of the debt instrument for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Date the debt instrument was issued, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentIssuanceDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentMaturityDateDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentPaymentTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the required periodic payments including both interest and principal payments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after accumulated amortization, of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Description of unused borrowing capacity under the debt instrument and conditions under which the commitment can be withdrawn by the lender.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentUnusedBorrowingCapacityDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average interest rate of debt outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_DebtWeightedAverageInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399
+ Details

Name: us-gaap_DeferredFinanceCostsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of interest capitalized during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Allowance for Funds Used during Construction
-URI http://asc.fasb.org/extlink&oid=6504829

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391
+ Details

Name: us-gaap_InterestCostsCapitalized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAccruedLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_SecuredDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2016Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2018andthereafterMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2017QuarterlyMaximumPaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2018QuarterlyMaximumPaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2019QuarterlyMaximumPaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2020QuarterlyMaximumPaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R42.htm IDEA: XBRL DOCUMENT v3.7.0.1

Share-based Compensation (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Allocated Share-based Compensation Expense $ 7,315 $ 5,817

Stock options

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Allocated Share-based Compensation Expense 4,749 3,708

RSU, RSA, and PRSU awards [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Allocated Share-based Compensation Expense 2,566 2,109

Research and Development Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Allocated Share-based Compensation Expense 3,274 2,584

Selling, General and Administrative Expenses [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Allocated Share-based Compensation Expense $ 4,041 $ 3,233

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R43.htm IDEA: XBRL DOCUMENT v3.7.0.1

Share-based Compensation Share-based compensation textuals (Details) - USD ($)
shares in Millions
3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Share-based Compensation [Abstract]

Proceeds and Excess Tax Benefit from Share-based Compensation $ 0

Options, Grants in Period, Gross 2.2 2.8

X

- Definition
The aggregate cash inflow comprised of the amount received from (a) employees to acquire the entity's shares under incentive awards, including stock option exercises and restricted stock arrangements, and (b) the excess tax benefit arising from such transactions.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 57 R44.htm IDEA: XBRL DOCUMENT v3.7.0.1

Share-based Compensation Share-based compensation, valuation (Details)
3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]

Fair Value Assumptions, Weighted Average Expected Term 5 years 7 months 5 years 5 months

Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00%

Fair Value Assumptions, Risk Free Interest Rate, Minimum 1.92% 1.27%

Fair Value Assumptions, Risk Free Interest Rate, Maximum 1.94% 1.73%

Minimum [Member]

Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]

Fair Value Assumptions, Weighted Average Volatility Rate 71.00% 67.50%

Maximum [Member]

Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]

Fair Value Assumptions, Weighted Average Volatility Rate 71.70% 69.10%

X

- Definition
[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]
+ References
No definition available.
+ Details

Name: halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems

Namespace Prefix: halo_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average expected volatility rate of share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R45.htm IDEA: XBRL DOCUMENT v3.7.0.1

Share-based Compensation Share-based compensation, unrecognized (Details)
$ in Thousands
3 Months Ended

Mar. 31, 2017

USD ($)

Stock options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Compensation Cost Not yet Recognized $ 53,470

Compensation Cost Not yet Recognized, Period for Recognition 2 years 11 months

RSAs

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Compensation Cost Not yet Recognized $ 7,281

Compensation Cost Not yet Recognized, Period for Recognition 2 years 1 month

RSUs

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Compensation Cost Not yet Recognized $ 22,742

Compensation Cost Not yet Recognized, Period for Recognition 3 years 4 months

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R46.htm IDEA: XBRL DOCUMENT v3.7.0.1

Stockholders' Deficit (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Dec. 31, 2016

Stockholders' deficit (textual)

Outstanding stock options and restricted stock units 15,500,000 12,500,000

Stock options

Stockholders' deficit (textual)

Number of shares of common stock issued as a result of stock option exercises 74,522 156,185

Stock options weighted average exercise price $ 7.78 $ 6.22

Net proceeds from stock options exercised $ 0.6 $ 1.0

Restricted stock units

Stockholders' deficit (textual)

Stock issued during period, shares, restricted stock award, net of forfeitures 252,305 106,389

Number of RSUs surrendered to pay for minimum withholding taxes 79,499 70,288

Payments for tax withholding for restricted stock units vested, net $ 1.7 $ 0.7

Restricted stock awards

Stockholders' deficit (textual)

Stock issued during period, shares, restricted stock award, net of forfeitures 0 807,036

X

- Definition
Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.
+ References
No definition available.
+ Details

Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 117 232 1 false 47 0 false 6 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.halozyme.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.halozyme.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 1004000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.halozyme.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.halozyme.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 2101100 - Disclosure - Organization and Business Sheet http://www.halozyme.com/role/OrganizationAndBusiness Organization and Business Notes 7 false false R8.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Fair Value Measurement (Notes) Notes http://www.halozyme.com/role/FairValueMeasurementNotes Fair Value Measurement (Notes) Notes 9 false false R10.htm 2104100 - Disclosure - Collaborative Agreements (Notes) Notes http://www.halozyme.com/role/CollaborativeAgreementsNotes Collaborative Agreements (Notes) Notes 10 false false R11.htm 2107100 - Disclosure - Certain Balance Sheet Items (Notes) Notes http://www.halozyme.com/role/CertainBalanceSheetItemsNotes Certain Balance Sheet Items (Notes) Notes 11 false false R12.htm 2108100 - Disclosure - Long-Term Debt, Net (Notes) Notes http://www.halozyme.com/role/LongTermDebtNetNotes Long-Term Debt, Net (Notes) Notes 12 false false R13.htm 2109100 - Disclosure - Share-based Compensation (Notes) Notes http://www.halozyme.com/role/ShareBasedCompensationNotes Share-based Compensation (Notes) Notes 13 false false R14.htm 2110100 - Disclosure - Stockholders' Deficit Sheet http://www.halozyme.com/role/StockholdersDeficit Stockholders' Deficit Notes 14 false false R15.htm 2111100 - Disclosure - Commitments and Contingencies Sheet http://www.halozyme.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 2303301 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.halozyme.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.halozyme.com/role/FairValueMeasurementNotes 17 false false R18.htm 2304301 - Disclosure - Collaborative Agreements Collaborative Agreements (Tables) Sheet http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTables Collaborative Agreements Collaborative Agreements (Tables) Tables 18 false false R19.htm 2307301 - Disclosure - Certain Balance Sheet Items (Tables) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsTables Certain Balance Sheet Items (Tables) Tables http://www.halozyme.com/role/CertainBalanceSheetItemsNotes 19 false false R20.htm 2309301 - Disclosure - Share-based Compensation (Tables) Sheet http://www.halozyme.com/role/ShareBasedCompensationTables Share-based Compensation (Tables) Tables http://www.halozyme.com/role/ShareBasedCompensationNotes 20 false false R21.htm 2402403 - Disclosure - Summary of Significant Accounting Policies Restricted Cash (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails Summary of Significant Accounting Policies Restricted Cash (Details) Details 21 false false R22.htm 2402404 - Disclosure - Summary of Significant Accounting Policies Inventories (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails Summary of Significant Accounting Policies Inventories (Details) Details 22 false false R23.htm 2402405 - Disclosure - Summary of Significant Accounting Policies Revenue recognition (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails Summary of Significant Accounting Policies Revenue recognition (Details) Details 23 false false R24.htm 2402406 - Disclosure - Summary of Significant Accounting Policies Research and development (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails Summary of Significant Accounting Policies Research and development (Details) Details 24 false false R25.htm 2402407 - Disclosure - Summary of Significant Accounting Policies Income tax (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails Summary of Significant Accounting Policies Income tax (Details) Details 25 false false R26.htm 2402408 - Disclosure - Summary of Significant Accounting Policies Net Loss Per Share (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails Summary of Significant Accounting Policies Net Loss Per Share (Details) Details 26 false false R27.htm 2402409 - Disclosure - Summary of Significant Accounting Policies Segment information (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails Summary of Significant Accounting Policies Segment information (Details) Details 27 false false R28.htm 2402410 - Disclosure - Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details) Details 28 false false R29.htm 2403402 - Disclosure - Fair Value Measurement (Details) Sheet http://www.halozyme.com/role/FairValueMeasurementDetails Fair Value Measurement (Details) Details http://www.halozyme.com/role/FairValueMeasurementTables 29 false false R30.htm 2403403 - Disclosure - Fair Value Measurement Textuals (Details) Sheet http://www.halozyme.com/role/FairValueMeasurementTextualsDetails Fair Value Measurement Textuals (Details) Details 30 false false R31.htm 2403404 - Disclosure - Fair Value Measurement Fair Value Measures (Details) Sheet http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails Fair Value Measurement Fair Value Measures (Details) Details 31 false false R32.htm 2404402 - Disclosure - Collaborative Agreements Collaborative Agreements Textuals (Details) Sheet http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTextualsDetails Collaborative Agreements Collaborative Agreements Textuals (Details) Details http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTables 32 false false R33.htm 2404403 - Disclosure - Collaborative Agreements Collaborative Agreements tables (Details) Sheet http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTablesDetails Collaborative Agreements Collaborative Agreements tables (Details) Details http://www.halozyme.com/role/CollaborativeAgreementsCollaborativeAgreementsTables 33 false false R34.htm 2407402 - Disclosure - Certain Balance Sheet Items - Accounts receivable (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails Certain Balance Sheet Items - Accounts receivable (Details) Details 34 false false R35.htm 2407403 - Disclosure - Certain Balance Sheet Items - Inventories (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails Certain Balance Sheet Items - Inventories (Details) Details 35 false false R36.htm 2407404 - Disclosure - Certain Balance Sheet Items - Prepaid expenses and other assets (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails Certain Balance Sheet Items - Prepaid expenses and other assets (Details) Details 36 false false R37.htm 2407405 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails Certain Balance Sheet Items - Property and Equipment (Details) Details 37 false false R38.htm 2407406 - Disclosure - Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) Details 38 false false R39.htm 2407407 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails Certain Balance Sheet Items - Accrued Expenses (Details) Details 39 false false R40.htm 2407408 - Disclosure - Certain Balance Sheet Items - Deferred Revenue (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails Certain Balance Sheet Items - Deferred Revenue (Details) Details 40 false false R41.htm 2408401 - Disclosure - Long-Term Debt, Net Long-Term Debt Textuals (Details) Sheet http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails Long-Term Debt, Net Long-Term Debt Textuals (Details) Details 41 false false R42.htm 2409402 - Disclosure - Share-based Compensation (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationDetails Share-based Compensation (Details) Details http://www.halozyme.com/role/ShareBasedCompensationTables 42 false false R43.htm 2409403 - Disclosure - Share-based Compensation Share-based compensation textuals (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationTextualsDetails Share-based Compensation Share-based compensation textuals (Details) Details 43 false false R44.htm 2409404 - Disclosure - Share-based Compensation Share-based compensation, valuation (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationValuationDetails Share-based Compensation Share-based compensation, valuation (Details) Details 44 false false R45.htm 2409405 - Disclosure - Share-based Compensation Share-based compensation, unrecognized (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationUnrecognizedDetails Share-based Compensation Share-based compensation, unrecognized (Details) Details 45 false false R46.htm 2410401 - Disclosure - Stockholders' Deficit (Details) Sheet http://www.halozyme.com/role/StockholdersDeficitDetails Stockholders' Deficit (Details) Details http://www.halozyme.com/role/StockholdersDeficit 46 false false All Reports Book All Reports halo-20170331.xml halo-20170331.xsd halo-20170331_cal.xml halo-20170331_def.xml halo-20170331_lab.xml halo-20170331_pre.xml true true ZIP 66 0001159036-17-000030-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001159036-17-000030-xbrl.zip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
Y5)\3Q]\A@H@2)6Q0G?+DAS% M-M-9F>))AP*));YC5)(&$GT_<*D@847FV?&!KRO&4.!U*XU+Z6QK^A!,:HR2;EBG_F'GZ7@ MCH/-Z5[)JB 9N5\;)3+K48MV%QW4)2MF(0"]&.,W$K_4(I.JL&YA<[-!^A"' M^50H* &=%R@*(-)506+20690=,4VUS1TT,.E:H+/Y=U7Y_?X'%-ZC;-FW]U5 MY\"@5@1W8Y&DB!T?5$:4JX&T6!L9&$6UZ=J]1&/6)%'2>D7INI:N"%&Z$J_ M-8)SYF4D[4%&[F'Z=*/.^R>E7X)C@.$K9?T_?FC\0'^G8"ZIO^7[7%0'YOM= MG.#FK-,#Q;#O8E3Z8S#*)N][C4T&F)=GK6_^8V/*^*HM+.?^MQFE_D29 #U] M:;A[&QLT7Z47F\\,"=Q@'#T6-[SJ"5>BN2"1L;I\@K\SS^72,,^R9_H.\;Z+$FS6(T4438ZV7,CY MO6*7R_4D:UZXP>8_D7"_6M)[5M+?3M);IRCI7,A+Z.PBY)2#EV:FG%";IA6) MDQ2)]BF*A!G*,R*6,I]4/J)D[*6 )Y"50T;YA.EKOUJ,ZNQ!+IC3!L0R!B#0 MT5LL+? (H8JM]Z$HS'E.RI'='\NQT]CXP?,W-S=#."-.7C^WN*M@< 76PV+) M \<%I)>2+/D>I1E=6=&GN1BE"-)RP9X._3+]5+V^HM3*.@>ZYI&B0=)B0F^W M"*@5!6,4V1H5Q0265] M_&+<1^8;-0(\U0G%H8K9SS :^L+5C\F=\UMBYPX)PQMB4HIF[H MD;=;!2\"^XR$,<;X-7 N!PQO=Q=$C'\I([VRTE.-NTZ=7H/GAS'HH!R'C=WT MKO%3@\MU<>B: GN)QEM.VY197Y[CZE[C4B.&^K2D&OPX0?PKK!5 @$W>@D19 M.5SM^N6)(F$GF\\D2*L*$"_5?QE9#I1>F9T4LOQ*U^V8QSX5M,EW=3:5>K1?UF,!S5[+0!4M!-9NB42'. M(WR?@9H"O27SX3G7N"1"5M64S1\?_R?D>?>N4\HU8_J8QLD9X?2 M>]SV06V M"661OCIJRK.ZN?/,%[*@_G#EZ3-EVN$A?H]!"CH[2R_LJF5&(OTQ9 8G-C'' MEZ>IK !=\:8KQPBKQ5SI*PF>4 )OJN3Q>F^1"5P)!2&A45.S77]#:.._8#,7S.) M9[2S[TBH=MIMOJ[-E?LZQ6+OEL:]=%:_.M7YQ.]/>@VH[\79"(NKX9,RECIU MO"LP]1*XLJSSXHOC\7@10YWTM[3!,6&FP2;TCDI^@IK1>$2ZX+-IN%\;AON- M'&ISP.?5TXCA10<)L)VG^64(]R4^)=@NXU?:.]( M^;YE]5"TTZ@VD;+;).^<9QCUT\NB?_S<$Q*0.<$9D0LJAW]2?9#ZA8&,KISF M5-YD%*"GK2#?=3_-VKN.Q^3S:+@KJGHAVO!L(X9:RM-5/<";O^&!9@P=0JI$ MK5TNX,)7B0G I4T%:-@34/HK3H\57=CDA"@E]31<_9?)(NJ^'GBQJKE[C;)V M2VWXKFZVQSYTW#)WE[N+,/M9N?E_5<__D[L_6.WS)[LALLG-Z+-59<#E$B3Q M7?BYL@'4(;16TLR>T,O1 T6CU'KK.W1EYP&;P')PA@&ARG%8&;&ECE;RC!A- MU42:6[\M; \I1IBKFF$UB5LV/BQ',*4R*GJ:6"QXB[R22K#'2>DG:X*:2D#( MK5;1+'G,JTDEV-5$-^"RP=(M"IK0=WKAPV7'WY9KROA]"^;*%2&](#J3!=PC MHW=2:3(/LV8T>F8M.X" H[5XN M?U_S/IY2/RM?Q!'9Q%?*COM"=MS!6\)_2B$WRTD7I9V"'PM#;!1@/=NDY2Q5[FZ.Y]A_)OZS]"WE?UB-#F.+)#% 3=HI!1AL[5P%CR'K.CPB,1] MG 5%5\<#(G=($ 6Y36ZCY7_S'N9&GC&/!/5RR&SX.(P?83=_5SU%[O(.4D%5 MNM)Y3WVPJ7&GCW'R;?&XX")SSHU1MP]U3NMF2(H6DWJ14U%EHDJ.0KMTD(32 M),#74^[%+[_17(V)ERT2_,)& JUXZDU>U3P,_T8W>IR#KQ(E8/9QA5O"=>ZJ MW&T&M^3\I+(/U90TVAAW")0]GP*XXX!S.TKL33-]U9@G-056M^:6<.LT!(@Q M^Y60>RG;PW:&RD$D>*][+R';C1A*LY)IU4D$O9#F-Q8OR'B'[L)+4K](,UA! M%8 @V+%(BV;Q19'\@]XLW)9:DG5TRW1:EFY<9AZ3.F2%&4E>:>/J]A1E'3ZN ML)N!RTU B#*O+2B':3SBDOQW8ZK#X.8T=[$BTR^WF"ZL";3)8O"#R!9\2L)_ MI/0I@__1YNAQB3.H7!]>E\0)Q37U[#LIX9^%2C=(U]I B= JR81[7G#GE=W\ M1/TY]^J13KZG_&20ZO*)1-X>!PUS40_T.Z";.>#CR%4@'4,[;ZS": M':&G)@1"I1_'<*;*H6;0Q_XWV0_%(2G@=9^<*/K&>P3%4X9._WQWN0"=OG05 M=X:7+_JZWII24^+:[Q@H$FM#TYS,:DC^J#Y\"S "T9SX51 M'5/TQ",I91\X^3P1DTA6PF#!"/;1ZI&YF(4WIS&3@YE@B!R#U&X9UJ0895H> M$DP/A7=Q5 LHGM1X&K= DO=?* UAXR[(,\)50'W[%)45K-N.8?; MI3GL#\=E%*]^^H470.-2:7CL V*EA7/SV_4+P#NA3LS;.!D+&5-=CH(LX!JG MS[T9-N+F7*EQ1-[7QXA>\!?O.Y#ID+6SV7H8\$-E]%"YZF=VPD"!YS!XV+GS M51KRI$WP(]?HO=>+,+06&W)JC2+LIIF^I',86IE+$11H1E9RNVC ,T= U.1A M9991SBU(V9-;<^^,03WF.!!#1",5F"F/_<7-#W6@NS3"GLDB(H_.%_PA@6.1 M)F9P9A6BIEN4[!SSX52(*WPQ+"A[=9&*H/J,YE^-%! 8M8##N1QUKO!Y M"I F"18I[:?%%\Q #?JUK7]?!882X]*1&ZM0JR56,1[PWCU.@6<+$T=MKUC: M-:#']&MG+^"[A+Z+0\IK$&$Y;R$==IH-@G!5E"M%G,QSYWK-[MG?H[R;O-\\"T)J[2RW 2-QBB07EF)*: 9?LR =0CU!S@A2">$:X86]S=% M:4Y&PV-)N3RG#E-IR+NK7E-Y]IBD KTZ4.;BJ5=667G57R*I*&"(K;2A&3NG MVE#8_#2.:+8TX_H5@%\\JYT"I--=G4%O@.*+8^A_Q4+>3\#L9",=;!@#/)[ M)Q:DRN091?2F4P0BG7B)["2>SO*,-1X\2L"Y(W6%4KK2?I0=[$PR%"!L*P$; M. M1=7.R2_ S4R2!\G/+ZPUARP:W) MHP=! Y'1=RG]^365P%#RDT_\45*TT["AM?*>^K#BSFV%.JJB!U[H2W5*^ %! M2-34TP*6:$Y*$@DL3PTZ=3#:)\Q34QYZ:!;CBG!ZEB95*,V"+\DMD7GM4Q"6 ME#4JG2A:X2CR\M#DH63-$O,^4CM5%IQI%J[XD-@/^OL: MQN" 9<4V W&>YV_#0QY')H.$D$&/#O1@) MG_R_,TS%$09=(!XYLU;\2 TVDK/"[N\QPY.I<)U.BHK2=13K)\0R]#O,Y22+ MH V44./>64C12NE1* S/E35H$P\A]2,X]<'?BN-OJBRBDC=2'#?%:U?G3LW, M@6OA"[15ES9:S;EXF"?(L4,#X*+B)2/Q3X _DZ%+.3OGT9LVA"6P*>6[;7D,E8IP3,T%FB.?YNW MB=!6"-^GE6:P^H-X]_H2!-)H-(,20!E&< MT8$V2\5[]0^30KC4&F0.C0;1+Z%$Z->Q,; &;ZDU^'_;0GN4KF^^[O)VZTUO MW^R\Z>U;[>VNWPXJ91AG63Q5_,9_O6_.OB-V33!R_F^#_E.&0$&E;PJ0^;=< MP?R(.;RU"3R,(=5/J8+!RQ3G8.T P3NI^9Y47)L LTAR[I]VZ.)(MQUF.VP/'W5"@"[WB:W"]+--9IML;TZG,_JW. MX&_J'NS;!,@4Q%$BRTK-Y/MO-"+]:@[4?5DO\>;+?I+ S&\?%.O65+2/CS4Q[Q*)QZ*7 MPYA>['$!, '=ZB9F63U<0$88U=7C($DQ7>'*?V&=F2JJ+GY?3"):;-\ !E 5 M;2FUMF$A#U<\4BI#C2^+9X'OM-L-M^!]U^@+UX^ ;2.$TDO]FTL;7W=7!LTX M!S\)_]&0;3=*X3S;4K+YTXMP@I]=ZY"KTT MU4C"]*UL7:5??6:,3*X(IT\^26@GLO2&"'LCO.0_?HCB2/SPDWJ>59_#?G\' M9J)NO.=V/'ABQY\+K _\V/I&UC?:'IM=UC5_/;\[=_Y^>?E)C<,*$+*,6)>F M!L6"P3@T(K,:>*7C@ HXA7'7D4WQA0+WE\2*&#PM-6@:XLEM'*7P(O5@H'>& M0.6JS[_8K01A08#WJ-S7;59M$YQ6G F>\RY1%$<()YHR1HPS0U2GP!?GINP9 M!>4C/>UJX8%*F#8&^@Y20+4JE4.D"S_"0*$F!P/XX:?4H83_,-M#)487^*0( M?"V#J$-Q'T38QWH6C\^,^G0@B/$)=99JM(AT0CCM_,I24\'H-[>Y!VO5B54G M*\-U \)?I4B+"#7:!Z@4G"&& 1G9VB2OLC$^RW@O/L?6ZDR9M'F)EI09DBL= M#+PR@X%FU9QIF!EP(XP[R&RO3LZ_-404.8'HD#QCO#,2F$ M3HDP5:<16NR^N6-E265)94EE265)94EUFJ1:.S=\3=M"B72V']GV(]M^Y#HO,PSY0:-IFOP MQD<].B-USIP_'FCBUL]8"8%#$33&V$)W47']90%*7GSX:P&N;A.,-L_SZO:C M-)_1\ Z)SZ@_IUE@E*F?JU$PJ?#SA#N3*,^>"&^$8^?5U "*-A3C7JBJ(-:# M"["H(1/W/);\'67R T2+2SPD%2HJ[\$+0ESD;!PG9PBER;,O=?I_>1\\],1L M:S+&S7 Q0'D.EO&U,9Q$3@@P$*M75%+H;1!.40H?&&K"?!)OBM/Q>/!*JH^>H1?R>YO@-'>CS8K;QXI[%%UBXKL> MRA?%I';D['E\*40D;O :M!J@OG"%?] *AF*RJL:JFE?7,E@>LCRT)7%*XX?E M?.L)V+G+1P$W3,KABD*.,5$*4,['49-9\AE7("C04I[00F4'1?_2JJZEM#"L M^6!BB&JIXG'LE6U;>FLAL*2RI+*DLJ2RI+*D.FI2V=H"6UM@:PML;8&M+3@^ M3]ZR&ZYC:PLLQ]G: LMT)\%TMK;@1&L+?O.HKJ"SMJZ@<]:X<)W//"619[%> MP5+8<2TSL5=Y"H\*9'?><2JOU^C]>.[0XC2[\7*6!*%+M\+ M1H0MZ:> :DE MN[6-[*<>QZAO8;."-J/ST@*$#!^*[T$J1TPRZR=&Y8QBS'/G M*\WPU$SI&BBD-':Z2,7KC+]>,9^AUD64S3%#DLY N@)L5;V/L6D45%PJDH? MYUH#7\M9P-,NJ=%5P1*,L4=;8H9^GW&_=GGJ-Y1F[EK!B#E_XS']WK>:H*^U2FUVAN:U&.\1U8"%$7_I4#LV1R MGA-?V+T8C*99 M_K5RRS.LR\'G4^B-$IQDJ$"$WP4_(BOE(&V)R))8C;MFR%SLHL:G0V%<:J-6 M%36R\QL>1M\%+L'QN @/&8^ VF*T;G5X-LE]I7TC:,EL%@;%75;F8.&?";T" M.:-7.'/"6RFVHK0#J,:)OBMRLY]/:8XY;$8A5W*[N'X(TAUC";O@,8XPM:,K M$!5X)'CE\"7<$QOCX? %KN!U,2D,G.('V8\2HX&T JBV /C,P;QRF9+(3PF? MM/IA3))L/'-UE[H;KUL'U'20>[,FBC51-BAG5JL+N#L]J3D5I(#X =;)_LDE5\4VW[#X MROE%/2D6@H%Y!@8O'K6,@(:GO#0\I:'),ZVU3X'VOP0E-&TX9=PA/C4.I0>; M/$JE*8KYQF$LS7OO/A%RATM<_](S#3RC)^1B:0IVL4Q_EM$B[YH_\FY@I94' MXDMVQO.[GZ C$@HKN-.SH8?N5!+/O7!UT\+;4::U \K\66(\R?5!NHK=GT)/ M?UH SIW+(D3CX7P)I+E$+ZJ>S1W(=1H!*@,S>S'\ 3I+(XHNFWJ:3,[C^%8Q-Q+&N'776= MP"-NHQB>B'G3TY=45;O4SO62-_RN^6,E&O15CVBP,!9G!.-YI5S,Y2.+86Q7 M 0V8U66H?-)4E^O(-%'JW"<>57GDM!0KF5+6B.Q(F5,J,D@>C=C! CC0MU3? M%-.Z<+Q3X)U2AD-X<)Z7*JN+X,>L"FG4C;PUA?BY)(TUM[S=F5*%0"^5$'.Q5"W,4RKI$EA&Q;L?"RX. [,DU(\Q]6B@$,_U$=(6-M-!0'>1 M9G%$4$)P8 Q-.![7N1<1@67-77X.K+#!Q[A2QQ*Y@D@O.6GBE=DZI/504.F9 M!MU!$X1S7&!/J5S&FA7.G5N<.O'=FU)]W2A/U'E)!4D\6DD7W;;9>.L1%QDH M1(E9X2LWHH>IJ>?0"4KXK)*$U=\ZYTTU3Z.2!>7H1>G6OW7:YQ>5D@($;P*.U ME, VQF_1?"Y59R="S,!Z9MH5]% ,)I:L02N37UHT*1>^%@5[XQ<4=:\U<^QI M?I"G>>ND3W-Y/*ZL65AQ1JFZU'^!-Y[QFG.&'J*CRN$5L.*VJ*#FPLXD%V?Y MC&NTLYSDF<>?CT'QQ8]X<,BUTWR8@GV!Q4+R-N?.W=+^YEJXY:VWM#,"7=,; MSLT'I(,7MU'<9@9'$A^64V\D"KR^<^?K6G5"Q"7Z254GI+]'0P9)7RT7S?)8 MPLC'>@3](W728_$\WM5%N#X7:YFI=HE+\17Y\XR4[5QD(]#V52YQ#(#Z1>4+C(-_,FE^/2V\4(G!F(DKU?! MZO?__E.>GMU[WNR]T:-UJ6O7/P$=?&#P+R!V'\+8__:?__9__EU?D<$'"+8E MDO2&X+9^AS/H6COH^B*J+($_/HOQ?_QP>XTSZ/Z[^3]?KG]P@A%\ &Q^UKOI M75]U.K?=;K_=;E_<#CK]WLW5H#FXO&YV!H.;'_YS03,\=0RLTPA/*982D$6O MNM0._;FB2:X@'8>;!JUF_VO9*5FM^KK0X0.#RM<\A_4" MOAS$?KXO+I!HK)6Y&S4_XGA9?"V;<$+*7SF$QHM= M5<_?Z2P&>Z::1VF<]RIU"RNDR8*O;KWCY'.GU:N7OX225PS>@X:?;?1KD8=K]$MZXQ% MRL70KS_?7:9FCJ"2W=#!63KSJGG(2E;9[:E8YNB[LAU.4 *HVBD*KD>%YQ'V MQ>]2JS2[Q9SR2OFMNH.VM:,=RD1$22H>L=$_SC,*NA+)*TEAO<(N6\HD[8(= MGX[D+4?I-HVYE0)U^4PVE7KA!XYGWF$XL[@LW296U^ZT/UQ=#3HW-]>#FW;C M\JK9ZW"L[NKVNGG9/K)8W96T]23E'"*=\S$3TZ=!K+9Z@E)4KE%Q5.YR36Q< MCWD9J?1UD6)X1Z'H.$]!$M(?W[_X29>QQS9^U..%)K[HGC=;O7ZCV^NV&ZUF MIUT=4/%%)4#%_<;;(@6_\O*WO?V6.,.'_? 'VL5:I7H]QAZG-Z>/WF[[AZ=I M]1RJYPYHN8)^>X78)%NUH"J:I[CTJLI?M-\L5UJNW L8-[M+&S/FLC]569_C MT/._W2=@]([.I /H^T*,QT?6C+'"L.?BT%D28PV@K!G!HE==Z1-OCKW[G$*H M$95KIRDJUZ1KB5T79OS;WMCJ"2J]D!C$=)528^ V6NV=4Z0N[WZ=EK>:QFH: MJVEVJVGZ[J#;L9IF9[;DB9B,LGG,-!RMXUB]X]AZQG%\":VV< .K5S\MMW'1 MJ(I3ZB(EN[9GK$0'\S^+.MBU4A7/1?V MK93(;ZSD+EK-RGCOI62KBQ#;^(<5SAH)9\]M=JUPVI!!Y5*YX;_N\B%5SEIW MR;I+SU<9M]V&]9>L2%B1*$2BY[;:RVU>)RX2-H2P+H2 1=N,I18GA F7!,-< MHZ]1,P/B9E*XA]8*\]:P?OJ--\!K9ZV="R^@>6Z M8^0ZBU^P=Q_GL_?H(*1B$GBA34P?XJF[EMC2GB?G8RG-4Q?^JT4C\2XHM0,\ M@]XRPG/5Q#H(GGEM7,:J+ZN^K/K:M_KJ]ZKKASAHGGFM^CKU$H4_X^3;61"= MR=%NUO>LWO<\OG+NECM8,8_JQ,NYK4BTRF$[K8K2S6K-[^ MIT3,// CQ/>9B%*)R\&PVUZ:BLSV(]A^A"5=8OL1;#^"[4WZ6)VB:*WN^,D?1YKYL!;"M M *X<$[W=JBY_?]!<\]H CU5@5H%9!;9O!7;A]GJ[GRA[$%SS6@7VJB#) =FI MB4@%^J:, "T>1!C/<&A4Y2:K5>Q'7*L]<-L=V[U@)<)*1"$1O69E1_&Q2,3) M1H7^D).3R]E=ZTS52,,<4Z5SMU7987STEW'=, MP'7\/$E$5-F4XAJ]D-KIPBUDO")HC]K;^_O#_'B#(I^=Q%IZ%3:0O)AF=6$? M&XRQVJQ&[&BUV;:QK5:GNHD^)Z_-#AWSB,GZSSS-@O%\/S!(JYNHG2#RPWPD MG#2,,VI@21X\#+0Y8U$VHJ? 3EGJT%I9C-A)60+++:P;)_=>%/Q%2Z3GA;:] MR[$M1J[A)0)NY8=@F ?C0-!ZC^5!'QK<<^[$D2$G:E$_7#B8= 3M.I@)^- MSBM^3^JEM"I_*?$,1'M.!!;_R@/J$W*=2&06E4K^QJ)2652JZFYO4:EL"->& MN"W^CZ*$1:6R7'D"7%D75*H3RF!\5B@ VJZW,;H#/+H/&[+# KULGFEHN)V! M17JQ60:KP>K$BE:#;:7!^KNO2S\(MGFM!COU85Q7\7269QCPQ]#_>!SXHGI# MUFK[(T;K:;OM"XM?927"2H0A$7V+7V7C1YLVOGBIF,3AR FFLP3$%$]>V]): M)PUT.I-^6U6"49[\I%\KG%8XJQ7.=G7X6:7.7#S-LOK%.D'6" M-FGH:%4WW;4V0F/C E8D7B$2S>HRC\Q5T73<5J]C%VXJI8;\]ZPQ;!0E'"XJI8KCP!KK2X*F]1 M_D(&?9QG:9PG/OPS45 KZ#2-!+@G,:6%[%3X0S[<:U]I7@MH@MJ$;K%PH%_= M7-"ZO_S7QFRMJK&JQJJ:EU'CPNVVJJLOK/N[?ZVF.?4B(V4P^O$4K<$B\3/S MYDD;!F]4#2:P;52.M=#SM#6VW9V,4-D9AA6LWPM5J50<2=.S"=>IN^1\\3VRA M/,LZ'6^@@8YM$'G';?4W3K3:4>16HJQ$/2M1W>[>.OJ/1:)L%*"RMM\OV(ZQ M,V.A1F0_8)UW-'Y,J^->]*IK=SUV1\9*EY6N;:1KX [:U94Q,D&"'8<(' = M/T\2.WKW[:NR=X+E4WOC?W\@/T=1UXV!E_:.QLQL0[.ZL(^-S%AM5B-VM-IL MZT!7:W^HB;5GGPJMY2I0SEZYL>T1CO:(<;:G)]H=1-M8@-F.C=T/(LJ%Q6R2 MO[&831:SJ;K;6\PF&\^T\5Z+CJ,H83&;+%>> %=:S*:]NWY7:"0"JWF('>MX M]XFPT\SKIPIV2T2I:3JC=PA4M>QHV;$N5'UEB5CSX(^77P.?0/O'0J0\ M&.H!3I>SH9<*0GFAL^;IT) U+W(P&B2_=K)?*I*'P+=XL=9OJ8Q<@U:S5=U)>"+>BY4K*U=KR=5O M5#=KX43D:6WAW##29T%GK4]4G9)R&Q=MZQ79*(.5J,HDJF\ERL89 M=@4^Y3J1R!!W:D?6@/5P+ CCFU2/GP0(8WO@#AH[FEQVBB",5IM9;6:UV9MI MLPMW4.&(Y9/79AM!RJ[Z][__E*=G]YXW>W^7SV8A%:QXX0]A91&-Q.@'7/JGI;7_ M\]_^_2=<)WB/__V?_S]02P,$% @ "H.I2A@$49J^#@ S:$ !$ !H M86QO+3(P,3JLB2EX[;KG:GO+0GGG*W M/5Z2W%(0^22AF@08 +2M_/H!P)WB!DJ.V2.Y?*#(M^)[ !X6@A]_?O%G]^=75X.=//WS\QW#X^]G=M75![< #(JQS M!DB 8SUC,;=^M9OE'W#3V@X#)DL??'"G6-NS\%#%A*"X4D@X)(R M[P*F*'#%R2 @?P;(Q5,,CC3!!:4B1Y!Y+!";@?B*/. ^LN%D,!?"/QZ-GI^? M=^;(I7\M/-BQJ3?:&^\>CO?W=P>6=)/P8_6P/;6+R;<<]'^D M'D\0AYB<4$("KYS!$6PD%CZ,)-%04@'#=L+7S)1G4 2.2'BR5KT?A0^SI+C& M!TRX0,1.?'A9\OEY7U/O'AT=C?33A)0[9812[.[H]R_7]QKLP:[>:E:D M]=',BIAO'58QG)3/J1!EXI$RG M%4S4D@G,5.O=WJ0LUUKM,"B6F&-E_>7M<1LSLIQ?0\8U6M/-DNYFE/<=+>M/ MS* 4OS=3R<'>F=&GD4T#(MBB=9-6QA?_Z-*6Y84&C,GDIX,U6<;DU\KV.("5 MQ ,34V(>=3%,F;L9 "_VW+@P$B9]M7(A8/($7"B!^R969-BBZV$JHILE!&%; M=[Z[)H:D7.'E,!70S0R.;6,C8AYUL;H!PF?F%L1,^JK&!D0(%5J0NA7?]'U, MIC2\(^^I+OLX[K?O8&KIS/0XZC7K\]>1SZ@/3&"92652>"U@SF JN>6@8!@/ M!OZPD;LC,]Z89$E!/J/0/91DL0-7.W&=&AE+4&WVR8#+PG8A\OQO=\J!J:E3 MD@43W&.?7#0Q]4FR@-M3=WP&INY(%BZ'S9T"3PEXD 06EL.Z(60".''0 X<#7AV^9U$9P M#XW!56JL6,\6V0P&%S %F9DZ=_ $)%A7S:V0VHCL!S-D8S56I&>+; :#*YG@ M$D$97EM]+9'8B.B^&:(9%5LP,T7_E0I8&;]02!UDN^/#W?'8!+)W6N@6(H_? M,O 13GJS4^+ ?;5DM3;TJT4W@O[>%/10EP8[T;9%N@&.KR >X$4$R%U?E6^E MI1'_G]:!_X^65&V]BY7_:QL/&:0>U+!Q9;PC*75X[H\/]\>[1KUT*'6C4**N MBR:423.>X'3&0&\>X!6W#;'K(KL>T8,R1+/RK%1@]8,MSJVP,&V:5U!1WRX? ME V0C%$76N-FML5FT'3LFE=2TA@!RW.5QA$0Z]S&0%HH9D/F.AGU(^:#LA%S M90.]><-EZGE8:.]E"GM.B;CO);Q*1[+#.Q-0!*\';?Z[3H7A:RKD$:OTB!E=60 M3WME15$G+4X*R-O@Z"Y1)C]BMP O@!2HX0.:S9U(NIG M /9+9@"4-$N+LS+R-G)T7U:PQ7NF$SI&,AO16UI.K4!O^?9FSM>4E;[19$VU M@/J9FOV2V8"JFK9Q\S1EA6JV*E(CH7[M8[]D[:,*E\U;X"@MUFX3V6U$-39W M2PL6%5!M])ST-26S!U O*D_4:GWV9T?L#"360_CA8+FV*6E#)GK!4WL#M3V&[5J]D/JF[*ADZ*3E#=5++HZ5E;B1 M[59YX1HU7W4BZJO-44FUJ49GXYJR\H(MO]LQ9UA%16/-6\H#*['-/K"S#\0F MYQ0FX#P2!C:=R0X'G%>,@3(UC7&PM+'8. Y^M(*,XFTP-*"DAEKKZVE;ZF@, M@Z59L YA\!1KW<9 VBX;S<'4RJB?A3DJF86I[JXW;Q[F7E#[VYRZ#C#U?B.V ML6B-2@EK_<:E<5GNE)'R3RN2L]D F+: U1)JV[?=<H]E%R[+ 1$1O5&/R>R6NMADMU]+:?5CC[VR^A,*5HO1&=%6*MN*A6^Q*Y3V MJ4-]I?!FJLYBR%$P2N2E'2[TF];'5U%>GZJHVMP],JS8&$4;FI,CRQFT;0PJ M,;TB,@C@ ;V\2L0L26\*B>4C)0Q"(M1F"?2R!;P&DJZG$726WPCZ\I#%!/3- M/JB@'2IZH8KS6V!Z)/$JR%?H:$1_Z:P1 _3#]3'.+:DU'"1M@Z 2H-=) %LE M@GMC^;^WY*G MX I=V.>I@':H::_K2J^\& 1"K MUFM\3JI\6]_KT!(,VP(7\"; !OH\Z)/!OE;6+T5KTZL#1EY("5A$2@M M_V8T\$\&^M,DQUB -[#"DVG##Z@<.]1#F*C3;)3I RLD](%AZCQH0B=@T;LT M(S.3#Y=-/NR[R?\-$!/ W,47](*]P+M%"\55XDD393\=_-#:P4;*GCHHQQ/J M"#U 4VE\B5OES_OIS%%KM!HI>^G@WKBM@\V4/71P,OD50\&5_+TW,SHU,CJA M.SV@6WU6S$[.6:&,)[:W(NWB4GC'HT2F>&Q1]&D2GE@@'8*)VANP[&GX:2/1 MP5&?42>P!4C2&W#@18-0&<#)?LU -UWFFJ:+3 M:VPKQY ZY:KL0+)'GY)3>XXEW.HGG9[+$9TZX"@3 %^P;@-)I@A[84IO&^&D M=+RP=&S$YU'SFNEE NDOROK+8*;&Z90MO,3-*652OIHD#K]&6@+!ZRCI;>'* MSNI9R9%&7V >?N-5&G4)P%6[A7G8FR?EU)Z^OS7?4R:&=0N<2\I2\#^_V&Z@ M#KQY")&3?=FIS)*1&]6V+S)5%D"4%MB*MF<5)W6U)BN)IF9XW'JV:&[7)ZYG!59992M.QCV-Z).":23K[K *-3); M>V-487*Z3-32QU*&[\5;-41L"V:1]OOQ4;]FVMK+(O5;^5GN%XHMC;)_/1:0 M$D*II9.;@ MAQ+JW&G3[5SD/X!W!VI%E\P>Z*,OA]K2ZM#D*!-7Z7?J70?.OF4:E36TX%U% MS6RD>O,:F;;Y-]/"KH2%'(3%:<(#PVH<%LY6A4^5,V72* MDJD#AZ'GV)NVQ*_8XJ[B%&5XII](]&WLJX/L:_TJHW\CURKKU2\+.0Z#%[7U MT9M(8XL+T37/^SD, \_[4T_2/Y?^@PCG0/).%&_VS^QK M:=(B;W3^5O],_@JRLU2OW\D>5-5AKM[%B8^R*78Q;8G?O(_Y2@F#:4 <94:4 M]Z4)7Y0!&LQ:K%%>SZ8MTB(+5(S*#"KIEL)9[QL__)4413-==Q?5%. ,V.KX M1T9&$_>?P]6>H@M+3_MB.)W>AMLQU)$A,I]59Y&H;DBQ\RCN'$&C.;2\6\:\ M_7'Z#D3 "#@/^:6_ZL?],1WBI2*9_,R%*'>@BJ@_;F2G-\!),]3$\@K/#/CZ M[RP'#W=UN(+WS9RN[/?U9Z]SV[SR>4O-\[=?5KK5#')LKR94H[8M-KSBV=L- M&BLAN)WBOX!%62TB3MDVT@::_N63H<%E3KR]T:F1X0?96;K_*_-B:F)U U%? M$[EX;](EH]XM8H*H5"?J^$^K-B.E3G=C[EEA5(;GW?WCW?VIQ/)67J%GQ)Q" MNU='\/:!>Y?L9EIE#79E*=\-VE'=33Z_7L"Z\G$?D-8S]\BC3$2G9--I-(D3 M;WM+_6A%^R9K')TZD3MJSPL=8?Y6__J]:*)Z@NQOX%Q31(KF5SWN0:B%ML61 M(N@$D.^[6 T3U89YG"P5%KQIQ]&WN=][&4A.X *=ZG-G)L6S/D\90V06+F4G MI[A>$3\0K=/H 5_'K(+N2L04Z[LG'$\7RA(B:8Z%)=J93" M%WBYM-U#GW[X'U!+ P04 " *@ZE*L!3:0G(7 6 P$ %0 &AA;&\M M,C Q-S S,S%?8V%L+GAM;.5=6W/;.+)^WU_ADWW&!#?BLK6S6TXRF9/:S#@5 M9\[N&PM76V=DTH>4DGA^_6E(=F+'LD29)"AGIFH<60; [@^-O@"-YM__^?EB M?O0Q-.VLKGY\1G[ SXY"Y6H_J\Y^?/;;*3H^??GFS;-__N,O?_\OA/[SXOW; MHU>U6UZ$:G'TL@EF$?S1I]GB_.C?/K2_'\6FOCCZ=]W\/OMH$%IW.EI]F,^J MW_^6?EC3AJ//[>QOK3L/%^9M[SSQ>+R;\^??_KTZ8?/MIG_4#=GSRG& M[/F77@^V2+^AFV8H?84(18S\\+GUSXZ PZI=/;O#0VZ:?[[7_A-;M29:Z^>K MOWYIVLXV-81AR?/__/+V=,4GFE7MPE0N//O'7XZ.UG T]3R\#_$H_?O;^S=W M!CDW\_J/JXOP@ZLOGJ<&SU^&9F%FU0LS3\.P>+,(%^VQ<_6R6K3O@PL MNYV'5P$:SEN@;_68\R9$&!L&!&B(Q&P-S%\?/>#BZC+\^*R=75S. :_G(S#4 M+(/_Z?-EJ-K0]N=FRV@CL_(JQ- TP;\/'T.U[#LQVT<;F94W%3QT43>SWC/R M\$@CL_!KO0B/IOI.YY$)?=>$2S/[(K/'E3]9G(?FN&W#HB_Z^XP].IOU)?SI M"FCXZ?^6L\MD57ISMW/("9CZ-2P^A,^+I9GWG[U]1A^9U0_)-CR:E;N]AR*U MGL^-K1OP*3Z&X[,FA(10^\#7'1GH,>:$;'65M/Y#3\/DG@MJB,''9;2;>>K0 M=S R+RYFB]7PH&Y>UM4"@@((#F9=J-S9=3 B*Y\,67I(6\]G/H4DMW5-^\XT M0,=Y6,R\F_%'#96/FM\HL_0R^[<_(O:'&9.)T 3]7\G 27YKV_/6\_M23 MF6Y#9F.JOKALPCFT@77YMFZ'9&[GT+F8/ '?8Q6M#\C=EC$'8NMFPR+Y3*"( M%E=OJE@W%ZN'[B*_2]^!R'QM9LW_F/DR_!),NVS"'MYPAZXC$OGM=UU-\F/& M&I&-3N9W9\<1">SFK>[N.2:)^SEE>PPQ$-%OZ^KL0V@N7@6;XJ;;O^Y)^_XC MC<-")['=UF<@LDZ:,U/-_EAI1M"6+Y;MK KM3LIV=!N(N--S\-I>F)49ND@; M'ZOG=9SI3IU');33''?H.BJ1F[_=S^RV>_L4=ELYM=[=)W*#(7M?O]O)[[T*0]_YF;+792]W"7\8CJ*@ [>PY% MXO+BPC17)_%T!HL%'F3 <5\?9LVJLW<0?739N]AOE*RD'_OZ,DG=24QG_7SN8^+MXPPV=E]C2<):&ZM9\W*+,[A\_*;$<7]Q%C/7]S4!JQ2P:%J[2MA: MMNC,F,OG@(EX'N:+]N:;A)) F%QGE/WU^NOR/D5@<5XNFW1 =$/4W-@P__$9 M$%!VZ59ZJI3DT2!><(8*R05RFAA4%-I+8[F,4MYE>)XRZ.KF&OS<'/_<@(5] M#,^W.Y9&"VZH5$@:2A&T88@IH9#G3"A.N%>4=N'ZEM =-^ZH;B#F^/$9>7;T M*KC^M1P+S_4OHR), !<45]P2CAE'=:!9OE@7Z5!_24!&)L#+_*Q=^?;]+AXRKWG5F:>35[ M(N?MS-C9'%R5KWERM[[:KNYV]R\I+W0P!4$%3 ;,O#- 3W!(=D21R7DRG MZW\"DUY?!?!%YNG,]A;AN]7]SKYE $XYTP(18R7R&MBV4FH4B)'4!$&Q-T] MXP\]R_7X.#Y>^Z_9/5DNVGK9N)2'O"E,NUG##TM)C]%*C8L0)'/($RE0095$ M-,8O6DV18'O(#7WBGWX-FMPG:WK%DEBA+,$:% MHPSY@!WP+C02P4@AI2F,X(^7&/[$)68T$"=T,;OSFW\AMK="W5SAY(&Q6W!/-*%LZ@0AB(( M9@I$/".*"8>IUX?N(/::N7HDF')I[F\(_K6NW+ZR\+5/24"9Z.@$THIC1"D# M"Z6H198043A&I//VT/V^$<6A%U(3*N5=IY 9%?(-*5>_AFTB>KM9:0H8C.$" M.2O ))0H,B#1($6'.MH"\\Z12,C<_3>?/H%XL=F9N;I4#2=Y+>A^;AU"V-W MYS)J6@3K&<*"&!1 WD#<,(-/1CI7**9Q)T,TI8I^_'36&?#*I:N_$)_N[K^I MWC6U"^W^HO)P[U):28@A "B)X"\R;! 7!0.G5('_";ZBC,/LZ#XI61D4L.S" M\GI6S=KSX'^N:[^_L#S>>-/.'\ M\,(R*& 3VOP-*XN;5N6T[9NI0I6LR(8))@/B#'M MD1-6(4*YY%$)ZX6;SCVY2_KN0'%C^Y(['TB(!F%I%(*YPB@6FB+J@K,&^/8F M'KH3,MPDUN- ]NB=WFL"FNL=:%-Y_W4'^J&MWJV=2BE=##)H0$$7B%F*(=@% MI^IZK]*JP \^$AQ\PD?!+>L>[[[:X.%.921*4I,B8$<@[HTN(ALX0SIP"DY5 M9)3VV#K*XSZ,IA(&Q2WO*< N6W@'(ATU41T '@Z=B[OD]5Q6]/T;F[6]\1OU>79ZLT\W*T4*DC''$':*H\4 MCS##IG#("UB:A0<];CKEPV7F>)67]AB>5QU+Y;3V5+@4%DEDE35(B1 0CU)3 MHWD!#LKANW)#3>L]5VY@['+I[F/GEA?+5?[*JW#9!#>[3H>^G(?K6[_'%W6S MN+X$_""?V].M!GE$J8M@G<42$<<-N$?!(R:*B()WVGD:#<%D$-]RS+S#T41P M0I@/S.;L*KF69S]C4R;^P$_N7?IL>GIR3-!PQ<6R$#;^#ES7^E]#/[9']:[< MI#Q0[BAGEO,J NAP>>-VN]);&T*,&D4/L:$@!8& H? (KQ+%E'&4B.E\TW2' M+HD<_).T]4;-'-Y..D8%JKL M)^(3I Y-FH \V,3WA";71&_;D=WW '-C[U(YAXE7&D$6I-$A MS"56[]/^:17\3Z:I9M59>^=XXDX)Q V2M+MS&66A@V2P@B)/@2@)B!"F$-?6 M<0[.!2$]+I7F\= '%IY14,LE+WM=']UPV]&H0ENK.%+ @+3[%!!F$"*16\) M#RJR"0_E;T+G=^8JQTH8AY[U$18!*Y"21='W("6ZJ]/OA2 M/'TG[X%=B=Y(932X>]^7?OB6;R&DC=Y$\#PE 84!WFA@L,"MCM)"0"X49X?N MC@TO$8.!-=%]S .]F)O'IQI8')['/SVYJ*5]>[4+2 ZZ8>'.Y56%$K)P!!1HD A@J%UR@3PF*7"SL:H0X_3&?GT MY6)0[+I:7?7T<1OE!'0S6OKIHY7I1/"!$ Q_!P!. M/O6W'TACY_Q.GR';"Y_!4V.G3PWMAZ#E"QJ8Y2F*!4'0I0 XI'[9(*MLBZE\O=Y-U>>?8L!Y&94Q'*4-]AT M(?ET 3]7U[1/8N+G];S^= 7DS1Y!(#&V#B/LY@#EY<_08S^:8Z 8-G MTMWZ8[>8?5Q'%JO+]DOX[OJ/,-U;,.HW<*F,U;: %>6< MNJ"46,:IO>0"=, MH4* %7#H$?%X8E)/C'6VBT[I]@,T'=E-R M"+<,S#T1:8>%$^Z$(90=?+G0"65J)(RS[>S>(O,DOIY5IG( SLNZW;[?NZ5; MJ0WED4/L2$(JI"JX3CODX.T5P4-D(*DE/1SB//MV$TK4P-AF"]-7IVS_FE7P M3W&I<^$H]#JN=?1)8V,8$]*0(*0G#XGY#H#_Z%8Q-*S2"(YKQ_ ML5:4=V3]R[MY07^^:\+%;+E^ 4Z[KI2U31\]:L RAD)K26$U*1*0!9V,9' $ M86TXCH[*@G8JU;1SQWC,V3+M4VNPV M0,DCA359*(2#%4AIKE#TX! XRXV+S@L1>M3'$M^]X(T&<[Y-2E>?5;/K]=+Y M58?;NI407L4111(&(-A#11&F0QLG))$0KW,."RN]>J 8&-VO^8MI=!=C6 M:3G7>_>[TAG2O8PQ +=:(4&B0C8( Y$09Q&P0O0M**/);N=G/F=2M1(*$\G8[?> M@[J7<-WJ5UJ34AP8:-R87NM#X!..-"!C#*A?8[CV/4I)WDY2_=-(53]XIQ.G MZR2'&R=OWY?*/6[ ,F@=32 \O7:0(1YG7;0.62N&H5?#?9<@@E8?KWBL3T]XFN[4ED3E?0%*B*-2'KLD;.J2,$.Y1H,!'9] MSJ>_^TW\OFAFE(Y-$*WW>$?(MNDX<"F4M3P V+;P'!!S&&F3[G6MAX0H,:IP$H<0PY7HG\.M&D8=[AY=C8IWQZH(+P;>O =KUL<3C!&^/84HF M(PF%*"#4*BSR5'-$HK'P@S."A5(T],BUF#1[)XO@C8OU9!KO,2$[#Y("5Z- M5SI01(LH$?!.4HZ!0DH8YS2)1(IAR@;_6?3=D%!/[ 1^25@:V@GL.'")';94 M^+2/*2G2D1E$I1-(<&T< 3AI@ICG K0K,H4O&G;97K!W*[T MQMV=2VXDQLXP9#BS2&DI4,$*CF+@QD/89@I[\%?=0?:T\V$]K<*I@W4._"37D=:^7NXSJ MJ,\M'4E%7X1!UEB/6' .N,:6>XY-\9R<%4.W>8>B#8\A,DYB.N6M\L-I?W0 M [AV>;\"4H=WLFSI50K!C.#$(4LP0R00C#Q,$')8*I@G@QGI%$C]B0X!\OC? M0\W9$]W@?ZC@UV\5A!SSV1_!_W<]3XKF5B+NEXV2XV;6PI]>P:_5V3IFZ;!, MQGIDB7EAI-2@F+E5R'-@V$A6(!,AA%8LR-"GKD.F0X&1Y/& 0)]:M!-WK^L& MYK):5\EQ5Q\:L*G7,^[_=[F^OO X*=YC]%(8HV*(&)0!(6"EK0:?PC/D0^02 M1XIEZ*% ,^VNY9;8<0'.)9R;.# N<7"S +^NS"U2N,\P93148($I$DQHI T3 MB!E/D1>>>H(%+XH>1PAYSNS'DK:1@3P$/_MK"#.]@SVMPSF2O;G)&^G$V8;6 MI<+86YO2*9,9#=A89!@.R,54!M^CP6!..%"\\,&,@1DH5[Y5W--TT3.]*./28 M=)#Y[HU+KIE^.W/7F>6GH?D(O[2[)_W!/J6TWLEH'!(67,54?PA%(3G2ECL0 M=*]8CM,QWX#6WD!T IY]R?Q)5E.JWGVV+P;UJ6LE#1&XP1#TX@:HA! M3, #+*5"$$>,C'TN_V0*L_M,U(99[P=0/B>^#?"LE)'S"K33O%ZE9NV^9;^U M7PD\&4ZE0T9%B203$<4H+-)4>D5%3-KOT'V 005B:+BR!0!A/D];Y*$"M3A/ M-WW\Q:R:M8ND)#]VJ,;0;8"2,5(H114RABA4@-^+; ]"ZX1=U@Y*W"/VPV9 M$MN&%)C1<,M=>*&^:U"[U^_8W+&T&I8'!05*#(F(BR* &TT=\)ZJE6A7,-TC M!3);5OA0.T9#@Y7O=NBZDMMN>?BF9KQ@.%^"]D 2T!^>C!>"@>$/YO,UJ2] M\79MOVD!WJ4VA(A1,IYDY:FQ'&) MB,+P3&9) -$&D]DCQ.1/3P2&@BG#H5+%NUH@]<#AS M35&_Y[XVLV;UJ(Z%5Z<=F\S?W8;[]K)Z+CUWH1LC_T0[J E/^I M\(BEF>= ^O:K86&-W_YU.BI&G^J3YLQ4UU4R86F_6+:S*K2C/G)SLF@&;#<_ M>'2(-S]V\[<9)6T?LE)&P:H0X1\IF?V@2$L:8UH!&E\SWG[OY_6;.3,_+@>X MR?]JKD[BZ0P$#9Z:KAVN*Y:D7+YZ#G2,#',G"HY]O4IB/XFI;MF=%@T$=,O* MK=-8#@:R+V[F 5'TI437P="T,OEMNL^X6N4'0]?A"/[FO="# >KNR[X.B*S5 MV>&M0KX'0]II.$LS>"N0.QC2=MK4ZS@W_;!@D/_QE_\'4$L#!!0 ( J# MJ4IKQ:&3]S, )UT @ 5 :&%L;RTR,#$W,#,S,5]D968N>&UL[7U9D]LX MMN;[_16>NL\N8U\ZNOL&UF[/V$Z/E^Y[GQA,B9FI*4G,IB27LW_]@)+(7*R% MXB:JJB(JRNDT )[SG0/@; #^_%_?9]-7WY)L,4GG?_D)_@Q^>I7,1^EX,K_] MRT]?/[]6G\W;MS_]UU__X\__Z_7K_]:?WKVRZ6@U2^;+5R9+XF4R?O7K9'GW MZI_C9/'+JYLLG;WZ9YK],OD6OWZ]Z?1J_<-T,O_E3_G_KN-%\NK[8O*GQ>@N MF<7OTE&\7'_[;KF\_].;-[_^^NO/WZ^SZ<]I=OL& 8#?E+WVMLC_]KIH]CK_ MU6N(7F/X\_?%^*=7@?UY"\GLP7RW@^2G[ZZW^\>K5!+DNGR:?DYE7^ MY]=/;Y\-Z8T(]9@@TN'^M)O?Y!M28NZ-#GH&I#\GR2_)]N8JGS:5WRN@=L_HE MWQMJL_*\=UNDIM-I?)UFP?SXEJC;+$ERA!9[?EV1@09CGI&MJIK6?.CS,'GB MA&IC\&X9K;8]5>C;&IFSV62Y'CXL-R:=+X/_$/R(214JCW9MC:Q<)[S6<+TQ\W4>K\:3\-OFC/PP5)=,?%Z& M_Z_UX>K&Q(L[/TU_;'[HO)JV![K!W[ M%KD[,&9+;!6QC=QF"@O1\N'M_";-9NN/'B._2M^6R/3Q)/M'/%TE[Y-XLLTL23S/*3ABB):+?I?/; M+TDVL\EU[C<]_>N)M)\^4C(^WP6K3'/P&R^8#>?/J>-W2F;U?;5*GW;(G.9CGZY2Z?C),MC M_I/19'F4NOU=NB.JJ@(<[=D6B:O9+,X>KFX^3\)D"1^*@^&^269-YK6[N68LLG8ZN< M[QNU9]9.S;LU';=7]M:F\V+Q,NUC69+]^,)[,WVS9O MXNG+',WNXJZB7BLO#*-KZI_T;)NH\',>?4_GK\?)3;R:OC3'JY*X=YP."4YG M\>1EF+L&O<^&:9W<]>BO9\GL.LGJTKIKC+8)O0OC9:/5=?*ZA*8FN0=&VDMT M4)K)9N%\%_ZZ;9W3U57EX(:2Y/LRF8_SM$RWM!PMT^N%D"I%=B4A.1D%(=-T MM$L5UFIP$R^NU[JP6KR^C>/[H!.0O4FFRT7QFWPE9J\!W!:X_N?VU]$+T3>/K9/J7GP(=T0F](P\L ,)Z(2FWUAFD+'=&0&V-E$[R MYZQ/\]+>--N*X%R\ZX=-VA+-/ND0I,A5^LE[T_C:;I(AG_Y:=E MF../OTSGRS"3W'3]H;#B;4RF,ZM6SJ[Z/JDWJXK.$520(V\9]H!(J)D&%!90 M40]5CTIU8* MHH)S0 B*=MJ,G:K.7GOU%,4Y7;0G:4TC]'Y/^G,>O7G&VN6ISUCA$FQG+/M4&<E!9V@57LFOYU/ M)Z/<15TFH[MY.DUO)\GB\,P^T"4B&"L0V+9,0H.5PIB"@FHK(:TM8WQ1,FX9 MI[YF_NX\Q2E+0,41(H48<4H9ZPW$C''NL"_XQU2PVGI"+DI/NH7M3-9@=<,O MPDYPK1 )2-$P";P0^I$?K. E&0:M1RU.1.=,TC:K+%M'.:H*?=LA;' ZW]0L MP4:A@))UQ)8;'"3UEX SF .MR[X>2&=2@0_I?'2J%CSVB9SB&N>A%QT4GB(/ MA7M<-#&4EV0SM*X(M7%ZU(4_O]F16.@NX7"L$*>7K,>.,N%>OGOZ:?2>R*IX MC+S'3%!Y:*I*XN?'QA&#@&&D#+1 &:FTUWX[P3C#LIH)V1%GP<,?KZ;)U4V! M^\=IO#ES58!_+-53=8A($RN0UM 2(#B"'&$#"Q2$!7U:4 >S/4T$F/:"S:#S M.WLYW:0QCB1X*O2..)+6.^"\0-@&BX,Q9PJP+/!@J!F>]K4A[1J\OLRT_8!4 M"=)7Z!TA1!C4$F@0W!,E.,N-DBW?RBD\[!Q/JY*MJC6-T?O]:,\@,SQ#5YJV M,CS;B%1)PI%LS^[FD4=$(NF,TM@JIJR&&!?44M-K,4I%WZY5&:2M0]37['\? MC^Z"I98]>FAE0):!34SFD)J2CZQ\79X@9\N-:(] MI,YN(?PM2Q>U_)%UQTAX@+CB4&FD/-3(*^(*;CT"E2HX^]TT6O1N6\6F+TU0 MH]%JMIKF=^'8Y#Y+1I/M$9'[:;*]"4'-TFRYO1AA+X\'=*:M3T2608B)!X(: M0)TCUNIROW5$U[:2 TR\E[DFI;5,D;U!\T0@QZ'UQXYQT#PE.BW3;[KA1TKE*YVD"0.I9M MJ#=@!(&Q1EODH5,HN*H*$ED@))FKG\%O.??0AQ+\4-#3 Z*#SECD'M'5S1,6 MC^0H=K:/J+<4"<<,-(12)K05K $*=1GB/"DK$37\D_;!Z\W7^$)UV%+_I#. MXR>U=.&G13Q:WY]Y-+9PXD@1(]0!A+#%6#+KB;%,%W@ 2L6PLQ4-9?S2$>@% MNS]T:I YC&&K4EL9C-/.J 27"+G@M2@J,64 2U*JKR3]:O0.@LZ=8;[ON,J MIT%46W Z_AY/E_%AT3UK%$G+!!"6&>FXE)88(VQ!F0+0#R^FTXOPFH!46WSK M@K=1Z6*FV9'C)/O:1T(#HJGEQN8_* >U0 6]6M#ZME]G@9=>A-H27OV=*:EC M">?!&1T(^J5UK[4<.=)4(N("Z)HBIKGQ KMR.2.NUP.FU?3K8AS9NB!W'R-L MZW68WW%@C&*.A/"<"@68ADP0M54EH?+3:W\$QK0%3$(DF'56,>H9D?H1(45Z M7%FZ"HQ55H)V F.G(?H["(QIZ:%W7,BPT2M-":%>E("0X5[(TK7\*P7&3@/O MMQ_$4$(*:'*77W&(!4/@*I=TE!L8JR[AA-*,>=G_HU 4%QH:B2N<)C$%E M%>1&.2FI],X)_\@]=L(,STWJ#/>]][B XS.GPC"3 /C,0XVE>*" M BAPN3\38>N?<><7+=.6\*HMW\!5^.?5?)Q':+[>!Q3RBN/UC6<^23[&#SFS MF[O8D_'7>4!\=YA]GSZT-7XD' V&@24:>F+"0@6X0J5]YQHD$H>8Z#DU,'M. MJ.M;9+/\HO^"()]F:CQ>PQ1/W??1=)6_+/TESFZ3]?13\_DJGF[Y>1_P7R;S MO!([L+:HH9>]?#QR A@0=EAI"-#<$(1\N<%"@@=X/5;?2CM$.=36:!.:3$;Q M],GU?^\GTV2Q3.?%_%LT6$M;&CX*YIXT3"E/C?468<(X*,T^ 09X&*9OK3P/ MT@W.^=_FQ\'2[*%-=6LV:N2%]M!HH#1T3AOJ@PE4\.XTJ%_.U9G_W+>6]0IP MPVTZVQ)T$RS4.!![G3\Z>[^A]O >>ZAGA!C %@$ID<%26^T5?30U<(,D>V=N M^GDVR!9!K._&9^DH2<8+'S#Y&&?+>9)=W6SWXK WG[:XU!HL D9B39G2 )N M">>&ENNI<*3^SM598*!O=>D#UZ$5>%4Z WJ^*_>WP8/1GG]^&DEX5Z'HJ\W/ M1!9I;H-=3!P)GAU%2DKNK/.&4,!\M=12-VCV],X6UXQ#1!@-S&OJA."BX)\( M.IB;%\\C]'H/^@RDL2'BPS[Q4C&$D'I9&@ (0:UZ>.=?'L5E5Q5RKJ M.@VKWWX!CL$" T49HI9C!SC4B!5X0.K8)19U599QPTJ<>MC]H5,75-0U%%4Z M3U&71"H8Z!AC SWG7"J-?4&5(&* 9U\ZPWU?4==I$/5ZVA$&U\XXIHVACBO* M;7#:"R,,R?IGC@=3U%5+>$U ZJNH"^1W?$H1>%,(602)9*2@BI,AQL][$5U] MB/HKZ@*, 2Z\%MA!3) AFI4*%6BMGT4>3%%7+=$UP*C/HJ[@99C@NT+C,%%4 M!]T2I581WN"1F<$4==627A.0^BOJ,H 2F%\T1Q%"83DG")2.HN.ROMDYF**N M6L)K@%%#V6W5)IZ/JRRCA_I$A%FLG6+6,42XI)"+DFX;++#++^YJ(-M6,.O+ M+>WZ#7J07SWBC'-,((*PT]8^QAX=JZ\IIYN] PJ&M0[<,-2EG3?$PY?#Y A M@N (,$(H\N!Q0R-PV#&P-D5;YS'Q>NC]GO1GD/&NH:O->2)>&AN>%T(K8KF7 MN2?YF+GBC/;YOE6;+PY7!GOOI5XGX=)GF L;QS##FEF(N9$("PX+R@ D]8]R M=!;FZDYB39"I7Y.ZKV@BFRW4]6*9!3MW;\%IA;Z114Q:HK6P@G E)6"/NJ<) MJU_GU]F5HI?G+>^/5:&G2V7VZRBN%9M>3>;SE=ET_-%ZF MVX+8?0I39ZS(6,"4T5)*(S0'!!-BGTR$7B\9.*Q '<@N[1>]QEJ2%$7YV>0V MH+FIS#^F#CL[13+^4FV:OF@>F;"S,82P$1*:_%VB $29/(6X_O54K2=+>IJ@S0!J+,[MBI!L ME"DN#TJ5ZT;%Y;CJ.)'DV&(4^,$$0V:"ETEU2\P:#W?TI,"=(1"52 \8-P@S00# L$PB.=+@\HO6DS4]+>0M(=6. M&Q<7'#[5QT#.?; P:*R(>*L$M% HYCCEQ"I?!#P@:7,\A+DPY>D"OMI;85;9V M&:]N/J4/\73YL#E2N.?4Q+$N$34(6F!\^!\4F&MG'C/3!(CZ"X*\,)FW!U+] M]/UZN?%IEK.SC0SL3=OO:!N%I-J/ MS*Z/L]6.S3[K'2DD)3&461/PP%1XZTI>!!/U/?+.XN\#CLXV@?9,&=7GYT__ MG8SA#H6JW#<2" HN@;5&TK!=013,W;+@WHKZ,;N>8[4U)7DXD]H8K[YT9,>A MY.("@O?)\BX=_\#) :4Y?;"($^&5<4!:[1S-KV8Q93&5#!OE7ENS[^/MDMIH5I\L?;9X MW&VOXEAD);NK0'S\E/BLO.UE5M)\DV9;I_&(G][I1R,*>,!'$" 9Q1IQ;IPN M_1;?X"Q2SX'^5A7Y_$#7]_V?VR45/8K#O:) M=4T$.N1$]HQB $NZY6-KY\, MZ.S4T_D]B58A/9,'4=U?B(!5@@+%+&=&.Q/,75+..*Y,K^^H5EA'VI+.8:_@ M1%0>I=SOY3H?TF6R[^Z<+3T-/SN;39;%]#/I?#D)\VT^FG3\U3!47C 3?EBD MT\DX#JNQCJ?YI9&?[Y*P)G^,LT#37;+,#8NS4O)U'J_"YO/H;/5%Q>=E^/]: M,E,8K5>1WQ->^:Z4.-8^PP<1C&U9S MRCP,5J?B!3_UA16D T&E6\*FBWWOBZ,=&$<4XC[\A:0P/ MQIP,?.ABT@!-]##/I;4JD1U2;@3.Y0CW/$+=LAQ@XG9S-0 MNMU!\Q.01_;/O$EDG5!*(&($051;B1"P!N40TLNI7?IMS) MS<+CS))8/Z36:^T[$7)+N'3IY/C)-,E,H.DVS0Z[ M.,]:1DSEE',A 876.6$Y8@4'SK(&4:76"^\[]'":8-*IZYK.9NG\\S(=_?+Y M+LZ2Q=5JN5C&\]S//NS''N@808PM$P(ZH+0P3"C&2_XP-0VNM[BDD%.+$'5> M(>'C2?:/>+I*WB?Q8I6M\T[G?ESH\^@N&:^F^1WXWP(A>3+&I]GG>)I\3D:K M+'"95'H]Z*1Q(DVU#'83D1)BI3 2%J*P"',3]E<7K*FFB=IN\3CV1%#E,2(? M]!Y)HXQ3PD$DL "JP$%9V6<.[^ S01U)-^T'MQY2P?45[GW\_](L#^@LKFYL M:IT'A4R:7:?5P,G.?&/-!]]=NI@OX@!C8VTSE.:)R6Q];I(]:4=7S]_R=9>T,,)JK&_4R0,YYY!Q8-KKY@R DE<<*F]KF_< M='8>O7N]: VN_I:,V2S8A9-X^C&^/_ (R,'V$;3$R^!I""\$R4_N>4$*WK@W M]1,6G1THZF.):(Y47UJPW\I7LS1;Y@>53;K8==SLQ!$B2-3ZN(S4CDN".6=4 M%/P#V.#"H2XTUHH9@3UR6$N@R[EG>/V[WV@.W3-S$\H M=:F9S\:/N,88 &F!=QY3003AA>28)GZ SQ .6S.;H'O^/;?6-ALI!ZBSWGL% M!-7.2.4*RX)9WN!ZJ,[>0SSWSGHB9&=)5KW\W>+<;2Q/?/3]\?4.ZF0T<2$F0=19!"@RA70;Z:6:<$U\Z2:OG9KE%[ MV,7Z1\9H2RBE!%%,H\VOS6,&]$;3^@Z@M9[;Z$W/:.8J#SG,]X;?\ M\>^3) M$WSV\RR_>.9+FJC9 )*DABC'%H-8>,\F1$@5D'C>X8;KC+%>[^K!? MV=K#KB_;9-=.M/B1C:/YB)/&B3PEP;-UQBBFL..:"%MBP2P;>)ZK;8'OTZ<. MH?Q]J]<@4UX7I55GUJ:W\_O5#[= MJ(?9.74#U=*-;:](:24Q)TI"[2U#V# J"SX!1O4]L,[">.?3C7J8]:X;^D$M M%LG23./%L:+ O7TBP1ST@DK-E(.8"(5IN38B:/J\N7V0#E(CN'I7B36UB^V$ M&5_-/^4!Q2S@H>/%9/%UGEXODFQ]M>A:W?.[GN>CR72R+L!_RFQU^[;E3T:: M083RQQ LPX0X1Q4L$3;0#OP=]A8T9Y\N#@/H/U2Z?:2'[MU=NB:?J6@VG2+8-9"^K M[(U0@PS'/,Q0BR DWBM;^C7(UD_;=^\+#D5KV@#VLLNKL10E(_H-"]TS@<)6H/X$NMQJ9AGFAKA,: & D5-0X47'+5("[56?G'X-2H M-73/9+]O8FY?TDU\9?WVP4V2Y06DJ_FAVMU3AHFTPC)_L,@0[CTB2'%1NOO" MRUYOTSQ1S\Y6;] ^KKUM>?'B+K_C/_R1E\=_BZ?/ H1VLLBK'L*T/;3]51TC MRE]H=(X)+C"D"@G \@-GNI;M[H"]5*K'X$-/@;S0D+OC+W\6[)8SD[?H@YWC+A%%$O'B544^?!?V*<+;A5J<&BI]1LS MSZXRK2)YEHKKKE]/VO7-=2:M]X]N'LDZ4E'>QM??I?/;_%7NW#W_D"R?_K4: M$7V\E':]?#M?++/UC5GO*E2K[^D1,44U0=0+K?*K*K'V'CCK25!W1B&K="U] M'SP>JSG?T3K2Q ** %"*8&T5U(*B@C='2/V' ULN,6\LFQ_>@6N*Q: +Q?,) MN2PF9"#W2*'#KN81D]I!C3A$P$DI%="PA$,:7=\ [[@(O)%HT]:!ZDGJ MT<3M[@Z1,\ !RK3 A-FF""XY Y30H9=2=!,8$>DWPBAWYH>##+]/@3QGRSV MW>\$?TH?XNGRX3H>_9(??XWG>W,)AYI'E'/&B-78(VB4AI)Q5E(;@!E>=+UJ2=%N0 M]"?F^23-TL+MJZF)M!TI>8 M/^5OEA\QO,LV47ZA-F<<2(VQ TR%OY1H:-C@3;N.*XK;M+;KHM&K1(].V2>M M(B0]P\)#ZI21B$I-4;G/4 SIL(WI&O+8)=%&6%RN; =I(/82=/VE[-""UKTO$I0P<62R4HM@B&0 J MU9F%Z3)L:ZJ)R Y*OS%"OT5=&*3U-005:"D\J7(9'PY)/FD2,4L-IY89 *B6 MQF,MY>-^!@9H734'.&T%BT82XL.+9TL'TDM4<6*6H5\4Q@!9TH[7;!7?U<36*LS @STC2ZP)SKF7R@5KD1K&N"MX M4*:!8]I9>6,'$[--B)K-U]IB/MPS"GN =U@))320PGOE<]-@PP."4@VO)+&# M.=PF1(W$+&N+^7#/R.&P['AK)3<,$ >"\5T/J#WYV)N5V(SN.COETL5GFU=?[$ M,=RA#A5Z1=)@#8/R02&D E1I]VCN(U"M?/2N9R M7Y?(AG5'4JT%SX.Y5F$!2PXQY_7O'NS)L6I;_K6A.=,2, ]+6+)8?@KJNCY> M,?Z89*/P#_%M]6+K0X-$FA.,/<$BH,$\$D@86J#@M:F_0/3DO;6^0+0'UGE4 MQB:+4399'\"YNOE'G$WR4'_.S?KX>V6E.3Q,9#"'*'^8VPAI(9.*T0+L@+ZM M[_3WY!>VK3:MPG4>Q5E3^OD^2^+QU?PI"]5MC_U#1))[$KQD$U@F#E(#I!0% M EZX^C9I3QYFVPK3&E1]*LL_D\GM75@2U;3:/8"1-TO%D MM/6R*^\8+_I%CDHIH8,(*HL">%R6M?'*.UY_+1!#UXHN\#F/+KR/E_D-$ ]V M?856:1=5UHD]_2-&+1&!4X0A8%76@TLS%&?6E% M8UCR@#?NZ1%18Y;#$P!.H F/$\^)$,W?VCY#"$#I#.?-,(>:%OZ=/9+3"GGG.%-?(,6X-*]? \"_UW01X0:'&=L#IVSQP MW^^3^6)][W(%R^!)ZTAR[;62$GEMB&0,,%K&2"SB]0N8X,4$$9O#TM\9]/*L M_ $Q/VD5$_O$3DFD'2" V@]0$R$-:B,7*'@RM87X>!#>^U"4[_F+-B!20Y>>I-'F*_C MZ31-Y_=[([;'.^6A::VA!)AS)[WB6#^N+Y[3!A>\##XFUSHZYS&TO\[C69HM M<[7,+]8\R>3>T3?BG"&"I20,<..,,,&H>+0P>?UZ$C3XP%U7()W73;?)YD^? M9IMDQ(?D=%]]UR"195QJS+ WPG'A:,Y\@0+%HOZFCBXTG-;7WXC;_5JLZ>=(A8<$P.5 M-\0Z+F50>>@>K5O<8 NYT$!> W3.952L%LE8IUF6_CJ9WP;3-QX%'3XQHG=P ME$ABR"G);R[ RA)+\S?A2N,*L08KQ85&^=J$:U!J4Z>&X/A0D440$*6,R5^G M@-@:*( M<0&18H &492E>E: ^F5MZ&("D3UA5SL.DD?%IUL?/5[<;\HITILTF]RN_R6; MS$>3^WBZ0SU.ZA\A*UGNUU&NO$0B,$-+-X][5O^A#S3XJ&670+4M^'@\7@,< M3\=9_.N)4G_>.3* ,0"%M8R@_*U IT5IH6N&&US\=1E1SBY0ZFL;N;BJ]6C?R"O.G',&2.@\H5!)8,J8C]4-[E@=?*BT M*Y >%:.C!WU>O#33]5L^5]EM/)_\>_T0J9J/]6H1(%]T^<7/=W&6'U%*QGD) M63)?K+]][M=SW.Q^FCXDR>1[D?:8,AO%;V= MA[4P*5^N>[=E_\B]H =Z112*_*UHCA .VZ3!2%M;@",HZ_/-BY,N"#VSJOQ0 MS-(6POW5,.VD^.@EDP?[14RSX!H1"C1P@BH40"0%K\IA-^Q;1UN18C7-:(37 M;UM'SJ,;1VXC'9YJG$UMA=@.39?FK$.L+"O3#8YMMWF;-V"-W\_'':3RO=+%Z%Y^+B%6$:8LL!QYS M0# &MD 6.^F';2K7U)*7:]5P@/U#==M#>) 6_ 5K['DTM=R,ENGHEZMU0<51 MDVUOGX@83S7U#E'JJ": X1+P EN<-RU*_/LO*).NP&V=C+ZT^>OGSZK.# 4 M?HIS!O<;\(<[1(9)J!U D" HF3-445E$A[5I\"919Y;Z(%2A551[L^0WQFHR MW@VAVWL^Z[0!(F6)"-I.#5&2*:I[-[%=9[QW M?W7W;[^$+Z_BZ>)P=KIOJK[.LU*-SITW/[JJ[EM4WU5(E3I\KL37SW"_:@D]WUHH#& &DXMAA1YAD@E+)2!)R)/AV-FE' WE3@ M8.3O-!S_")]4-_R] ] %BPP8Z; #B@!)"F1],-LN*?)764OZB*/4 _8/U6T/ MX0N(_%V4QOXF(G\$:&D@9A)ARAU#4H""Q^"F#M U/Z^HJT?^3@*VQPJ19389 MY0&%G.(J-2$_MH\ $0@RPB@%7@H89J@M9RGY0NJP885VE:0/4,RG,UR"R MQ:?/7T]5G.?](N"?T2#ZB;!-I#\(4,$0#"66PDK5Q MJ&#HB5MOCFI.WW&W]+%5Q "U3-'\#31MD=*(65?PX8@; M>(UO#7GLDF@C+"Y7MH,,A?L7)7;F;M>21-H>!KW),_Y>39Y/VT5:4L <-%YRCCD-NDU*_:;"U#]E MVIFGV(H\&V PF#SH/H_8QY,L-S@2M5BL9NM,R.+%,[3_2*=AM.ED^7#DD=_^ MB(B(M]!:$ 2 G?+Y]:=.%%+06@TH_W4^/V/P8NEU@9R(*H_(&E&OA]380#)$16 X:Q]$H'04"'\_L8"PD0 >MGY%N_ /TW-A_: M$\IO9UIL_*2S3HL-"='&/U,( P8LD-P[QTH[U//ZTZ+U:]U_#].BEE#.E,M< M1]L[/5B6E_[:/>9^U5EV?4*NL,IV=4#L-[$%G M@^N=4*,"<\HAY-@XISG6PLM2!%[W&1 \TPFURBIP\(3::3@.QG:]@&,^E AG MB'1$<8FP!E086R + )/#SEO7U)(^SOO4 _8/U6T/X4&FY2]88\]<_]S*"37E ME!'60 >=)0(SZU!I$]GP3\/)T U#U)5/J)T&[&4?.$)60RJ00=(AH2U1CI6\ MRD8OJ?TNE*A-<"_KJ"-6##&A%.0"6J$UU805O"D,!I0GN@3%J05J;P;6DQ"7 M^]73HK:[]G2+* 45SM.$SM"$9; M./:J+6\7BU4RMJML,K_=G+M9X[-XLMDNW/?@Q$\6!P\JGCY89(@'7G+DG 4. M>P^$V@+-H!*,#E"[6A#Q+JWI$K?A.W%%?5?S[Q[ :-ZJ\:)60 M2%CL)0+!GZ),68 4)K"0!K$-ZK2[L\LZT.(A8][7#/B8I:,D&2]\0/S4Y?-H MWP@+++GQ# AJB51.<*@*GKFE]8^F=F?&M:]G;<,TB*WVA86YGA8?DN75C4^S MFV2R7&7)P3Q?T[$CK:4PG"HKK<#*,,+P5AH,40KK)PQ:KYPYUT;< 8R][LN+ M_$'Q0.N7^/L_)\N['+G 8?C%[H7[V.YZXG"1AD(JS9!%F"N3WR,DBDF)-#>5 M\LC]U*!TO4=VBUQO.]UF P_38IK?[/PE;:Y7=8>,G _6 )30*T^!55P!6]@" MR#:YCY-=D&[UA-Y@?(DCUN35:KE8QO.<]0^K8Z^ M?VM2*"\Y)TH K'P1!O/ M#2TPY8[4]PCX!6GDN6'MOF9N-9O%V?)[7QR,QG%@8'1*%W-E[GQD$XG MHTFWU7.5"%#C= WH^G[_Y%F++)V''T<;_ZR':^0KT;MYM"XL7\,AZ%O )\W" MC^7A7H?SOQ\81!Y@9XI''!@&IB49&,PN]!C:_T!%769@ZYLRLLBS\ M=*PT;V?["$G"$4 XF$94$,J(0&3+'X3,Z:&4V341S0]OO#8'8M E M?ET?K'PR&Q^.5,0=ZA9A*Y@70!DG*- KJ&P7]J,[4'4 MF]^QA^0\XW>T'.AXYTA:*;%4"&I',1: ,N"+6:BTTL.N2VM'H!6UI#%JOQ>= M&61!V%!5Y605V7T3W-\?ILD\^9Y?'SB[GLR#77?X+;E][0.]$ 4?@TIE.9?! MR7"TW):!!'WN%!5=N3:%D+8/46V1ZM7TE^SOJX]_1^"P+']H&'E%J)22.8(( M= )IC&5I6V$ZP/< NQ)B4VSZ6K-+AC\DARI7GC8+@#B@N*1,!V7$AC' >,$) M 6: 4[4+-^!T) 82* F$OTL7BX_))E)Y;E?;Q=D\4/=(SV2Z6B:5SMT=ZQIA MKJ%7&!&'H+#.::G64U<) 8(Q7ZF2L^M3=7N8T \FG\SUE\T(5O3\A[S\%U!5H/[OXB&?U\FWY[,TXFN?*1 M_(=%UVAY?5=(;N=(<(2U-U(C MJ0VR#FJ+"TXX\/4O$NGN">RV-^G.T.K+L5)!-<=DM,K6_J7[/IJN M@EV=5]7EV=K5$F:MQ=QML8.(^ &Y M =" ^X6"2Z)^211(PN5/SL4V^!3G?YP;QN7W4W50]*;$PP9#/ M=>]+&K3A)LUF/LVNEG=!0ZOXL6T,'W%'I,FO- +<$BW#_YURUD-(-?=05(J. M=^WK-F"TN@O<]",1H0!3@Z'6B&MI /86%4AR*?I\&O6@9]ROVNSUGGO&>] Y M] 98Z(<*U\^T,G[DH)-:.VH=8TH#I*"6!>"02MBC@M=TZ_O3N1_/J/8N@!X/ M0=<&M4J*MY7Q(XPLE#A8>#C-><2;]:4][&TO@#RT^!<-! MA6M^3\K;4I3H[3SX,P'69)F,[N;I-+T-SLWA=/J!+I%'A&)B VN+,'<,D5( M036SHOZ1Q.[>M.E76FDG0)YWSC1M@CF0L,[C84H3+^Z&4N?_*: [7R5/GIP]=WQGDT?XYV2.I62V6Z2S)J@1U:H\9>4U _N8B-A)(@KT!$*R?WPUZ MIHT;Q%W IW(7#("/63I>C9:+,+^V[QB?4M?0WOKGSH7H/VET2<#>]AQW=.>C166L"ID))K* 5C#!K."\8Q]7U:;77+ M)\ZA!GL?DST-S]Z,MY,?'.5>80FI]X +#[0UGKJ"#X?5T$,8I\OCP,NC];"X M7-D.T['O5:3G$66]QV2)Y]HQJZA5CD.4WW4JRYW4DSY#Y34>'ZTLB8./R9Z& M06_RK/68+ WT4RVMCP;8-#;Z;&-W7"5;:V& M8\=.=S2/)+*:$Q8^8#''G#EE?<$9, VN?SY=NA=L<+4 ;<]*\Y3WXR<-]_6) MN%4:,&H1)=@9YXW3I=NDU. /I382VVX=: VDWZ9"#-*8&X@>M)1(V=P-E]_C ME62SR7S?Y59[VT8<,H<%,TIBP!SP5JG'W4[2/E^$JEI,VUOX:S;= M9JDN<, =GYV9-7_1HWNEDD92=>]8V5H8BB"EV(H,5A6^S_]0_!G_T_>/E^76RV^R__ M^H=?/KXB']GKUW_XG__VW_[E_WKUZG_1#V\\7JSO;O+]T6-EGAWSC??[]OC5 M^]LF/_SF79?%C?>WHOQM^RU[]>KTE[SF#[OM_K=_KO_G^'[3\?UE_S MF^Q-LVOQ^/M/__TT^^___[G[Y_+W9^+\LM/P/?#G_J_=?$WZG][U?W: MJ_I'KP+P*@S^_/VP^8-7>;@_-+8EC'2__OW)[_\>-K\=8(Q_:OYK_ZN'[7._ M6'TV^.E_O7WSL?'SU79_.&;[=?Z'?_MOGG>BHRQV^8?\VJO_^=\5\%HOO:US*^?_\2N+!]\H68(UPP%L&;H MO[_PX>/];?ZO?SAL;VYW%3T_&>#7 'Q\"M85NH:$GW5 CK'Z^(.6\7ZJAFYN M%_'33UK&?.IH8K]QT7\??]8R=KN0G?:,XICM+/>,)Y^\B'E7_]:;ZD_M+]9? M'Y'?QG@KJH,/Y]^/^7Z3;QK1?/!I;[OYUS]4?UK='5Y]R;+;U?NRN,W+X_W[ M7;8_DOU&_-?=]K:.4^3SX5AFZ^,J2G#,HC3 :2APRA$-? 0Y\5,1Q=R'<-5\ M>)7O7_WRL8/1_,BVH3^HOZI^\\H,V M\OYW:<8>LUVL';!](F]7YQM%V?;5!UV*E&NO*#=Y6>5!W5_*RO4+K=3^QD_K MH@KNM\=7#QJLSH><^5.XZI9)3=%>=S^_?2O MG65*4L;CF"<^CSE"40JCJ+.,28A650;ZN6BCSHLCT(9%E3$X!"<]%(<@FW&8 M#6!>''_N&)83MZFI59.W(;HKK_JW7=[3.X0ZF]))T#>B=3;)7X;:6?6H<-=5 MK2G>*@"(P"3T@9_@:JJ(4NS3WB)-X>K89]:;=3W-,T7N:[>HEWH]?\_SX ME[*XN]WNOWS*/N_R%4MI',4HCD K\V6"^//(=\*VK95%3K:IH)RV[U;80Y&9VS0?S"],Z*2Y=T MSQY?&OK7__'?MWE9_?VO]V_R;Q6]W[>'5;WT1" D,* T#2%&@"2=\31DD:8" MFIB<4 -[=%7"44'3ESPCBI5%;RIV]65/FEC7*C="E9S.V>!Z<4IGQ:G+6F>/ M,V6U>YMG=799+[ ?GL+@Q4VVW:_2.&)1+!@CD(0"T2CA/0;(8:(E>E8L3Z9] MPQ%ZPJ8K?G885]3 RW M=\=#(\OAV_SF4)QEM,V!W84IFXLDEW3)FQT2E@M9B M0&-461)APEA, \@8CCJ+01#KY6X:=F93J<"B2DF3JJ]2+OBTI5(25$ZF4H&6 M2JFRNUR54O9$0J7TV#%1*=!:))3@$$4$!S3E$(0,QKBSZ(= ;V-!P\YL*@4L MJI0TJ?HJY8)/6RHE0>5D*@6T5$J5W>6JE+(G$BJEQX[&/@ Y'/(CVV6'0[,2 MET 1I$F,*20B"*.$A'&?NX& 8,U<$S7^%7I4U[6=\BZ"-&E;_N:)HNSN=O!J";9?$* P \..0%Z?UL-%P*%_.VBVRT M>5OL\_NW6?E;?DSO]IM#FTS'$0Y9FO( <(:BB)$XZ*?\8H MO!,LK\&E.>7695!.KB<@3TUL=7ASHKG/,S.BF(94+D/O3)THK'8O-:UAQY]=IN7K:TH9H"A$%4I- =!$*4IX?WJ(N!416KT+#A6FC,HKT&EJ3.: M[,G)C'OBU%1&G3,G&O,L+2,28T;C,A3&T(?"9L=2U9?RMBBS8\[SS\>/=;JU M/6[S3M/"-(%)4LW,6<2XSSC'Y]DZ#R*EG4\S2\[UI@7GU>B\,SQMX3&B55: MIF)458BTR72D2",\C2J3#7Z7HE!6?'FB5/88DE6L7SY^*IL)XOT3@W&EBY2S MA(9^Q'! 8B;\SB B:@K51&3.AMC#H",^$)C^[X?7.>+] M6KOB-;YH;[VZ:D?5'=H%-*'^H1)WK>=X#UB/=:FM8L<-N@Q-G\[=BQO/D_"L MN3]].BGXJ3B=Q?E49OO#=:63Y*:XV]>EBD*<$B98A-(41("@I+^";?17K-A4VCM'T_7"OK2;:4!IM@W'B53?B_8 M3ILL3'VMNC:^9VN3/^FUR^SPE>PW]3_J$I??LMV#ZVWGPB\K07U?")B@) QB M A(?!FE_ YA@I5IL]JRZ7M.L$#:EPYH_#+!6"=AS)9 45SCMD2^YVCD+[XHK MG[8H=[,.*LO@V)JH]598AF8Z\.OQ6JDCYF35DGS+MKOZZ$Q:E!\KX^>ED97/ MTY3#-,%!*EC*X^J?O3RG(E"21P,SKL\I=LA>71?EJT.%;;#TIR9^)ES*J=U$ M-*K)FQZ#3K3L,C\CXF6!U&6HE0U'"NL=3E&/FKSQ.?V+XDCP,$8!"J,$,$HC M%'?V:#4U5Y(C;2M3G)JVDXH9,"DI1I.0J*A%6ORYT:)+](Q)D3&E"U$B M"Y$E9F1UZ/7^6WXXWEQ*QA '<8@%BCB)05K]7S6-[4N%@IBIB)&A*<>*-$!G M199,B973I@DY51,H SJ=J-0X42-298GA9>B5+6<*)[U03;D^?LW*G&:'?,.* MF[K._L,G#X*084I()9,BY#&-A6!)]7\!Y:@RF0#) 69HQ=T :X"]JI_JVWA# M:+-5\AYG:F2$6:)X&2/,EC.%DVZH^+Y'/X3?70_-?LAW]2MHK#@<#V=@[[/[ M1@$^Y=^/M*+DMQ5FT(\("7$HPH2GD0A2VJ'"0NU FFLLCK.+,WRON'XX7EL/ MO,:%*V\XKCLWO%]K1[S&$\4S'<[;4$Y&E]1\:CH[1:G$C/(1P9ZJ,9>A MZ)-Y^_A5E$E9MAX3/@]1]8$JYF$":@P$4"$X8*' +"8PC'S@@T3Z>3:W*):K M)G.]YV;$MPTI,6O('TQ)#)W5%1(;'$O/WM9?\\W=KH)T(;4MRVK[H08,&.XC2*C4&=U^ M4[\V_W-VDW>/20@_J";4[2$;3\3-[:ZX MS_./QV+]V[OFAEU7PR;R*69!"#$(8R0@P(G?V0L3KO3TH[X5URL/-2"O.-TL M5%-T ^;D9'D:TA2UM<7DG8@[H9JI%,-%?D:4TIS39:1EV=I&9$6,QJ7(2N&/A0V.Y:1G/RRWQX/ M'S[^TMD4@E*:Q!SA0' *""&\SYT88T:RHFAK GGYQ4Q>5,G3DAF'K!G*38/, M^V--XY^6H3T/N9+7($V.%ZE%NKZ,:Y(10];6["[-!M_TI4X$C2(JDC -,0I) MA)(X[$53B$CIUN<$<%S/VB2V$E_827RC6W9JBL:TM&PW;3LJ[@Q/TX3SK.Z] M2+S)6IZ]5EV&SD_IL.HZG6VNE5?E\O+;MJZ,]1S.GXOF(DM^6C0\?"J.V6[X MW^NC4C\7Q__,F[3Z4CN/+ M T&J 7H50N\^/WIGC)J+A=,WJ.)BXZ+;4G>Q\N34Q2-(5U[OV2FX'*X\HS[@ M=KW3=A/)K)?.UBV6$:06P,.E]=J96V;VD/8^+[?%)BW*]D?U[P6KP$E-P"_D*"HV25FCI3N>\/"PJ=R M+_JQPNJS[3E'K#7K6/_@ =B0G*FBLHTVE*^RLBYN\D_9]_-=G/Y^#4$\%(PA M*F)&(881%(3%,!*8(1Q*ETPS,>%.\4ZHO K6H/+';-?81C@:41$;S"YCR%OQ MY$GM#UOL2%]!S:_SLLPWEW$I.S)B1?I81/>RR[OK_K67]\5A^Z!6E*""1F$0ZH(0$B#Y MPF@V;#G<#>^?5BJN!R\N=0CGJY(F0=O87K9-UIB/999G\9ZF?;J<)ICS51P,;2@=P=OQ9ELRL* QJD3-"013%" M)"0$B\XHQI";*)^RL>D5[]! ]+(>HXGRJ9.KHWA.6354NA,VC[Q,YP3J]I@H M:5739GB):J;OS*B*&7)DHEZO#X>[RB!%D N!$Q\"S'C,(QZCSJ ((F"N7)*& M9E.M;8//7+%D"=57*P=,VE&JU^,43J92)QR*"J7(ZG+52=41"672XL9$E=[= M'0_';+_9[K^L" Z#5$01I@*D20(X3OW.:IBD%J1)Q=IL^E2<09J+E!*_^DKE MBE@[KGII>2,A8?HL2;]>6]S<%/OQ66D: TR!SU&< M)H&(:0B"J+.,&%:\8VS#HG,].X$T7!2SPJVMZ7MR6:<,V='6IW;F"I.0)*$/(I!P M$K $QG[864L3%AAJDZ25>71)9V%+FT=-/7) H+D67;28)3*$),<1"C!/B4,7#6.I 8JH^*J7DD2'OMRHQ633%R MQ:<-19IMS6J,)15MTB%WH0*EY_+XC8OC_=U$>$CV6_JHMBW M]=&RTV,5-.()H#3@D9\@$" 0LJ!];@TFW _TGB$R-*HRX Q?&>J0>E5S>#U, MTY>#3$F7$[59^%9=EC\!N_(::(HL.W[&9YRUL>.LMHE?AOC9=^OB&SM6>9/? MA+Q@E-[WCW4@@'DJ?)$F(.0<< CKZS0GR]Q/?14]M&'/L12.CL\K_7=XK% M MNR;%7:9LM8\6J[[7,2 $0PH-BG M/@E3DB"8!MTC[) ($EI1/ 5[2U \K9=]K)!MJ'F.>':@>;,\QR/!FX[J:;"^ M<-73\4A6];39>DGUOF:[HJ[KG%>_^+4WUU9T3D&$ 1:,T) 32#@-PK S%;.4 MRLB3\:6F3SU5@YGH2]7=+7*V*=9W]>\W)7[F MY^X!'(/N]F=I*:\\JP4:^6$KSV.^/J/'5JB95X#MN%!8["IJB>7;;/UUN\_+ M^Z&PMQ8A2F, $60)8 P 'PM".HN4^4HE(DSL.!;%/;[G9HTOW]R6Q;?3,XN=&.(TX#@). DH9#0.8M9;#%FJ5 S6Q(YC:>JA>=L!-C5- M,J)13I.F8E!-D\[D#6'-)$DC%(U(D@UBER%)5CPI['<[S0(W;_KG(F#@PQ 0 M%G"?,$QH2E/4&\*)VCL^ZI]WO%]'@S3)?5.W?*G)C2)5;JO[O)%Y MET:?O65HBHD#E^KTZ')AO)#_E[(X'%9)Z@-$4$ H(&E 04HBT1E-@8^LK.'+ MF9IH^;Z9,.3G1>4O-3A+Z_62G!HNU=NGT^HJ_5]&"9UV=;[!HK,PK\;Q,N3) MEC.RR_$Z',G*%EFO[V[N=O7-)9[?EOEZVZPR5G_>Y4TML_V&W!3EQ1$3#U3[_4EOY)*]SDV&3&L+X-(2?N"$]G ?N M>)N!/\VXS@:.J(GD="TH)Z?+:C4MX1VVU-"'*Z_WHFFTH1]7WB.YOGJHU],* MM:U&&)'TR=MY&>(_O=O%S./+4AY<5$.(?;]- 6\LLUBRGU*_,XD%IBNCO4# M&X99L(PAI1RXQV2< ^]5*^B;L6F8_]HFTFKV.WD5_3&:=#)?%7:7(7UV7)'- M>M7Y47WGXT/^+=_?Y<^\+P(8P(!&B0\H#Q,>5$+9GO7#D'(JNZ5G;LC=\.J? MIFC!+>$9G1?Y&AEG]KA>QF"SZ,^%YRIL,25_.7-7_6M15FG)MWSP=QB&B'((X2I4M/-NTZ/[$P@.J1+V6NLS%HE6@Y MI9N+8S7->T3OX/GZH?C52+T&ZL3RIT#BB!"Z:(IE2*(3SY[US^P"#J Z<*IPVAN-9F(#O3U=O#K=-66(0A2 M",9Q#&@L*OM)9SM*8J5DT(Y%QVG@D[G9 .:5]_F^O:"C
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�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end

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 01, 2017
Document Information [Line Items]
Entity Registrant Name	HALOZYME THERAPEUTICS INC.
Trading Symbol	HALO
Entity Central Index Key	0001159036
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		129,840,030

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 45,188	$ 66,764
Marketable securities, available-for-sale	133,797	138,217
Accounts receivable, net	12,452	15,680
Inventories	14,290	14,623
Prepaid expenses and other assets	16,627	21,248
Total current assets	222,354	256,532
Property and equipment, net	3,741	4,264
Prepaid expenses and other assets	172	219
Restricted cash	500	500
Total assets	226,767	261,515
Current liabilities:
Accounts payable	3,079	3,578
Accrued expenses	24,935	28,821
Deferred revenue, current portion	4,093	4,793
Current portion of long-term debt, net	29,601	17,393
Total current liabilities	61,708	54,585
Deferred revenue, net of current portion	38,802	39,825
Long-term debt, net	184,430	199,228
Other long-term liabilities	326	358
Commitments and contingencies (Note 9)
Stockholders' deficit:
Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock - $0.001 par value; 200,000 shares authorized; 129,822 and 129,502 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	130	130
Additional paid-in capital	559,659	552,737
Accumulated other comprehensive loss	(49)	(6)
Accumulated deficit	(618,239)	(585,342)
Total stockholders' deficit	(58,499)	(32,481)
Total liabilities and stockholders' deficit	$ 226,767	$ 261,515

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Mar. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000	200,000
Common stock, shares issued	129,822	129,502
Common stock, shares outstanding	129,822	129,502

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues:
Product sales, net	$ 11,434	$ 12,940
Royalties	13,982	11,387
Revenues under collaborative agreements	4,152	18,172
Total revenues	29,568	42,499
Operating expenses:
Cost of product sales	7,544	7,762
Research and development	36,935	40,100
Selling, general and administrative	12,615	10,806
Total operating expenses	57,094	58,668
Operating loss	(27,526)	(16,169)
Other income (expense):
Investment and other income, net	287	229
Interest expense	(5,448)	(3,876)
Net loss before income taxes	(32,687)	(19,816)
Income Tax Expense	210	0
Net loss	$ (32,897)	$ (19,816)
Basic and diluted net loss per share	$ (0.26)	$ (0.16)
Shares used in computing basic and diluted net loss per share	128,615	127,615

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement of Comprehensive Income [Abstract]
Net loss	$ (32,897)	$ (19,816)
Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities	(40)	187
Foreign currency translation adjustment	(4)	0
Unrealized gain on foreign currency	1	0
Total comprehensive loss	$ (32,940)	$ (19,629)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities:
Net loss	$ (32,897)	$ (19,816)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	7,315	5,817
Depreciation and amortization	602	489
Non-cash interest expense	487	1,054
Payment-in-kind Interest expense on long-term debt	0	1,890
Amortization of premiums on marketable securities, net	16	213
Loss on disposal of equipment	44	0
Recognition of Deferred Revenue	(1,723)	(1,524)
Recognition of deferred rent	(114)	(70)
Other	(5)	0
Changes in operating assets and liabilities:
Accounts receivable, net	3,228	6,867
Inventories	333	(856)
Prepaid expenses and other assets	4,668	(2,522)
Accounts payable and accrued expenses	(4,413)	(4,565)
Net cash used in operating activities	(22,459)	(13,023)
Investing activities:
Purchases of marketable securities	(54,830)	(126,431)
Proceeds from maturities of marketable securities	59,194	21,908
Purchases of property and equipment	(99)	(1,099)
Net cash provided by (used in) investing activities	4,265	(105,622)
Financing activities:
Proceeds from issuance of long-term debt, net	0	148,046
Repayment of long-term debt	(2,989)	(3,885)
Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement	(393)	285
Net cash (used in) provided by financing activities	(3,382)	144,446
Net (decrease) increase in cash, cash equivalents and restricted cash	(21,576)	25,801
Cash, cash equivalents, and restricted cash at beginning of period	67,264	43,792
Cash, cash equivalents, and restricted cash at end of period	$ 45,688	$ 69,593

Organization and Business	3 Months Ended
Organization and Business	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	Organization and Business Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies. Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators’ proprietary compounds. The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex^® recombinant, and it works by temporarily breaking down hyaluronan (or “HA”), a naturally occurring complex carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE^™ Technology. We license the ENHANZE Technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), and Eli Lilly and Company (“Lilly”). We receive royalties from two of these collaborations, including royalties from sales of one product approved in both the United States and outside the United States from the Baxalta collaboration and from sales of two products approved for marketing outside the United States from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates. Our proprietary development pipeline consists primarily of pre-clinical and clinical stage product candidates in oncology. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 has been demonstrated in animal models to work by temporarily degrading HA surrounding cancer cells resulting in reduced pressure and increased blood flow to the tumor thereby enabling increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. Through our efforts and efforts of our partners and collaborators, we are currently in Phase 3 clinical testing for PEGPH20 with ABRAXANE^®(nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (“PDA”) (Study 109-301), in Phase 1b clinical testing for PEGPH20 with KEYTRUDA^®(pembrolizumab) in non-small cell lung cancer and gastric cancer (Study 107-101) and in Phase 1b/2 clinical testing for PEGPH20 with HALAVEN^® (eribulin) in patients treated with up to two lines of prior therapy for HER2-negative metastatic breast cancer. Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC and Halozyme Switzerland GmbH.

Long-Term Debt, Net (Notes)	3 Months Ended
Long-Term Debt, Net (Notes)	Mar. 31, 2017
Debt Disclosure [Abstract]
Long-term Debt	Long-Term Debt, Net Royalty-backed Loan In January 2016, through our wholly-owned subsidiary Halozyme Royalty LLC (“Halozyme Royalty”), we received a $150 million loan (the “Royalty-backed Loan”) pursuant to a credit agreement (the “Credit Agreement”) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the “Royalty-backed Lenders”). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (“Collaboration Agreements”). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the “Royalty Payments”). The Royalty-backed Loan bears interest at a per annum rate of 8.75% plus the three-month LIBOR rate. The three-month LIBOR rate is subject to a floor of 0.7% and a cap of 1.5%. The interest rate as of March 31, 2017 was 9.9%. The Credit Agreement provides that none of the Royalty Payments were required to be applied to the Royalty-backed Loan prior to January 1, 2017, 50% of the Royalty Payments are required to be applied to the Royalty-backed Loan between January 1, 2017 and January 1, 2018 and thereafter all Royalty Payments must be applied to the Royalty-backed Loan. However, the amounts available to repay the Royalty-backed Loan are subject to caps of $13.75 million per quarter in 2017, $18.75 million per quarter in 2018, $21.25 million per quarter in 2019 and $22.5 million per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first to pay interest and second to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date. Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps. Because the repayment of the term loan is contingent upon the level of Royalty Payments received, the repayment term may be shortened or extended depending on the actual level of Royalty Payments. The final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050. Currently, we estimate that the loan will be repaid in the first quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January 1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to 105% of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan. As of March 31, 2017, we were in compliance with all covenants under the Royalty-backed Loan and there was no material adverse change in our business, operations or financial condition. During the three months ended March 31, 2016, accrued interest in the amount of $1.9 million was capitalized and added to the principal balance of the Royalty-backed Loan. We began making principal and interest payments against the Royalty-backed Loan in the first quarter of 2017 and therefore had no capitalized interest in the three months ended March 31, 2017. In addition, we recorded accrued interest, which is included in accrued expenses, of $0.7 million as of March 31, 2017 and December 31, 2016. In connection with the Royalty-backed Loan, we paid the Royalty-backed Lenders a fee of $1.5 million and incurred additional debt issuance costs totaling $0.4 million, which includes expenses that we paid on behalf of the Royalty-backed Lenders and expenses incurred directly by us. Debt issuance costs and the lender fee have been netted against the debt as of March 31, 2017, and are being amortized over the estimated term of the debt using the effective interest method. For the three months ended March 31, 2017 and 2016, the Company recognized interest expense, including amortization of the debt discount, related to the Royalty-backed Loan of $4.0 million and $2.6 million, respectively. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. The outstanding balance of the Royalty-backed Loan as of March 31, 2017 was $158.9 million, inclusive of payment-in-kind interest expense of $10.2 million and net of unamortized debt discount of $1.3 million. Oxford and SVB Loan and Security Agreement In December 2013, we entered into an Amended and Restated Loan and Security Agreement (the “Original Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”) (collectively, the “Lenders”), amending and restating in its entirety our previous loan agreement with the Lenders, dated December 2012. The Original Loan Agreement provided for an additional $20 million principal amount of new term loan, bringing the total term loan balance to $50 million. The amended term loan facility was scheduled to mature on January 1, 2018. In January 2015, we entered into the second amendment to the Original Loan Agreement with the Lenders, amending and restating the term loan repayment schedules of the Original Loan Agreement. The amended and restated term loan repayment schedule provided for interest only payments through January 2016, followed by consecutive equal monthly payments of principal and interest in arrears starting in February 2016 and continuing through the previously established maturity date of January 1, 2018. Consistent with the original loan, the amended Original Loan Agreement provided for a 7.55% interest rate on the term loan and a final payment equal to 8.5% of the original principal amount, or $4.25 million, which was due when the term loan became due or upon the prepayment of the facility. In June 2016, we entered into a Loan and Security Agreement (the “Loan Agreement”) with the Lenders, providing a senior secured loan facility of up to an aggregate principal amount of $70.0 million, comprising a $55.0 million draw in June 2016 and an additional $15.0 million tranche, which we have the option to draw during the second quarter of 2017. The initial proceeds carry an interest rate of 8.25% and were partially used to pay the outstanding principal and final payment of $4.25 million owed on the previous loan agreement with the Lenders. The remaining proceeds, including any drawdown of the additional $15.0 million, are to be used for working capital and general business requirements. The remaining $15.0 million tranche is subject to an annual interest rate equal to the prime rate as reported in The Wall Street Journal on the draw-down date plus 4.75%. The repayment schedule provides for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of January 1, 2021. The Loan Agreement provides for a final payment equal to 5.50% of the initial $55.0 million principal amount and, if we exercise our option to draw an additional $15.0 million in 2017, 7.25% of the principal amount of the second draw. The final payment is due when the Loan Agreement becomes due or upon the prepayment of the facility. We have the option to prepay the outstanding balance of the Loan Agreement in full, subject to a prepayment fee of 2% in the first year and 1% in the second year of the Loan Agreement. In connection with the Loan Agreement, the debt offering costs have been recorded as a debt discount in our condensed consolidated balance sheets which, together with the final payment and fixed interest rate payments, are being amortized and recorded as interest expense throughout the life of the loan using the effective interest rate method. The Loan Agreement is secured by substantially all of the assets of the Company and our subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc., any of our intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same; and make any voluntary prepayment of or modify certain terms of the Royalty-backed Loan. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our subsidiary, Halozyme, Inc. The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, a material impairment in the perfection or priority of the Lender’s lien in the collateral or in the value of such collateral or the occurrence of an event of default under the Royalty-backed Loan. In the event of default by us under the Loan Agreement, the Lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Loan Agreement, which could harm our financial condition. As of March 31, 2017, we were in compliance with all covenants under the Loan Agreement and there was no material adverse change in our business, operations or financial condition. Interest expense, including amortization of the debt discount, related to the Loan Agreement totaled $1.4 million and $1.3 million for the three months ended March 31, 2017 and 2016, respectively. Accrued interest, which is included in accrued expenses, was $0.4 million and $1.1 million as of March 31, 2017 and December 31, 2016, respectively. The outstanding term loan balance was $55.1 million as of March 31, 2017, inclusive of $0.1 million of accretion of the final payment and net of unamortized debt discount of $2.9 million.

Stockholders' Deficit	3 Months Ended
Stockholders' Deficit	Mar. 31, 2017
Equity [Abstract]
Stockholders' Deficit	Stockholders’ Deficit During the three months ended March 31, 2017 and 2016, we issued an aggregate of 74,522 and 156,185 shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $7.78 and $6.22 per share, respectively, for net proceeds of approximately $0.6 million and $1.0 million, respectively. For the three months ended March 31, 2017 and 2016, we issued 252,305 and 106,389 shares of common stock, respectively, upon vesting of certain RSUs for which the RSU holders surrendered 79,499 and 70,288 RSUs, respectively, to pay for minimum withholding taxes totaling approximately $1.7 million and $0.7 million, respectively. In addition, we issued zero and 807,036 shares of common stock in connection with the grants of RSAs during the three months ended March 31, 2017 and 2016, respectively. Stock options and unvested restricted units totaling approximately 15.5 million shares and 12.5 million shares of our common stock were outstanding as of March 31, 2017 and December 31, 2016, respectively.

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.

Summary of Significant Accounting Policies Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Restricted Cash and Investments, Current [Abstract]
Restricted cash	$ 500	$ 500

Summary of Significant Accounting Policies Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory [Line Items]
Inventory, Net	$ 14,290	$ 14,623
Hylenex recombinant
Inventory [Line Items]
Inventory, Net	1,700	2,300
bulk rHuPH20
Inventory [Line Items]
Inventory, Net	$ 12,600	$ 12,300

Summary of Significant Accounting Policies Revenue recognition (Details)	3 Months Ended
	Mar. 31, 2017
Period prior to expiration
Collaborative agreements termination notification
Notification period for termination	30 days
Period after expiration
Collaborative agreements termination notification
Notification period for termination	90 days

Summary of Significant Accounting Policies Research and development (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Expense	$ 36,935,000	$ 40,100,000
In-license technologies [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Expense	$ 0

Summary of Significant Accounting Policies Income tax (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Net	$ 0
Income Tax Expense	$ 210,000	$ 0

Summary of Significant Accounting Policies Net Loss Per Share (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net loss per share (Textuals) [Abstract]
Shares excluded from calculation of diluted net loss, amount	16.4	13.0

Summary of Significant Accounting Policies Segment information (Details)	3 Months Ended
	Mar. 31, 2017 Segment
Segment Reporting [Abstract]
Number of Operating Segments	1

Fair Value Measurement (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities
Amortized cost	$ 133,843	$ 138,223
Gross Unrealized Gains	1	25
Gross Unrealized Losses	(47)	(31)
Estimated fair value	133,797	138,217
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities
Amortized cost	33,158	40,221
Gross Unrealized Gains	0	1
Gross Unrealized Losses	(18)	(15)
Estimated fair value	33,140	40,207
US Treasury Securities [Member]
Schedule of Available-for-sale Securities
Amortized cost	70,002	94,002
Gross Unrealized Gains	1	24
Gross Unrealized Losses	(29)	(16)
Estimated fair value	69,974	94,010
Commercial Paper [Member]
Schedule of Available-for-sale Securities
Amortized cost	30,683	4,000
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated fair value	$ 30,683	$ 4,000

Fair Value Measurement Textuals (Details) $ in Millions	3 Months Ended
Fair Value Measurement Textuals (Details) $ in Millions	Mar. 31, 2017 USD ($)
Fair Value Disclosures [Abstract]
Available-for-sale securities maturities, next twelve months	$ 124.8
Number of available-for-sale securities in unrealized loss position, less than one year	8
Other than Temporary Impairment Losses, Marketable Securities	$ 0.0

Fair Value Measurement Fair Value Measures (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	$ 0	$ 0
Available-for-sale Securities	133,797	138,217
Assets, Fair Value Disclosure	172,611	199,133
Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	34,814	60,916
Commercial Paper [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	4,000
Available-for-sale Securities	30,683	4,000
Corporate Debt Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities	33,140	40,207
US Treasury Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities	69,974	94,010
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets, Fair Value Disclosure	104,788	154,926
Fair Value, Inputs, Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	34,814	60,916
Fair Value, Inputs, Level 1 [Member] \| US Treasury Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities	69,974	94,010
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets, Fair Value Disclosure	67,823	44,207
Fair Value, Inputs, Level 2 [Member] \| Commercial Paper [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	4,000
Available-for-sale Securities	30,683	4,000
Fair Value, Inputs, Level 2 [Member] \| Corporate Debt Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities	$ 33,140	$ 40,207

Collaborative Agreements Collaborative Agreements Textuals (Details) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2017 USD ($) Compound	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)
Collaborative Agreements (Textual)
Additional maximum proceeds receivable from collaborators of license and collaborative agreement upon achievement of clinical development milestones for elected targets \| $	$ 62,500
Sales-based payment to be received upon the first commercial sale \| $	12,000
Deferred Revenue (Textual) [Abstract]
Deferred revenue relating to upfront payment license fees and annual maintenance fees \| $	42,895		$ 44,618
Roche [Member]
Deferred Revenue (Textual) [Abstract]
Deferred revenue relating to upfront payment license fees and annual maintenance fees \| $	34,877		35,709
Baxalta [Member]
Deferred Revenue (Textual) [Abstract]
Deferred revenue relating to upfront payment license fees and annual maintenance fees \| $	$ 8,000		$ 8,200
Roche [Member]
Collaborative Agreements Terms
Number of product compound combinations licensed to develop	13
Number of exclusive right targets	3
Number of targets elected	8
Number of targets elected, additional exclusive targets	2
Number of additional targets, optional	10
Collaborative agreement target selection period	10 years
Duration of royalty receivable	10 years
Collaborative Agreements (Textual)
Deferred revenue, revenue recognized \| $	$ 800	$ 800
Baxalta [Member]
Collaborative Agreements Terms
Duration of royalty receivable	10 years
Collaborative Agreements (Textual)
Deferred revenue, revenue recognized \| $	$ 200	200
Lilly [Member]
Collaborative Agreements Terms
Number of product compound combinations licensed to develop	5
Number of targets elected, additional exclusive targets	2
Number of additional targets, optional	2
Number of targets elected, additional semi-exclusive targets	1
Duration of royalty receivable	10 years
Notification period for termination	60 days
AbbVie [Member]
Collaborative Agreements Terms
Number of product compound combinations licensed to develop	9
Number of targets elected	1
Number of additional targets, optional	9
Duration of royalty receivable	10 years
Notification period for termination	90 days
Janssen [Member]
Collaborative Agreements Terms
Number of product compound combinations licensed to develop	5
Number of targets elected	1
Number of additional targets, optional	4
Duration of royalty receivable	10 years
Notification period for termination	90 days
Pfizer [Member]
Collaborative Agreements Terms
Number of product compound combinations licensed to develop	6
Number of targets elected	5
Number of Returned Targets			1
Number of additional targets, optional	2
Duration of royalty receivable	10 years
Notification period for termination	30 days
Pfizer, Janssen and AbbVie
Collaborative Agreements (Textual)
Revenue Recognition, Event-based or Milestone, Revenue Recognized \| $	$ 0	$ 6,000

Collaborative Agreements Collaborative Agreements tables (Details) $ in Thousands	Mar. 31, 2017 USD ($)
Roche [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets	$ 20,000
Additional Exclusive Targets And Annual License Maintenance Fees	23,000
Clinical development milestone payments	13,000
Regulatory milestone payments	8,000
Sales-based milestone payments	15,000
Total Proceeds from Partner of License and Collaborative Agreement	79,000
Baxalta [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets	10,000
Regulatory milestone payments	3,000
Sales-based milestone payments	4,000
Total Proceeds from Partner of License and Collaborative Agreement	17,000
Lilly [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets	33,000
Total Proceeds from Partner of License and Collaborative Agreement	33,000
AbbVie [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets	23,000
Total Proceeds from Partner of License and Collaborative Agreement	29,000
Janssen [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets	15,300
Total Proceeds from Partner of License and Collaborative Agreement	15,250
Pfizer [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Upfront license fee payment for the application of rHuPH20 to the initial exclusive targets	12,500
Total Proceeds from Partner of License and Collaborative Agreement	16,500
Other collaborators [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total Proceeds from Partner of License and Collaborative Agreement	$ 93,750

Certain Balance Sheet Items - Accounts receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accounts Receivable, Net, Current [Abstract]
Accounts receivable from product sales to collaborators	$ 8,023	$ 7,854
Accounts receivable from other product sales	2,090	2,234
Accounts receivable from revenues under collaborative agreements	2,921	6,151
Accounts receivable, gross	13,034	16,239
Allowance for distribution fees and discounts	(582)	(559)
Total accounts receivable, net	$ 12,452	$ 15,680

Certain Balance Sheet Items - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory, Raw Materials	$ 868	$ 761
Inventory, Work in Process	12,885	12,850
Inventory, Finished Goods	537	1,012
Summary of Inventories
Total inventories	$ 14,290	$ 14,623

Certain Balance Sheet Items - Prepaid expenses and other assets (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid manufacturing expenses	$ 6,327	$ 9,663
Prepaid research and development expenses	8,345	8,613
Other prepaid expenses	1,525	1,661
Other assets	602	1,530
Total prepaid expense and other assets	16,799	21,467
Less long-term portion	172	219
Total prepaid expense and other assets, current	$ 16,627	$ 21,248

Certain Balance Sheet Items - Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property and equipment, gross	$ 16,223	$ 16,183
Accumulated depreciation and amortization	(12,482)	(11,919)
Property and equipment, net	3,741	4,264
Research equipment
Property and equipment, gross	10,483	10,479
Computer and office equipment
Property and equipment, gross	3,395	3,373
Leasehold improvements
Property and equipment, gross	$ 2,345	$ 2,331

Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Depreciation and amortization
Depreciation and amortization expense	$ 0.6	$ 0.5

Certain Balance Sheet Items - Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Summary of Accrued Expenses
Accrued outsourced research and development	$ 11,970	$ 9,522
Accrued compensation and payroll taxes	5,045	11,539
Accrued outsourced manufacturing expenses	3,670	3,225
Other accrued expenses	4,276	4,552
Total accrued expenses	24,961	28,838
Less long-term portion	26	17
Total accrued expenses, current	$ 24,935	$ 28,821

Certain Balance Sheet Items - Deferred Revenue (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Deferred revenue
Total deferred revenue	$ 42,895	$ 44,618
Less current portion	4,093	4,793
Deferred revenue, net of current portion	38,802	39,825
Roche [Member]
Deferred revenue
Total deferred revenue	34,877	35,709
Other collaborative agreements
Deferred revenue
Total deferred revenue	8,018	8,209
License fees and event-based payments
Deferred revenue
Total deferred revenue	42,895	43,918
Research and Development Services
Deferred revenue
Total deferred revenue	$ 0	$ 700

Long-Term Debt, Net Long-Term Debt Textuals (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	Jun. 30, 2016	Dec. 31, 2013	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Royalty-backed Loan
Debt Instrument [Line Items]
Issuance date			Jan. 26, 2016
Total loan balance			$ 150,000
Debt Instrument, Description of Variable Rate Basis			8.75% plus the three-month LIBOR rate
Debt, Interest Rate			9.90%
Debt Instrument, Maturity Date, Description			final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050
Prepayment fee, percent			105.00%
Debt instrument, covenant in compliance			in compliance
Interest Costs Capitalized			$ 0	$ 1,900
Accrued Interest			700	700
Lender Fee			1,500
Debt Issuance Cost			400
Interest Expense, debt			4,000	2,600
Outstanding loan balance			158,900
Capitalized interest expense			10,200
Debt Instrument, Unamortized Discount			$ 1,300
Maturity date			Dec. 31, 2050
Royalty-backed Loan \| 2016 [Member]
Debt Instrument [Line Items]
Royalty payments to be applied to debt instrument			0.00%
Royalty-backed Loan \| 2017 [Member]
Debt Instrument [Line Items]
Royalty payments to be applied to debt instrument			50.00%
Royalty-backed Loan \| 2018 and thereafter [Member]
Debt Instrument [Line Items]
Royalty payments to be applied to debt instrument			100.00%
Royalty-backed Loan \| 2017 Quarterly Maximum Payment [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment			$ 13,750
Royalty-backed Loan \| 2018 Quarterly Maximum Payment [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment			18,750
Royalty-backed Loan \| 2019 Quarterly Maximum Payment [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment			21,250
Royalty-backed Loan \| 2020 Quarterly Maximum Payment [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment			$ 22,500
Royalty-backed Loan \| Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate			0.70%
Royalty-backed Loan \| Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate			1.50%
Secured Debt
Debt Instrument [Line Items]
Total loan balance			$ 50,000
Interest rate, stated percentage			7.55%
Interest Expense, debt			$ 1,400	$ 1,300
Outstanding loan balance			55,100
Accretion of debt balloon payment			100
Debt Instrument, Unamortized Discount			$ 2,900
Term loan, increase		$ 20,000
Maturity date			Jan. 01, 2018
Final payment			$ 4,250
Final payment as percent of original principal			8.50%
Accrued interest, noncurrent			$ 400		$ 1,100
Senior Loans [Member]
Debt Instrument [Line Items]
Issuance date	Jun. 07, 2016
Total loan balance			$ 70,000
Interest rate, stated percentage			8.25%
Debt instrument, covenant in compliance			in compliance
Outstanding loan balance			$ 55,000
Maturity date			Jan. 01, 2021
Debt Instrument, interest only period			interest only payments for the first 18 months
Debt Instrument, Unused Borrowing Capacity, Amount			$ 15,000
Debt Instrument, Unused Borrowing Capacity, Description			prime rate as reported in The Wall Street Journal on the draw-down date plus 4.75%
Final payment as percent of original principal			5.50%
Final payment as percent of additional draw			7.25%
Senior Loans [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Prepayment fee, percent			1.00%
Senior Loans [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Prepayment fee, percent			2.00%